Registered Members Login:
   
Forgotten Your Details? Click Here To Recover +
Welcome To The ShareCafe Community - Talk Shares And Take Stock With Smart Investors - New Here? Click To Register >

2 Pages (Click to Jump) V   1 2 >

pacestick
Posted on: Aug 27 2017, 03:53 PM


Group: Member
Posts: 339

well the kiwis are enjoying it anyway . Barnaby Joyce is the the number two nominated person to be new zealander of the year 2018
  Forum: Off Topic Chat

pacestick
Posted on: May 30 2017, 06:57 PM


Group: Member
Posts: 339

Expect a move to taxation by distance travelled so much a kilometre
  Forum: Macro Factors

pacestick
Posted on: Mar 19 2017, 04:52 PM


Group: Member
Posts: 339

sorry should have posted second half 2017
  Forum: By Share Code

pacestick
Posted on: Mar 19 2017, 04:23 PM


Group: Member
Posts: 339

Goldman sachs presentation New York

http://www.beachenergy.com.au/irm/PDF/6513...InvestmentForum


Note the excess gas destined for the spot market second half 2016

  Forum: By Share Code

pacestick
Posted on: Jan 8 2017, 06:22 AM


Group: Member
Posts: 339

Based on the increase POO I am expecting a small increase in the dividend compared to the last half .
  Forum: By Share Code

pacestick
Posted on: Mar 6 2016, 07:13 AM


Group: Member
Posts: 339

adr comparison web site

http://stockpar.com/index.php?id=2
  Forum: By Share Code

pacestick
Posted on: Feb 24 2016, 10:49 AM


Group: Member
Posts: 339

I have no idea . They have dealt with the immediate short term financial crisis . There will be more contracts to come both from AMGEN and others over the next twelve months as the company edges towards profitability
  Forum: By Share Code

pacestick
Posted on: Feb 23 2016, 03:47 AM


Group: Member
Posts: 339

Unilife and Amgen Enter Strategic Collaboration for Injectable Drug Delivery Systems

Amgen to invest up to $75 million in leading technology platform
Collaboration includes license agreement and master development and supply agreement





YORK, Pa., Feb. 22, 2016 /PRNewswire/ -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS) today announced a strategic collaboration with Amgen (NASDAQ: AMGN), a leading biotechnology company, for injectable drug delivery systems. The collaboration, which includes licensing, investment, development and supply agreement components, is centered upon the use of Unilife's portfolio of prefilled, customizable wearable injectors for medicines to enhance the patient experience.

Under the terms of the collaboration, Unilife has granted Amgen exclusive rights to Unilife's wearable injectors within select drug classes for use with certain Amgen assets, while preserving rights previously granted to other Unilife customers. Unilife has also granted Amgen non-exclusive rights to all proprietary Unilife delivery systems within the therapeutic areas of oncology, inflammation, bone health, nephrology, cardiovascular and neuroscience.

"Unilife looks forward to a long-term strategic collaboration with Amgen to drive value for patients, prescribers and payers," said Ian Hanson, senior vice president and general manager of Unilife's Wearable Injector business unit. "Unilife is pleased to advance its leadership position in the wearable injectors market to meet growing demand for biologics and other medicines. Our prefilled, pre-assembled and ready-to-inject delivery systems are easy-to-use and enhance patient experience."

"We are pleased to enter this collaboration with Unilife," said Alison Moore, senior vice president of Process Development at Amgen. "One important pillar of Amgen's strategy is to invest in leading drug delivery technologies to more effectively meet the needs of patients suffering from serious illnesses. Unilife continues to develop technology that could provide patients with innovative and meaningful enhancements to drug administration."

Under the strategic collaboration, Unilife can receive up to $75 million. At closing, Amgen paid a nonrefundable $20 million license fee and purchased a $30 million senior secured convertible note from Unilife. Amgen may purchase up to an additional $25 million in senior secured convertible notes over the next two years ($15 million in January 2017 and $10 million in January 2018). These payments are in addition to Amgen's $15 million payment to Unilife in connection with the exclusivity letter entered into on December 31, 2015.

In addition to these payments, Unilife expects to generate future revenue from the strategic collaboration with Amgen. The collaboration includes a master development and supply agreement that captures key terms for the development, production and supply of Unilife delivery systems. Development programs will commence in 2016.

About Unilife

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S.-based developer and commercial supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, insulin delivery systems, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, Penn. For more information, visit www.unilife.com

General: UNIS-G

Investor Contacts (U.S.):

Investor Contacts (Australia)

Todd Fromer / Garth Russell

Jeff Carter

KCSA Strategic Communications

Unilife Corporation

P: + 1 212-682-6300

P: + 61 2 8346 6500



Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K, those described in the "Risk Factors" set forth in Unilife's prospectus supplement, dated as of and filed with the U.S. Securities and Exchange Commission on February 22, 2016, and those described from time to time in other reports which we file with the U.S. Securities and Exchange Commission.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/un...-300223649.html

SOURCE Unilife Corporation

  Forum: By Share Code

pacestick
Posted on: Jan 31 2016, 07:25 AM


Group: Member
Posts: 339

https://www.youtube.com/watch?v=Sv5iEK-IEzw
<h2 class="hd">Search Results</h2>
      ► 2:55<h3 class="r" style="font-size:18px">Eddie Izzard- Death Star Canteen -
      </h3>
youtube death star canteen 2

darth vader death star canteen-eddie izzard

eddie izzard death star canteen download

lego star wars cafeteria

darth vader cafeteria

jeff vader

youtube to mp3

youtube funny












  Forum: Off Topic Chat

pacestick
Posted on: Jan 30 2016, 06:09 AM


Group: Member
Posts: 339

I would be surprised if AMGN -UNS deal is the only one going on the ASX at the moment, but I would be amazed if AMGEN UNIS deal is the only one going on with AMGN on the Nasdaq . AMGN is a very large company in a very healthy financial position with a very large number of activities occurring
  Forum: By Share Code

pacestick
Posted on: Jan 30 2016, 02:38 AM


Group: Member
Posts: 339

why would they pay 15 million non refundable and walk away. A lways possible I suppose if not getting what they want but not I would think very likely. AS to it being over by the 31st as per the original release I would point out that the result of the Morgan Stanley negotiations was due by 31 December but there was no announcement before 4 January. So I will not be concerned if the announcement does not come before the end of next week.
  Forum: By Share Code

pacestick
Posted on: Oct 2 2015, 08:24 AM


Group: Member
Posts: 339

http://www.bloomberg.com/news/articles/201...il-to-the-world








Before the most recent round of sanctions went into effect three years ago, Iran was able to sell oil to 21 countries. By mid-2012, that was down to six: China, India, Japan, South Korea, Taiwan, and Turkey. Rather than immediately pull back on production, and risk damaging oil wells by slowing them down, Iran decided to store its excess crude. As it scrambled to build onshore tanks, the government loaded millions of barrels onto its suddenly out-of-work fleet of crude-carrying vessels.

The Iranians eventually reduced their oil output by about a third, to a low of 2.5 million barrels a day in mid-2013, according to data compiled by Bloomberg. As exports fell to 1 million to 1.5 million barrels a day, Iran kept filling its tankers with oil it couldn’t sell. By this summer, a large portion of its tanker fleet, one of the world’s biggest, sat parked off the coast, filled with 50 million to 60 million barrels of crude and condensate, a lighter form of oil used to make petrochemicals.

Since the nuclear agreement between Iran and six other nations was reached on July 14, the regime has been preparing to ramp up its exports and sell that stored oil. A small number of Iranian tankers believed to have been storing crude has left the Persian Gulf in the past several weeks, according to data compiled by Bloomberg. Three of those ships have since disappeared from detection by failing to report their location.

Iran’s crude output has been rising for two years and now stands at about 2.9 million barrels a day, the highest level since 2012. It won’t be allowed to sell that extra crude until sometime next year, when the International Atomic Energy Agency verifies that Iran has complied with curbs on its nuclear program. The monitoring needed for that to happen probably won’t be in place until January or February, say three Western diplomats familiar with the nuclear monitoring process.

Oil Minister Bijan Namdar Zanganeh says sanctions will be lifted sooner. When they are, he says, production will rise immediately by a half-million barrels per day, and after four to five months, by an additional half-million barrels. He says that by then, “we will reach to a figure between 3.8 and 3.9 million barrels a day.” Saudi Arabia is pumping 10.5 million barrels daily.

Even if Iran can increase production as quickly as Zanganeh claims, it may have to incentivize buyers by offering lower prices or by trading oil for goods or services, says Sara Vakhshouri, president of SVB Energy International, an energy consulting group in Washington. That’s because the Saudis have used long-term contracts to lock in customers who not long ago bought Iranian oil.

The sanctions put in place in 2012 shrank the economy by about 10 percent by March 2014, according to the U.S. Congressional Research Service. A report by Anthony Cordesman of the Center for Strategic & International Studies in Washington estimates that Iran needs about $170 billion to develop its oil and gas potential. The decline in oil prices has led to a drop in Iran’s own investment in its oil and gas sector—from $40 billion in 2011 and 2012 combined to only $6 billion last year, Zanganeh says. The International Energy Agency estimates about half of Iranian production comes from oil fields that are more than 70 years old.

Much of the money Iran has made through its remaining crude exports since 2012 is being held in escrow accounts in the various countries still buying Iranian crude. To reduce Iran’s access to cash, Congress passed a law requiring that Iran spend oil revenue only on goods from its customer countries. The Department of the Treasury estimates Iran will be able to retrieve half that amount, or about $56 billion. That’s still not enough to restart full oil production. And so the government is looking for foreign investment.

Since July, political and business delegations from Austria, Germany, Italy, and Spain have visited Tehran. “I think European companies are very eager to be involved in our projects,” Zanganeh says. Iran has not met with U.S. companies, he says. “It seems they have received the order from the U.S. government not to have the meeting. The doors are open for them like others.”

Some Iran watchers say Western companies will proceed with caution. “You’re not going to see an energy gold rush in terms of capital investment in Iran anytime soon,” says Mark Dubowitz, executive director of the Foundation for Defense of Democracies in Washington and a supporter of tougher sanctions. “The majors are still reluctant to make multibillion-dollar commitments to Iran.”

—With Jonathan Tirone, Julian Lee, and Grant Smith

The bottom line: Iran says it will be pumping 3.9 million barrels a day by March, but its oil fields are old and need investment.


  Forum: Macro Factors

pacestick
Posted on: Sep 3 2015, 08:30 AM


Group: Member
Posts: 339

Unilife Announces Review of Strategic Alternatives

Morgan Stanley Appointed as Strategic Advisor in Response to Expressions of Interest from Third Parties




YORK, Pa., Sept. 2, 2015 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS and ASX: UNS), a developer, manufacturer and supplier of injectable drug delivery systems, today announced that in response to third-party initiated expressions of interest, the Company's Board of Directors has engaged Morgan Stanley & Co. LLC to conduct a review of strategic alternatives to maximize shareholder value.

Potential strategic alternatives to be explored and evaluated during the review process may include a possible sale of the Company, a strategic partnership with one or more parties or the licensing of some of the Company's proprietary technologies. The Unilife Board of Directors will not provide any commitment regarding when or if this strategic review process will result in any type of transaction, and no assurance can be given that the Company will determine to pursue a potential sale, strategic partnership or licensing arrangement.

Mr. Alan Shortall, Chairman and CEO of Unilife, said: "In keeping with the Board's commitment to act in the best interests of all shareholders, we have determined at this time that it is prudent to explore strategic alternatives to determine the best opportunities for enhancing shareholder value. Unilife management will continue to operate the business as normal during this review process to serve the needs of existing and prospective pharmaceutical customers."

About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's portfolio of innovative, differentiated products includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto injectors, wearable injectors, insulin patch pumps, ocular delivery systems and novel systems. Products within each platform are customizable to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, PA. For more information, visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

General: UNIS-G

Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, or other events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.



To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/un...-300136764.html

SOURCE Unilife Corporation

  Forum: By Share Code

pacestick
Posted on: Aug 27 2015, 08:49 AM


Group: Member
Posts: 339

p { margin-bottom: 0.25cm; line-height: 120%; } OK I made a mess of that so here it is typed




Rig count overview and summary




usa 21 august 2015 885 up 1 change from last year down 1011







canada 21 august 2015 208 down 3 change from last year down 197







international july 2015 down 28 change from last year down 264

  Forum: Macro Factors

pacestick
Posted on: Aug 27 2015, 08:45 AM


Group: Member
Posts: 339


U.S.21 August 2015885+114 August 2015-101121 August 2014Canada21 August 2015208-314 August 2015-19721 August 2014International July 20151118-28June 2015-264July 2014
  Forum: Macro Factors

pacestick
Posted on: Aug 27 2015, 08:42 AM


Group: Member
Posts: 339


<h1 class="title module">Rig Count Overview & Summary Count</h1>AreaLast CountCountChange from Prior CountDate of Prior CountChange from Last YearDate of Last Year's CountU.S.21 August 2015885+114 August 2015-101121 August 2014Canada21 August 2015208-314 August 2015-19721 August 2014International July 20151118-28June 2015-264July 2014



Baker Hughes has issued the rotary rig counts as a service to the petroleum industry since 1944, when Hughes Tool Company began weekly counts of U.S. and Canadian drilling activity. Hughes initiated the monthly international rig count in 1975. The North American rig count is released weekly at noon central time on the last day of the work week. The international rig count is released on the fifth working day of each month.

The Baker Hughes Rig Counts are an important business barometer for the drilling industry and its suppliers. When drilling rigs are active they consume products and services produced by the oil service industry. The active rig count acts as a leading indicator of demand for products used in drilling, completing, producing and processing hydrocarbons.

Baker Hughes Rig Counts are published by major newspapers and trade publications, are referred to frequently by journalists, economists, security analysts and government officials, and are included in many industry statistical reports. Because they have been compiled consistently for 70 years, Baker Hughes Rig Counts also are useful in historical analysis of the industry.

The working rig location information is provided in part by RigData.

  Forum: Macro Factors

pacestick
Posted on: Jun 24 2015, 06:37 AM


Group: Member
Posts: 339

arty I know where you are coming from having spent a small part of my 63 years living in a country that activley suppressed the media I am deeply concerned for the future of democracy in australia when there are demands for unpopular in some circles opinions to be suppressed . The fact that their are individuals who would even consider this is a worrying trend of intolerance that if carried out would leave australia a lesser nation.
  Forum: Off Topic Chat

pacestick
Posted on: Mar 15 2015, 04:07 PM


Group: Member
Posts: 339

It may be that Barton sold because he intended to put the money into one of his other companies which he has been doing . The company is KRC he says it has great future on a mining programme for this year I have considerable doubts
disclosure I hold KRC but not PYC
  Forum: By Share Code

pacestick
Posted on: Mar 6 2015, 07:30 AM


Group: Member
Posts: 339

http://www.reuters.com/article/2015/03/05/...N0M10Z420150305

ISIS has torched one of the fields they controlled as Iraqi forces approach
  Forum: Macro Factors

pacestick
Posted on: Oct 10 2014, 05:33 AM


Group: Member
Posts: 339

It looks like profit taking has taken over and holders will have to wait on the next announcement of a contract to see another surge in price . Expect the Nasdaq shorts to make the most of the time between now and then and push the SP south
  Forum: By Share Code

pacestick
Posted on: Oct 9 2014, 07:34 AM


Group: Member
Posts: 339

given last nights nasdaq trading we could see 59 or 60 cents today. With the possibility that theer will be a further rise tomorrow
  Forum: By Share Code

pacestick
Posted on: Oct 7 2014, 07:13 AM


Group: Member
Posts: 339

This should catapult the company into profit over the next few years and the medimmine contract could be as big
  Forum: By Share Code

pacestick
Posted on: Sep 14 2014, 04:44 PM


Group: Member
Posts: 339

September 9, 2014
Unilife Corporation Announces Financial Results For the Fourth Quarter and Full Fiscal Year 2014


YORK, Pa., Sept. 9, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the fiscal fourth quarter and full fiscal year ending June 30, 2014.

Recent Highlights

  • Revenue for the Full Fiscal Year of 2014 was $14.7 million, an increase of approximately $12 million or over 400% compared to the prior year. Deferred revenue, which is cash that has been collected and is expected to be recognized within the coming 24 months, for the Full Fiscal Year of 2014 increased to $13.3 million.
  • Cash receipts from customers were $23.7 million for the Full Fiscal Year of 2014, an increase of $22.5 million compared to the prior year.
  • The net operating cash flow loss was narrowed by 20% over the year before, despite a significant increase in R&D investments. Over half of the Company's total annual operating expenses were invested in R&D during the Full Fiscal Year of 2014.
  • At the end of the fourth quarter of Fiscal Year 2014, Unilife had 12 active customer programs, an increase of two programs since the end of the prior quarter, across all six of its product platforms.
  • Since July 1, 2014, Unilife has commenced commercial sales of the Unifill® syringe utilizing an existing commercial manufacturing line. Commercial sales of other products from the Unifill family, including the Unifill Finesse® and the Unifill Nexusâ„¢, are scheduled to commence during the middle of the 2015 fiscal year on additional manufacturing lines that are either in the process of being configured or are now operational and in the process of being qualified.
Mr. Alan Shortall, Chairman and CEO of Unilife, commented: "Fiscal 2014 was a year of rapid growth in revenue, customers, supply agreements and production capabilities. Having made significant investments in R&D during the last three years, we have achieved a critical mass in product range, capabilities and industry expertise. Those investments are now generating revenue at an attractive growth rate as we enter into and execute upon supply agreements with a growing number of pharmaceutical customers."

"During Fiscal Year 2015, we look forward to achieving significant growth in revenue via commercial sales, customization fees and upfront payments from a multitude of customers and active programs. In parallel, we expect to increase capital expenditures in response to growing customer demand while moderating our investments in R&D and keeping SG&A largely stable. We also look forward to completing a number of additional significant supply agreements, which have taken longer than originally anticipated to complete but are now approaching the finish line. Based upon current cash on hand including the recently completed ATM, along with scheduled payments under existing and imminent agreements, we feel confident that we will have sufficient cash to offset our full year operating activities for fiscal 2015," Mr. Shortall concluded.

Financial Results for the Full Fiscal Year 2014

Revenue for the Full Fiscal Year of 2014 was $14.7 million, compared to $2.7 million for the same period in 2013. Deferred revenue increased to $13.3 million as of June 30, 2014. The Company's net loss for the Full Fiscal Year of 2014 was $57.9 million, or $0.59 per share, compared to a net loss of $63.2 million, or $0.78 per share, for fiscal year 2013.

Adjusted net loss for the Full Fiscal Year of 2014 was $38.8 million, or $0.40 per share, compared to $38.0 million or $0.47 per share for the prior year. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization, interest expense and the change in fair value of financial instruments.

Unilife reported $10.8 million in total cash and restricted cash at the end of Fiscal Year 2014, which ended on June 30, 2014. This does not include $12.4 million in net proceeds generated through the completion of our ATM facility in August 2014, or other cash receipts generated by customers since July 1, 2014.

Conference Call Information

Management has scheduled a conference call for 4:30 p.m. U.S. EDT on Tuesday, September 9, 2014, (Wednesday, September 10, 2014 at 6:30 a.m. AEST), to review the Company's financial results, customer partnerships and future outlook. The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen-only Webcast. An archive of the presentation and webcast will be available for 30 days after the call. To listen, please go to: http://ir.unilife.com/events.cfm.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

Non-GAAP Financial Measures

U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure. The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures. Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense.

Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table.



General: UNIS-G




Investor Contacts (US):

Analyst Enquiries

Investor Contacts (Australia)

Todd Fromer / Garth Russell

Leigh Salvo

Jeff Carter

KCSA Strategic Communications

Westwicke Partners

Unilife Corporation

P: + 1 212-682-6300

P: + 1 415-513-1281

P: + 61 2 8346 6500



  Forum: By Share Code

pacestick
Posted on: May 26 2014, 06:54 AM


Group: Member
Posts: 339

"King River Copper Limited (“King River” or “the Company”) (ASX: KRC) has noted today the increased interest and price movement of its shares.
The Company is not aware of any material information that has not been previously disclosed to shareholders.
The Company has not yet commenced drilling. The first drilling is planned to commence next
Wednesday, May 28 at the shear zone on Chapman Hills, followed by a diamond drilling program at the
Chapman outcrops.
The phase 1 drilling program will be spread over 7 different locations and is expected to take up to 6
weeks.
All drill core will be stored on site, then delivered to Perth early July for cutting and assaying.
Recent bulldozer work providing access to the 2 drill site locations at Chapman outcrops has exposed
further copper carbonate (malachite) in quartz veins and breccias that has been lodged for assaying. Any assay results received that are viewed by the company to be material will be released on receipt.
The Chairman, Anthony Barton is also presenting the company to a large group of London investors in
the evening of May 28.
There is no other information known to the company."
  Forum: By Share Code

pacestick
Posted on: May 13 2014, 10:34 PM


Group: Member
Posts: 339

cantor fitzgerald update following latest quarterly


Equity Research
Unilife Corporation (UNIS-$3.19)
Rating: BUY
Target Price: $8.00
Focus on the Forest, Not the Trees; Reiterate BUY and $8 PT
EPS
2013A
2014E
Prev
2015E
Prev
2016E 1Q
(0.16)A
(0.12)A
—
0.00E
0.01E
— 2Q
(0.19)A
(0.17)A
—
0.00E
0.01E
— 3Q
(0.17)A
(0.15)A
(0.06)E
0.04E
0.05E
— 4Q
(0.26)A
(0.05)E
—
0.05E
—
—
REV
2013A
2014E
Prev
2015E
Prev
2016E 1Q
0.7A
3.2A
—
27.5E
—
— 2Q
0.7A
3.6A
—
27.5E
—
— 3Q
0.7A
1.4A
8.7E
41.1E
42.2E
— 4Q
0.7A
4.1E
9.1E
42.0E
—
—
FY
EPS
Prev
P/E 2013A
(0.78)A
—
(4.1)x 2014E
(0.49)E
(0.40)E
(6.5)x 2015E
0.10E
0.12E
31.9x 2016E
0.39E
0.43E
8.2x
REV
Prev
EV/REV 2.7A
—
138.9 12.2E
24.6E
30.7 138.0E
139.1E
2.7 273.6E
274.7E
1.4
EBITDA
(mil)
Prev
EV/
EBITDA (56)A (36)E 23E 76E
—
(6.7)x (28)E
(10.4)x —
16.3x —
4.9x
SUMMARY: While we are generally hesitant to discount the importance of a
company's revenues in a given quarter, Unilife's quarterly results and commentary
from management on the conference call give us sufficient comfort to argue that
investors should not focus at all on the $1.4m of revenues that the company reported
in 3Q:14. With $10.9m in total cash receipts (from upfront cash payments and
customization fees), the company significantly improved cash burn and announced
that three Unifill programs will begin generating product revenues during the second
half of calendar 2014. Between these programs and others that the company has not
been able to disclose (but on which it is collecting customization fees), Unilife is on
track to be profitable in FY:15. As such, we reiterate our BUY rating and $8 price
target.



3Q Results. The $1.4m in revenues was light of expectations due mostly to
timing issues resulting in $2.7m being delayed until 4Q. More importantly, in
our view, was the $8.3m in deferred revenue recognized during the quarter;
this stems from customization fees that Unilife books as revenue based on pre-
specified milestone schedules. There were no product sales in the quarter, but
management indicated that products will begin shipping on three different Unifill
programs during the September and December quarters. R&D expense ticked
up meaningfully during the quarter as the company classified COGS related to
customization programs as R&D; that will shift to traditional COGS once these
programs transition to commercialization.
Balance Sheet. Unilife exited the quarter with $40m in cash due to the $40m
cash injection from OrbiMed (two more $10m payments coming in December
2014 and June 2015) and the $9.4m debt repayment. The company's balance
sheet restructuring is expected to reduce annual interest payments, while the
coming revenue ramp should eliminate any further concerns about liquidity.
The company does expect significant increases in capex spending going forward
due to planned capacity expansions. At present, Unilife has capacity to produce
~60m Unifill units per year and is in the process of building out additional
assembly lines to ramp to several hundred million units annually across the
entire product portfolio. This will be important once the Occu-ject and wearable
injector programs move into commercialization over the next 1-2 years.
Pipeline. Without providing specifics, management noted that it is already
collecting cash from supply agreements that have not been formally announced,
hinting that at least one is for the nascent wearable injector opportunity. In all, the
company is engaged on 10 different programs at present and hopes to disclose
more details in the coming quarters.
Current Statistics
Market Cap ($Mil)
Avg. Daily Trading Volume (3 mo.):
Shares Out (Mil):
$327.9
1,312,009
102.799
The Disclosure Section may be found on pages 4 - 5.
Enterprise Value ($Mil):
375May 12, 2014
Valuation
We use a blend of a DCF analysis and an EV/revenue multiple on our CY:2016 sales forecast,
discounted back to the present. For our DCF, we use a weighted average cost of capital of 15%
and a terminal growth rate of 2%, which gives us a share price of $8.25. We also applied an EV/
revenue multiple of 3x on our CY:2016 estimate of $362m and then discounted it back three
years at a 15% discount rate. This analysis yields a share price of $7.79.
We therefore blend these two methodologies to arrive at our 12-18 month price target of $8.
Risks




Supply Contract Delays. Unilife’s business model depends on securing long-term supply
agreements, so any delays could have a significant impact on revenues.
Regulatory Delays. Many of Unilife’s programs are drug-device combinations, so delays
in obtaining regulatory approval for these products could impact the business adversely.
Competition. While Unilife has a differentiated product, it competes with much larger and
significantly better capitalized companies.
Liquidity. Unilife believes that its present pipeline is sufficient to make the company
substantially profitable within the next two to three years, but delays turning pipeline
projects into sustainable revenues could exacerbate the company’s liquidity, particularly in
light of the $41 million in cash burn in FY:13.
  Forum: By Share Code

pacestick
Posted on: Apr 24 2014, 06:22 AM


Group: Member
Posts: 339

Unilife Responds to Malicious Blogs

YORK, Pa., April 22, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS) today issued a response on behalf of its shareholders in relation to a series of malicious blogs containing false and misleading information published over recent months by short sellers on the Seeking Alpha website.

Unilife has requested that the SEC investigate these short sellers and their associates for stock manipulation and illicit gains. Unilife categorically refutes any allegations of wrong-doing by the Company, its directors, officers and management. In particular, Unilife would like to address the following:

Most of these allegations relate to a wrongful termination lawsuit by a former employee who was terminated "for cause," and the related SEC review of the matter, which Unilife first disclosed more than 18 months ago and has repeated in subsequent regulatory filings and earnings calls.

Unilife has refuted these allegations, declined a settlement offer by the plaintiff, and expects to prevail should the case proceed to trial. Unilife has co-operated fully with the SEC in its review, provided extensive information, and responded to all questions. Unilife does not believe that there are any grounds for any action to be taken against the Company.

Unilife has never paid anyone to publish articles about it. No officer has ever sold Unilife stock since the Company listed on NASDAQ in 2010, with the CEO and COO having purchased in excess of $4 million in Unilife stock in recent years. The CFO's departure was not due to a resignation but part of a long-term succession plan. Mr. Shortall has never been a director or officer of a Company that has failed, or gone bankrupt. Unilife has successfully been through numerous due diligence processes conducted by multiple global pharmaceutical customers, investors, analysts, financial auditors and regulatory bodies. By way of example, Unilife last month completed a $60 million non-dilutive debt financing with OrbiMed, the world's largest healthcare-dedicated investor. OrbiMed, together with its outside experts and advisors, undertook extensive due diligence over several months into all aspects of the Unilife business including its products, staff, patents, contracts and commercial pipeline.

Unilife encourages the SEC to act quickly to address these illegal actions by the relevant short sellers and their associates. Unilife's team, which is now more than 190 strong and consisting of some of the most highly qualified industry experts, will continue to drive the business, serve existing and new customers and build shareholder value.

About Unilife Corporation
Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

Investor Contacts (US):

Analyst Enquiries

Investor Contacts (AUS)

Todd Fromer / Garth Russell

Lynn Pieper

Jeff Carter

KCSA Strategic Communications

Westwicke Partners

Unilife Corporation

P: + 1 212-896-1215 / 212-896-1250

P: + 1 415-202-5678

P: + 61 2 8346 6500

SOURCE Unilife Corporation
  Forum: By Share Code

pacestick
Posted on: Apr 4 2014, 06:39 AM


Group: Member
Posts: 339

sheik john key seem sto have been a quiet achiever

<h1 class="breadcrumbs">News & Issues > Issues > Economic Contribution to NZ</h1> <h1 class="pageIntroText">Oil is our 4th largest export (after dairy, meat and wood), with a value of around $2.2 billion</h1>
Economic Contribution to NZ and Industry Quickfacts
Oil and gas already make a significant contribution to the New Zealand economy:

  • Oil is our 4th largest export (after dairy, meat and wood), with a value of around $2.2 billion.
  • Gas is an important contributor to domestic industries and electricity generation – generated 18% of New Zealand’s electricity supply in 2011.
  • Oil, gas and minerals industries contributed over $4.2 billion to GDP in 2009 (with oil and gas contributing over $2.5 billion).
  • The oil and gas industry invested $1.2 billion in petroleum exploration and production in 2011.
  • Government collects around $300 million in company tax per annum.
  • Government collects around $400 million in royalties per annum from petroleum (and has collected over $4 billion in royalties to date).
  • At a minimum, the industry provides 3,730 full time equivalent jobs and supports a further 3,970 FTEs in other parts of the economy (total FTEs nationwide 7,700).
  • New Zealand companies capture between 30 and 80 per cent of the construction of major oil and gas projects in New Zealand, and there is the potential to capture more.
  • The government will receive around 42%[1] of the profit of new oil and gas developments.
  • Future royalty income from known oil and gas reserves = $3.2 billion net present value. Royalty income could rise to $12.7 billion with a 50% increase in exploration.

Production and reserves
  • One producing petroleum basin – Taranaki – but a further 17 recognised petroleum basins.
  • 19 producing oil and gas fields in Taranaki.
  • 52 wells were drilled in 2011, up from 45 in 2010.
  • Oil production declined 14% in 2011 to 17 million barrels.
  • Total remaining oil reserves declined 11% due to on-going production and a downgrade of ultimate recoverable reserves at the Tui field.
  • Gas production dropped 10 per cent from 2010, mainly due to a decrease in demand for gas-fired electricity generation.

    [1] The 42% figure is the combination of current royalty rates (the higher of 5% ad valorem and 20% accounting profits) and corporate taxes (28% of accounting profit, noting that royalties are a deduction for the purposes of income tax). The 5% ad valorem royalty gets paid for a very short period of time, typically one year or less, with most royalty collected at the 20% rate.
  • First well drilled in 1865 at Moturoa on the Taranaki foreshore. Since then over 1,000 petroleum wells have been drilled in New Zealand, of which more than 350 since 2011 and 197 offshore (of the 197 offshore wells, 176 are offshore Taranaki).
  • Kapuni was the first oil/gas field in New Zealand. It started production in 1969.
  • Total number of permits (first quarter 2012): 1,030 of which:
797 (77.4%) minerals permits




83 (8.1%) petroleum permits.

  • Oil exports dropped 14% in 2011 to 16 million barrels due to decreased production from fields
http://www.pepanz.com/news-and-issues/issues/economic-contribution-to-nz/




  Forum: Macro Factors

pacestick
Posted on: Apr 1 2014, 07:23 AM


Group: Member
Posts: 339

31 March 2014 The Companies Manager Australian Stock Exchange Level 8 Exchange Plaza 2 The Esplanade Perth WA 6000 CAPITAL RAISING King River Copper Limited (ASX: KRC) announces that it is completing arrangements for a capital raising of $504,000 at 6.3 cents per share for the issue of 8,000,000 shares from sophisticated and professional investors. The fund will be used for upcoming exploration activities and working capital. The shares will be issued upon completion of the documentation. Yours faithfully
  Forum: By Share Code

pacestick
Posted on: Mar 20 2014, 10:33 AM


Group: Member
Posts: 339

There was an announcement this is just the result of shorts being caught with their pants down on the nasdaq . The announcement I reefer to was the bank putting up 60 million that shorts had argued would never happen
  Forum: By Share Code

pacestick
Posted on: Feb 24 2014, 01:50 PM


Group: Member
Posts: 339


How Cash Would Be Seen by the Media if Invented Today
Antonis Polemitis (@polemitis) | Published on February 23, 2014 at 10:50 GMT | Analysis, Crime, Lifestyle, WalletsinShare26 Share451 Antonis Polemitis is Managing Director of Ledra Capital. He has written a series of blog posts about bitcoin which can be found here. In this article, he casts a satirical eye over how a new currency ‘cash’ would be described by the press if invented today.


Breaking News: Bizarre, Shadowy, Paper-Based Payment System Being Rolled Out Worldwide!
World governments announced a plan today to allow citizens to anonymously carry parts of their wealth on their person and exchange it with others using small pieces of colourful paper.

The paper is printed with nationalistic and Masonic imagery, along with numbers that purportedly represent the amount of wealth each piece of paper represents (if the paper is not a counterfeit).

Each of these pieces of paper is formally a ‘note’ from each nation’s central bank, but they are also attracting the term ‘cash’. This is a technical matter that is too complex to cover in our basic primer. Suffice it to say, that it is representative of the complexity and user-unfriendliness of this new system.

So-called ‘dollar bills’, or ‘notes’, as they are formally known.
Are ‘bills’ too complex?
These pieces of papers (also known as ‘bills’, ‘dollar bills’, ‘George Washingtons’ or ‘Dead Presidents’ among the shadowy community of anti-banking libertarians who have been the primary users of cash to date) will differ from country to country and are not redeemable outside national borders.

In what will come as a surprise to generations who have grown up with calculators and computers, bills only come in fixed denominations, requiring users to maintain a large number of these pieces of paper that must be aggregated to execute a transaction and then re-aggregated to ‘make change’.

The latter is a complex process of returning to the payee the excess of the payment using yet other bills. (Don’t worry if this sounds complex, we had trouble understanding it ourselves at first and it is certainly not ready for the average consumer in its current form.)

Mike Smith, VP of Employee Training at Sears has said:

“I cannot imagine training tens of thousands of our employees to use cash, verify that it is genuine, and learn to ‘make change’ without making errors. This is going to require a wholesale installation of special change-making hardware – so-called ‘cash registers’ – and millions of dollars of employee training, while creating long lines and delays for consumers. Furthermore, we would need to adopt new security procedures and armed guards to avoid theft of the physical bills while in the store or during transport to our bank. We cannot see ourselves adopting cash under these conditions.”


Perfect tool for criminals
The launch of cash has provoked an immediate reaction from law-enforcement agencies worldwide that universally condemned the development.

Mike Smith, the recently confirmed FBI Director, had this to say:

“‘Cash’ is a 100% anonymous and untraceable payments technology. It is like a weapon of mass destruction launched against law enforcement. It is the perfect payment mechanism for criminals, drug cartels, terrorists, prostitution rings and money launderers. We don’t know how we will be able to combat such a technology and we fully expect that a new generation of super-criminals will emerge, working in the shadows of a world where they can conduct their illicit affairs without leaving a trace.”

Even officials within the banking system have their doubts about the new plan.

Banking Superintendent of New York State Mike Smith said: “I can’t think of any reason that a law-abiding individual would want to use ‘cash’. At a bare minimum, we believe there should be a licensing procedure for individuals or businesses that plan to use cash – a ‘cash license’, as it were.”

This license would limit cash to trustworthy individuals who keep detailed, auditable records of all their cash transactions in order to keep New York safe from criminals, he added.

Others have concerns about forgery and counterfeiting.

“Ultimately, even with all the fancy inks, ‘cash’ is just a piece of paper. We fully expect criminal groups and rogue nation states to print fake cash in order to profit or to disrupt the economies of their enemies,” said Mike Smith, an analyst at Stratfor.

“In the interim, we are certain that cash will trade a discount in the real world, given the risk to a counterparty of accepting a forged piece of paper; no doubt cash is a huge step back from the modern cryptography in place throughout our current financial system.”

<h2 id="yui_3_10_1_1_1392839079391_16876">Consumers unprotected</h2>Though hard to imagine, cash operates with no consumer protection at all. If your ‘bills’ are stolen or lost, they are gone forever.

“I just don’t understand why there is nobody that I can call to reinstate my ‘cash’ if I lose it,” says Mike Smith, a businessman from Toledo. “What type of idiotic wealth and payment system doesn’t maintain transaction and ownership records?”

Moreover, there appears to be no authentication mechanism associated with cash payments or transfers, let alone one that matches modern security standards. Once someone has gained physical control of your ‘bills’, they are free to spend or use them as they wish and there is no way to reverse the transaction, stop them or even identify who has stolen them.

Even simple destruction of a bill, which, as you recall, is just a piece of paper, could result in losses. According to the Director of the newly founded Bureau of Engraving and Printing, mutilated bills that are more than 51% destroyed must be mailed in for a special investigation that will determine if they should be replaced or not.


‘Physical wallets’ reveal security flaw
Proponents of cash have dismissed these concerns saying that various hardware manufacturers, such as Coach and Gucci, will shortly be releasing ‘hardware wallets’ in leather and suede. These wallets are meant to hold the bills and fit into a pocket or purse.

“Once your bills are safely ensconced in your Gucci wallet and securely placed in your pants pocket [the front pocket is recommended as a ‘best practice’ for security], it is almost impossible for them to be stolen, lost or destroyed,” said Mike Smith, VP of Communications for Gucci NA.

Some early adopters, however, have reported that the hardware wallets have security flaws.

“I was out in Bangkok two weeks ago, at a bar, and I forgot my Gucci wallet there,” said Mike Smith, a visiting tourist. “When I returned the next morning, my wallet was there but my cash was gone!”

We contacted Gucci regarding this hacking attack, but a spokesperson would not comment “about confidential customer financial matters”.

Even criminals have not been immune to the risks of cash. The notorious ‘Silk Road’ drug-dealing marketplace mysteriously closed last week, after vendors and customers left envelopes full of cash (on which they had very clearly written their names) in an anonymous drop-box managed by the exchange.

“Theft of the cash due to a bug in the envelope-sealing process,” was cited as the cause.

While technical experts believe that it might be possible that the glue on the envelope was not correctly applied, they also warn that a ‘bill’ is basically a private and public key at the same time, and note that there might be dangers involved in letting anonymous criminals hold the private keys to your wealth.


Physical presence required
In what might be most unusual limitation on cash, it only works for payments within 26 inches or less (the so-called ‘arm’s length transaction’, as hackers in the community have colourfully dubbed it), because it has to be handed from one (human) party to another to execute the transaction.

This requirement for the exchange of cash is widely thought to be a fatal flaw by traditionalists.

Mike Smith, VP of Retail Banking at Chase said:

“A form of payment that cannot be used at a distance, cannot be used for e-commerce, cannot be used by mobile devices, cannot be used for machine-based transactions, or cannot be scripted or programmed, cannot be thought of as a payment system. I will admit, as a form of performance art, ‘cash’ transactions are an amusing experiment, but this has no applicability in the real world of banking, finance or commerce.”

He added: “Furthermore, given cash’s association with criminal activities, we will be refusing to offer banking services and terminating the accounts of any customer that uses cash in a business or personal capacity. It is the only way we can ensure we remain compliant with our regulatory obligations.”

Remarkably, if you attempt to use cash in a different country from the one that issued it, it will categorically be rejected.

In order to use cash abroad, you will have to go to designated points, usually in airports or certain banks, with limited hours of operation, that will ‘exchange’ your bills for others printed by the country that you are visiting.

These ‘exchanges’ have high fees – usually 2-3% for each exchange, meaning that tourist will lose 5% of their cash or more on a typical trip just in these exchange costs. This seems extraordinarily high for what is, ultimately, an exercise in multiplication or division.

<h2 id="yui_3_10_1_1_1392839079391_16890">A step backward for economics</h2>Economists are flabbergasted that lawmakers have allowed cash to be adopted despite their strong objections. A key policy tool of central banks has been the use of positive and negative interest rates to manage economic growth. It appears that this will not be possible with cash.

Mike Smith, a leading economics blogger for the New York Times said: “This is a sad day for macro-economics. If cash ever catches on in any meaningful sense, it will reduce our control over the levers of the economy significantly, by providing a mechanism for depositors to opt out of negative interest rates. Given the fact that it might keep us from preventing the next depression and will definitely reduce tax collections, one could even consider it ‘evil’.”

<h2 id="yui_3_10_1_1_1392839079391_16893">Environmental and health impacts</h2>Environmentalists expressed concerns about the impact of cash on the environment.

Mike Smith, recently appointed Executive Director of the Sierra Club said: “You would have thought that in 2014, we would have moved beyond pesticide- and water-intensive cotton farming [retracted: cutting down trees], treating the cotton with dangerous inks, and transporting it with fossil fuels, only to represent a value, such as ‘20’, that can be represented electronically at effectively no cost to the environment. When will we ever learn?”

Public health officials also warned that cash could be an excellent vector for disease transmission.

“We tested several ‘bills’ in our labs recently and discovered that the average bill has 20 times more bacteria than a toilet seat,” said Mike Smith, Director of Research at the Mayo Clinic. “Our advice is that people should avoid cash in general and only handle it if absolutely necessary.“

“Children, the elderly and immuno-compromised individuals should not handle cash under any circumstances.”

<h2 id="yui_3_10_1_1_1392839079391_16896">What comes next?</h2>Proponents of cash think it will ultimately be a widely adopted technology that will spread around the world, enabling in-person, mid-tier transactions (not micro-payments, but not mega-payments either) in a manner that is invulnerable to electric or Internet outages and that will usher in a new era of more ‘human’ commerce.

We try to keep an open mind at this publication toward new technology, but, to date, we have a hard time seeing the positive case for cash.

Certainly criminal groups will take advantage of cash’s perfect anonymity to wreak havoc on law enforcement and tax collection, something that is deeply undesirable.

Among law-abiding citizens, we can envision some possible adoption in dense urban hipster communities like Williamsburg, where ‘wallets’, ‘cash’ and ‘making change’ could be yet another reflection of their tongue-in-cheek view of modern societal systems.

Other than that, it would be hard to recommend that the average consumer or merchant becomes involved in what is still today a very buggy system, filled with risk, inconvenience, high transaction costs, and possible disease transmission.

Even if handled perfectly, cash will certainly tar your business and personal life with the seedy reputation of the drug dealers, terrorists, money launderers and anti-establishment anarchists who use it today, threatening business and banking relationships, and raising eyebrows among law enforcement and your community.

Originally part of Ledra’s bitcoin series, and published here with permission: ledracapital.com/bitcoin
Ledra bitcoin digest newsletter: ledracapital.com/subscribe
[i]On Twitter: @polemitis and @ledracapital [/i]

Empty wallet, environmental damage and criminal images via Shutterstock

  Forum: Off Topic Chat

pacestick
Posted on: Feb 21 2014, 07:20 AM


Group: Member
Posts: 339

BIg jump yesterday on the six monthly results looks like shorts got burnt
  Forum: By Share Code

pacestick
Posted on: Feb 4 2014, 07:24 AM


Group: Member
Posts: 339

Unilife Corporation Announces Financial Results For Fiscal Year 2014 Second Quarter

YORK, Pa., Feb. 3, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ:UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended December 31, 2013, (the second quarter of Fiscal Year 2014).
Recent Highlights
• In November 2013, Unilife signed a long-term commercial supply contract with Hikma Pharmaceuticals PLC ("Hikma") for the use of Unifill® prefilled syringes with an initial list of 20 generic injectable drugs. Product sales to Hikma will commence in early calendar 2014, with a minimum 175MM units per year to be purchased following a high-volume ramp program. In addition to product sales, Unilife expects to receive $40 million in upfront and milestone payments over the next two years. Unilife received the first payment of $5 million from Hikma during the second quarter of fiscal year 2014. Additional milestone payments have also been received during the third quarter of fiscal year 2014.
• In November 2013, Unilife signed an agreement with MedImmune, the global biologics arm of AstraZeneca, to customize and supply devices from its platform of wearable injectors for use with several target drug candidates from MedImmune's portfolio. Unilife is receiving regular payments from MedImmune under the contract.
• In December 2013, Unilife signed a contract with a global pharmaceutical company seeking to use Unilife's Ocu-ject™ delivery system to deliver a target injectable therapy into the eye. Revenue under the program is scheduled to commence during the third quarter of fiscal year 2014.
• In December 2013, Unilife signed an agreement with Novartis to supply clinical products from one of its platforms of injectable drug delivery systems for use with a targeted early stage pipeline drug. Unilife began to generate revenue under the Novartis under the program during the second quarter of fiscal year 2014. Additional payments are expected as the program continues this calendar year.
• Unilife also continues to receive milestone payments and revenue from other customer programs. This includes $5 million in payments from Sanofi during the first quarter of fiscal year 2014, with an additional $5 million being received during the current third quarter of fiscal year 2014. In total, Unilife has invoiced for more than $20 million since the start of fiscal year 2014, with the majority of that cash having been received since November 2013.
Mr. Alan Shortall, CEO of Unilife, commented: "This has been a strong quarter for Unilife, in which momentum continues to build. Many significant new long-term contracts have been signed with leading pharmaceutical companies including Novartis, MedImmune and Hikma. Milestone payments and revenue are increasing as a result of our execution of these and other customer programs. I expect this pace to continue as additional contracts progressively emerge from our large, expanding commercial pipeline."
Financial Results for Three Months Ended December 31, 2013
Revenue for the three months ended December 31, 2013, was $3.6 million compared to $0.7 million for the same period in 2012.
The Company's net loss for the three months ended December 31, 2013, was $16.3 million, or $0.17 per share, compared to a net loss of $14.6 million, or $0.19 per share, for the same period in 2012. Adjusted net loss for the three months ended December 31, 2013, was $8.3 million, or $0.08 per share, compared to $9.7 million, or $0.12 per share, for the same period in 2012. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization and interest expense.
Unilife reported $6.7 million of total cash and cash equivalents, including restricted cash, as of December 31, 2013. This does not include $6.2 million in cash generated under the Company's ATM facility with Cantor Fitzgerald in January 2014.
  Forum: By Share Code

pacestick
Posted on: Feb 1 2014, 09:45 AM


Group: Member
Posts: 339

The cooper may be atrcating overseas interest
  Forum: Macro Factors

pacestick
Posted on: Jan 24 2014, 06:00 AM


Group: Member
Posts: 339

legal suit against unilife fails to get to court

Unilife Announces Dismissal of Shareholder Class Action Lawsuit






YORK, Pa., Jan. 23, 2014 /PRNewswire/ -- Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS) announced today that a recent shareholder class action lawsuit against the Company and certain corporate officers in the United States District Court for the Middle District of Pennsylvania alleging violations of federal securities laws was voluntarily dismissed by the plaintiff.

The notice of voluntary dismissal was filed by the plaintiff after no additional shareholders of the Company petitioned the court to serve as lead plaintiff in the lawsuit before the December 31, 2013 deadline.

As previously reported, the class action lawsuit was always considered to be frivolous and based mainly on the meritless allegations made by a former employee of the Company.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, intraocular delivery systems and novel delivery systems. Each of these innovative, differentiated technology platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

Investor / PR Contacts (US):

Analyst Enquiries

Investor Contact (Australia)

Todd Fromer / Garth Russell

Lynn Pieper

Jeff Carter

KCSA Strategic Communications

Westwicke Partners

Unilife Corporation

P: + 1 212-682-6300

P: + 1 415-202-5678

P: + 61 2 8346 6500

SOURCE Unilife Corporation

  Forum: By Share Code

pacestick
Posted on: Jan 20 2014, 08:55 PM


Group: Member
Posts: 339

The nasdaq is closed tonight if as can reasonably be expected the sp continues to rise tomorrow the gap between the ASX and the Nasdaq will be another difficulty for the shorts to overcome . That is no cheap way out by buying on the ASX. I for one will not sit up worrying about the poor little shorters . Imagine the carnage if the Nasdaq opens with another contract signed . From memory there is a days delay in transfering between the two exchanges so if a shorter wants to to buy on the asx and places an order tuesday morning they wont be able to access those shares on the Nasdaq before thursday am I right?
  Forum: By Share Code

pacestick
Posted on: Dec 29 2013, 05:06 PM


Group: Member
Posts: 339

frank kellys 12 days of christmas hilarious


http://www.youtube.com/watch?v=NQkF7fpw-wI
  Forum: Off Topic Chat

pacestick
Posted on: Dec 20 2013, 08:52 PM


Group: Member
Posts: 339

smell the fear of shorters they must really be in trouble
  Forum: By Share Code

pacestick
Posted on: Dec 20 2013, 07:34 AM


Group: Member
Posts: 339

frank kellys christmas countdown

http://www.youtube.com/watch?v=NQkF7fpw-wI
  Forum: Off Topic Chat

pacestick
Posted on: Dec 17 2013, 04:32 AM


Group: Member
Posts: 339

and yet another income producing agreement
Unilife Signs Agreement with Global Pharmaceutical Company Seeking to Use Ocu-Ject™ to Deliver a Drug into the Eye

Ocu-ject provides a tenfold improvement in the precision of delivering doses as small as 10 microliters

YORK, Pa., Dec. 16, 2013 /PRNewswire/ -- Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS) today announced the signing of an agreement with a global pharmaceutical company seeking to use the Unilife Ocu-jectâ„¢ ocular drug delivery system to deliver a target injectable therapy into the eye.

The identity of the global pharmaceutical company, one of the market leaders in ophthalmic therapies, as well as other terms of the agreement are not disclosed for commercial purposes and due to confidentiality requirements. Unilife will begin to generate revenue under the program in January 2014.

Unilife's Ocu-ject platform offers a breakthrough technology for the accurate and precise delivery of small dose volumes measured in microliters (uL) into the eye. Most ocular therapies for the treatment of conditions such as age-related macular degeneration, diabetic retinopathy, and diabetic macular edema are administered via intravitreal injection using a standard 1mL tuberculin syringe and needle. The potential for gross dosing inaccuracy is inherent with such conventional devices, which can compromise the ability of the drug to fully comply with its regulatory labeling requirements. Ocu-ject provides a tenfold improvement in the precision of delivering doses as small as 10 uL, which helps pharmaceutical customers ensure compliance with dose requirements on the drug label.

Mr. Alan Shortall, Chairman and CEO of Unilife said: "In tune with our commitment to address unmet needs within the pharmaceutical industry, we have created a new, significant drug delivery device category. Ocu-ject represents a game-changing delivery technology for ocular therapies, which is a large, fast-growing segment of the pharmaceutical market. We are pleased to have signed our first agreement for the Ocu-ject device platform, which is being pursued by a number of pharmaceutical companies seeking to maximize the clinical and commercial potential of approved and pipeline drugs that are targeted to treat a number of eye disorders. We look forward to serving these customers to address unmet market needs for the accurate, precise delivery of drugs to the eye."

About Ocu-jectâ„¢
The Ocu-ject device platform is designed to deliver drugs with small dose volume of between 10 microliters and 500 microliters for delivery into the eye with a level of accuracy and precision not possible with conventional syringes. It is designed for use with injectable therapies designed to treat diseases including Age-related Macular Degeneration (AMD), Diabetic Retinopathy, Diabetic Macular Edema and Uveitis. By minimizing over-dosing, the device platform has the potential to reduce the risk of increased intraocular pressure (IOP) and potentially minimize damage to the optic nerve. By further minimizing the risk of under-dosing, the platform has the potential to help avoid delivery of a drug outside its therapeutic window where its clinical efficacy may be compromised. The Ocu-ject platform also employs the highest grade drug contact materials unlike syringes currently used to inject into the eye.

To address specific customer, drug, and patient requirements, products from the Ocu-ject platform can be customized in a variety of configurations including prefilled, with either an attachable or integrated retractable needle, or for use with a drug vial. They are designed for intuitive use by clinicians, employ ergonomic features and have the potential to minimize patient pain and maximize safety.
  Forum: By Share Code

pacestick
Posted on: Dec 2 2013, 06:41 AM


Group: Member
Posts: 339

twelve month high with more to come
  Forum: By Share Code

pacestick
Posted on: Nov 28 2013, 06:27 AM


Group: Member
Posts: 339

looks set bto break above 80 cents and move to 1 dollar before end of year
  Forum: By Share Code

pacestick
Posted on: Nov 21 2013, 09:55 AM


Group: Member
Posts: 339

now at 71 cents up 40%
  Forum: By Share Code

pacestick
Posted on: Nov 21 2013, 05:56 AM


Group: Member
Posts: 339

Unilife Signs Long-Term Supply Agreement with Hikma to Enhance Delivery of Generic Injectables

Unilife to receive $40MM in upfront and milestone payments
15-year supply agreement to launch initial 20 generic injectable drugs in syringes from Unifill platform
Unilife to begin commercial supply in FY 2014, annual minimum unit volume to exceed 175MM





YORK, Pa., Nov. 20, 2013 /PRNewswire/ -- Unilife Corporation ("Unilife") (NASDAQ: UNIS, ASX: UNS) today announced the signing of a long-term commercial supply contract with Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) for the use of Unifill® prefilled syringes with a range of generic injectable drugs.

Under the 15-year global agreement, Unilife will supply Hikma with customized prefillable delivery systems from its Unifill® platform, including the Unifill syringe and the Unifill Nexus™ ("Unifill products").

Hikma has selected an initial list of 20 of its generic injectable products to be used with Unifill products. Unilife has granted Hikma exclusive global rights to its Unifill products for use with these specific generic injectable products. Additional injectable drugs may also be added to the exclusivity list subject to agreement by both parties.

Unilife will commence product sales to Hikma in early 2014. Under the terms of the contract, Unilife will supply Hikma a minimum volume of 175MM units per year following a rapid high-volume ramp up period.

In addition to product sales, Hikma will pay Unilife $40 million in upfront and milestone payments. An initial upfront payment of $5 million will be paid to Unilife immediately, with an additional $15 million in payments expected during 2014. The final $20 million in milestone-based payments will be paid the following year.

Market demand for generic injectables is rapidly shifting from vials to prefilled syringes. However, conventional prefilled devices prevent universal attachment with any ISO standard needle hub or IV connector and are also associated with patient safety risks, including spontaneous disconnection and the leakage or occlusion of medication. The superior design of Unilife's Unifill Nexus addresses these issues and is expected to rapidly become the preferred choice to deliver generic injectable drugs.

Mr. Said Darwazah, Chief Executive Officer of Hikma, stated: "This agreement supports our strategy of developing higher value products and we are extremely pleased to be partnering with Unilife to develop our generic injectables capabilities. We look forward to leveraging Unilife's innovative platform of Unifill syringes to differentiate our injectable products and to increase our market share."

Mr. Alan Shortall, Chief Executive Officer of Unilife, stated: "Unilife has developed a full range of innovative and highly differentiated syringes under our Unifill platform to accommodate the needs of all prefilled biologics, drugs and vaccines. This strategic partnership with Hikma enables us to rapidly penetrate the large and fast-growing market for generic injectables. Hikma is one of the world's fastest growing pharmaceutical companies, and a top three supplier by volume in the $7 billion U.S. market for generic injectables. Together with our recently announced long term supply contract with Sanofi, this partnership with Hikma instantly positions Unilife to become one of the largest suppliers of prefilled syringes in the world."

The Unifill® Platform

Unilife has developed an extensive proprietary platform of prefilled syringes under its Unifill® brand. Unifill is the world's first and only known platform of prefilled syringes with automatic and fully integrated needle retraction. Designed for intuitive use by healthcare workers or self-injecting patients, an audible, tactile click signals the injection of the full dose and the automatic activation of the needle retraction mechanism. Users can control the speed of needle retraction directly from the body into the syringe barrel by relieving thumb or finger pressure on the plunger to eliminate the risk of needlestick injuries or the aerosolization (splatter) of blood or tissue residue. Unifill syringes are compatible with standard filling and packaging processes, with USP compliant materials in the primary drug container.

The Unifill Nexusâ„¢

The Unifill Nexus is a glass prefilled syringe that can be universally attached to ISO standard needless luer access devices (NLADs). The Unifill Nexus is designed to address patient safety concerns relating to the reported malfunction, breaking or clogging of some conventional glass prefilled syringes when attached to NLADs. Unlike some other needleless prefilled syringes, it features an ISO standard luer lock tip that is designed for universal attachment onto standard needle hubs and IV connectors and prevents the risk of spontaneous disconnection or leakage of medication. Like other syringes within the Unifill platform, the Unifill Nexus is compatible with standard filling and packaging processes and has USP compliant materials in the primary drug container.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, intraocular delivery systems and novel devices. Each of these innovative, differentiated technology platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

About Hikma

Hikma Pharmaceuticals is a fast growing multinational group focused on developing, manufacturing and marketing a broad range of both branded and non branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectable" and "Generics" based principally in the Middle East and North Africa (MENA) region, where it is a market leader, the United States and Europe. In 2012, Hikma achieved revenue of US$1,108.7 million and profit attributable to shareholders of US$100.3 million.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

Investor / PR Contacts (US):

Analyst Enquiries

Investor Contacts (Australia)

Todd Fromer / Garth Russell

Lynn Pieper

Jeff Carter

KCSA Strategic Communications

Westwicke Partners

Unilife Corporation

P: + 1 212-682-6300

P: + 1 415-202-5678

P: + 61 2 8346 6500



SOURCE Unilife Corporation

  Forum: By Share Code

pacestick
Posted on: Nov 12 2013, 07:27 AM


Group: Member
Posts: 339

Quarterly figures have improved and look like they are going to continue to do so

YORK, Pa., Nov. 11, 2013 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ:UNIS; ASX: UNS), a developer and supplier of injectable drug delivery systems, today announced its financial results for the quarter ended September 30, 2013, (the first quarter of Fiscal Year 2014).

Recent Highlights

  • In September 2013, Unilife announced the signing of a long-term supply contract with Sanofi. Unilife has agreed to supply Sanofi with the Unifill Finesseâ„¢, a customized device from its Unifill® platform of prefilled syringes with automatic, needle retraction, for use with the anti-thrombotic therapy Lovenox®/Clexane®. The contract period can extend up to 2024. In October 2013, Unilife received the first $5 million payment from Sanofi under the commercial supply agreement. Revenue from this payment has not yet been recognized, and was recorded as deferred revenue in the September 30, 2013 balance sheet.
  • Earlier today, Unilife announced another cornerstone agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to customize and supply devices from its platform of wearable injectors. Under this agreement, Unilife will supply MedImmune with customized devices from its platform of ReadyToGoâ„¢ wearable injectors. Several drug candidates from MedImmune's portfolio may be selected for use with Unilife's wearable injectors under the agreement. Unilife begins generating revenue starting in Q1 FY14 on the basis of customization and supply of its products to MedImmune.
  • Unilife continues to accelerate the expansion of its customer base, and has multiple customers in its commercial pipeline. Information regarding each customer partnership will be announced when it can be disclosed.
Mr. Alan Shortall, CEO of Unilife, commented: "As I have said all along, fiscal year 2014 is the inflection point for Unilife when we begin to show rapidly increasing revenue. As such, we reported revenue of $3.2 million in the first quarter of Fiscal Year 2014, which is an increase of 360% over the same quarter in the prior year. Although the comparison is against a small base, it is significant in that it shows the inflection point in our revenue. From here, I expect the slope to be significant.

"As we continue to increase our investment in R&D and operations, which is increasingly offset by our revenue, we are also narrowing our operating loss. As such, we have reported a 10% decrease in operating loss for the first quarter compared with the prior year period. The loss per share has narrowed by 25% to $0.12, compared with the prior year period. I anticipate sequential quarterly growth in Fiscal Year 2014, as well as significant annual growth this fiscal year and beyond.

"We are focused on rapid and significant growth in the long-term. To accomplish this, we will continue to increase our investment in R&D and operations, much of which will be offset by our increasing revenue. I am pleased with the results we are getting from our investment in these areas. A look at the breadth and quality of our product portfolio on our website shows how far we have come over the last two or three years. Although we can be cash flow positive this year, if we wanted to do so, it is not in the best long term interest of our shareholders. This is because limiting our investment in R&D today can dampen the growth we anticipate in 2017 and beyond," Mr. Shortall concluded.

Financial Results for Three Months Ended September 30, 2013

Revenue for the three months ended September 30, 2013, was $3.2 million compared to $0.7 million for the same period in 2012.

The Company's net loss for the three months ended September 30, 2013, was $11.2 million, or $0.12 per share, compared to a net loss of $12.5 million, or $0.16 per share, for the same period in 2012. Adjusted net loss for the three months ended September 30, 2013, was $7.1 million, or $0.08 per share, compared to $9.1 million, or $0.12 per share, for the same period in 2012. Adjusted net loss excludes non-cash share-based compensation expense, depreciation and amortization and interest expense.

Unilife reported $9.4 million of total cash and cash equivalents, including $2.0 million in restricted cash as of September 30, 2013. This does not reflect the first $5 million payment from Sanofi under the commercial supply agreement, which was received in October 2013.

Conference Call Information

Management has scheduled a conference call for 4:30 p.m. U.S. EST on Monday, November 11, 2013, (Tuesday, November 12, 2013 at 6:30 a.m. AEDT), to review the Company's financial results, customer partnerships and future outlook. The conference call and accompanying slide presentation will be broadcast over the Internet as a "live" listen-only Webcast. An archive of the presentation and webcast will be available for 30 days after the call. To listen, please go to: http://ir.unilife.com/events.cfm.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio of proprietary technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel systems. Each of these innovative and highly differentiated platforms can be customized to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

Non-GAAP Financial Measures

U.S. securities laws require that when we publish any non-GAAP financial measure, we disclose the reason for using the non-GAAP measure and provide reconciliation to the most directly comparable GAAP measure. The presentation of adjusted net income (loss) and adjusted net income (loss) per share are non-GAAP measures. Adjusted net income (loss) represents net income (loss) calculated in accordance with U.S. GAAP as adjusted for the impact of share-based compensation expense, depreciation and amortization and interest expense.

Management believes the presentation of adjusted net income (loss) and adjusted net income (loss) per share provides useful information because these measures enhance its own evaluation, as well as investor's understanding, of the Company's core operating and financial results. Non-GAAP financial measures should be considered in addition to results prepared in accordance with GAAP, but should not be considered a substitute for, or superior to, GAAP results. A reconciliation of net income (loss) to adjusted net income (loss) is included in the attached table.

General: UNIS-G




Investor Contacts (US):

Analyst Enquiries

Investor Contacts (Australia)

Todd Fromer / Garth Russell

Lynn Pieper

Jeff Carter

KCSA Strategic Communications

Westwicke Partners

Unilife Corporation

P: + 1 212-682-6300

P: + 1 415-202-5678

P: + 61 2 8346 6500



  Forum: By Share Code

pacestick
Posted on: Nov 12 2013, 04:41 AM


Group: Member
Posts: 339

Unilife Announces Supply Agreement with MedImmune for Wearable Injectable Drug Delivery Devices






YORK, Pa., Nov. 11, 2013 /PRNewswire/ -- Unilife Corporation (NASDAQ: UNIS, ASX: UNS), a U.S. based designer, developer and manufacturer of injectable drug delivery systems, today announced an agreement with MedImmune, the global biologics research and development arm of AstraZeneca, to customize and supply devices from its platform of wearable injectors for use with molecules in MedImmune's pipeline.

Under this agreement, Unilife will supply MedImmune with customized devices from its platform of ReadyToGoâ„¢ wearable injectors. Several drug candidates from MedImmune's portfolio may be selected for use with Unilife's wearable injectors under the agreement.

Mr. Alan Shortall, Chief Executive of Unilife, said, "This is the dawn of a new era for injectable drug delivery where a very sophisticated new class of wearable, disposable devices will allow patients to deliver the most advanced therapies with maximum comfort and convenience. I am delighted that Unilife is setting the standard in serving biotech customers, such as MedImmune, and their patients within this category."

"We are pleased that MedImmune selected Unilife's technology after conducting a thorough evaluation process to identify simple and convenient wearable injectors that can be used to administer an injectable therapy wherever the patient is," Mr. Shortall concluded.

Unilife will generate revenue starting in the first quarter of fiscal 2014 on the basis of the customization and supply of its products to MedImmune. Additional terms of the contract have not been disclosed.

The wearable injection category is expected to generate device sales in excess of $3 billion within five to seven years.

Conference Call Information

Unilife is hosting its quarterly earnings conference call at 4:30 p.m. U.S. EST today, during which the Unilife management team will review its financial results for the quarter ended September 30, 2013, this contract, other commercial partnerships and its future outlook. To listen, please go to: http://ir.unilife.com/events.cfm.

About the ReadyToGo Wearable Injectors

The Unilife portfolio of ReadyToGo wearable injectors is a game-changing platform that addresses the unmet needs of biotech customers in delivering high-dose volume therapies wherever the patients are. The ReadyToGo wearable injectors are supplied to the patient prefilled with the drug and ready-for-injection with no extra steps or parts required. Only three simple steps are required to inject the dose: peel, stick, click, with an on-body safety interlock, a Flexwearâ„¢ comfort catheter and an electronic user interface among an array of features that maximize patient comfort and awareness during all stages of use. The devices are designed to minimize disruption to a patient's normal daily lifestyle during the period of dose delivery.

The ReadyToGo wearable injectors are designed for integration with standard filling processes, utilize standard materials in the primary drug container and require no terminal sterilization. A fully programmable delivery regimen allows the bolus, basal or variable rate of dose delivery to be customized to specific customer, therapy and patient requirements. The electronics in the device can be easily detached and disposed for markets that require special electronics disposal procedures. A video of Unilife's platform of wearable injectors can be viewed on the Unilife website at http://bit.ly/19MYWTA.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel devices. Each of these innovative, differentiated platforms can be customized by Unilife to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

Investor and PR Contacts (US):

Analyst Enquiries

Investor Contacts (Australia)

Todd Fromer / Garth Russell

Lynn Pieper

Jeff Carter

KCSA Strategic Communications

Westwicke Partners

Unilife Corporation

P: + 1 212-682-6300

P: + 1 415-202-5678

P: + 61 2 8346 6500



SOURCE Unilife Corporation

You are subscribed to Unilife Corporation Investor Relations' e-mail alerts as calder@wix.com.au.

To update your e-mail and alert preferences, please click here.
To unsubscribe, please click here.

Unilife Corporation
250 Cross Farm Road , York, PA 17406
Service provided by Shareholder.com
  Forum: By Share Code

pacestick
Posted on: Nov 6 2013, 05:41 PM


Group: Member
Posts: 339

very high silver values at cato

KRC_ASX_Surface_Assays_Catto_6Nov13_FINAL.pdfKRC_ASX_Surface_Assays_Catto_6Nov13
_FINAL.pdf
  Forum: By Share Code

pacestick
Posted on: Nov 6 2013, 02:03 AM


Group: Member
Posts: 339

http://www.asx.com.au/asxpdf/20131104/pdf/42kmcdd5hc178w.pdf

new mineralisation intersected at Cato.

However the more light should be thrown on the scene to help see what KRC is sitting on when the assay results are returned. Although not stated by the company I gain the impression that they will come back as each sample is finished with and not wait for one final summary
  Forum: By Share Code

pacestick
Posted on: Oct 30 2013, 05:43 PM


Group: Member
Posts: 339

http://www.brrmedia.co.uk/event/preview/kh4apepbhq/117160

recent presentation in london
  Forum: By Share Code

pacestick
Posted on: Oct 30 2013, 03:23 PM


Group: Member
Posts: 339

http://www.proactiveinvestors.com.hk/marke...me-project.html

This article sums up recent positive activity
  Forum: By Share Code

pacestick
Posted on: Sep 21 2013, 04:56 PM


Group: Member
Posts: 339

http://www.youtube.com/watch?v=ooPy8tX3h94

sadly linda was recently diagnosed with parkinsons . She has sent a message to the world to keep on singing


http://www.youtube.com/watch?v=ooPy8tX3h94
  Forum: Off Topic Chat

pacestick
Posted on: Sep 10 2013, 06:13 AM


Group: Member
Posts: 339

Unilife Signs Long-Term Supply Contract with Sanofi for the Use of Unifill® Syringes with Lovenox®

Unilife grants Sanofi long-term exclusivity subject to Sanofi purchasing 150 million Unifill syringes per year following a four-year ramp-up
Unilife to receive a minimum of $5 million and up to $15 million in milestone-based payments





YORK, Pa., Sept. 9, 2013 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS), a U.S. based designer, developer and manufacturer of injectable drug delivery systems, today announced the signing of a long-term supply contract with Sanofi.

Unilife has agreed to supply Sanofi with the Unifill Finesse™, a customized device from its Unifill® platform of prefilled syringes with automatic, needle retraction, for use with the anti-thrombotic therapy Enoxaparin Sodium sold under the brand names Lovenox® and Clexane® ("Lovenox"). The contract period can extend up to 2024.

Unilife has granted Sanofi the exclusive use of the Unifill Finesse with anti-thrombotic drugs during the contract period. Following a four year ramp-up period after market entry, exclusivity will be maintained, subject to Sanofi purchasing a minimum of 150 million units of the Unifill Finesse or other Unifill syringes per year.

Unilife can supply its Unifill syringes, including the Unifill Finesse, to additional customers in all other therapeutic classes outside of anti-thrombotics.

In addition to future revenue from the sale of Unifill Finesse syringes, Unilife may receive up to $15 million from Sanofi in milestones based payments with $5 million of these payments expected in 2013.

This supply contract replaces and supersedes all other agreements previously signed between both parties regarding the Unifill syringe platform. For commercial purposes and due to confidentiality clauses in the Agreement, additional terms of the contract are to remain confidential.

Comments by Alan Shortall, CEO of Unilife

"Our Unifill syringes set a new standard for the delivery of all prefilled biologics, drugs and vaccines. Like other game-changing products in our broad device portfolio, the distinctive visual, safety and functional benefits of Unifill can be leveraged by pharmaceutical customers to enhance and differentiate their injectable therapies. We thank the Sanofi Industrial organization for their innovative vision and their support, and look forward to a long-term partnership."

"The signing of this supply contract reaffirms the business model we have worked so hard in pursuing. The long-term contract provides the customer with continuity of supply. The provision of exclusivity within a drug class also provides the customer with an opportunity to leverage our device's competitive advantages to drive user preference and differentiate their drug brands against competitors," Mr. Shortall concluded.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, ocular delivery systems and novel devices. Each of these innovative, differentiated platforms can be customized by Unilife to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

About Unifill Syringes

Unifill is the world's first and only known platform of ready-to-fill (prefilled) syringes with automatic, user-controlled and fully integrated needle retraction. With USP compliant materials in the primary drug container and supplied as per standard filling and packaging processes, Unifill syringes eliminate the need for bulky ancillary safety products which can increase transportation, packaging, and storage costs for prefilled drugs by up to 70%.

Designed for safe, simple, and convenient use by healthcare workers or self-injecting patients, an audible, tactile click signals full dose delivery and the automatic activation of the needle retraction mechanism. Operators can control the speed of needle retraction directly from the body into the syringe barrel to eliminate needlestick injuries or aersolization (splatter). The plunger is automatically locked after retraction to prevent product re-use or needle re-exposure, and encourage compact, convenient disposal.

Each product within the Unifill platform can be customized to address specific customer, therapy or target patient needs. Configurations from the Unifill platform include the Unifill Selectâ„¢ with attachable, retracting needles, the Unifill Assureâ„¢ for the patient self-administration of viscous biologics and the Unifill Finesseâ„¢. Unifill syringes are manufactured at Unilife's production facilities in York, Pennsylvania.

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

  Forum: By Share Code

pacestick
Posted on: Aug 18 2013, 05:35 PM


Group: Member
Posts: 339

Reminds me of the old story about the compulsory religious observance in the Army
At the time it was compulsory to give a religous affililiation and attend the relevant services on sundays

The choices wee R.C.. C of E, and OD that is roman catholic , church of England , other denominations New recruits filled out a card saying which and were each sunday morning marched off to services
A new recruit wanting to avoid the lot wrote in his card sun worshipper expecting to be able to get sunday morning off
Much to his surprise he was awaken at 5.30 on sunday morning by the RSM
OK laddie your Deity is about to come over the horizon I expect you out on the parade ground performing your religous rituals in order to great him
  Forum: Off Topic Chat

pacestick
Posted on: Aug 15 2013, 06:47 PM


Group: Member
Posts: 339

drillsearch 2p reservess jump 157%

http://www.drillsearch.com.au/sites/defaul..._28.5_mmboe.pdf

should jump a bit over the next few trading days
  Forum: By Share Code

pacestick
Posted on: Jul 18 2013, 06:44 AM


Group: Member
Posts: 339


Unilife: Taking Positions Ahead Of A Key Fiscal Year
Jul 17 2013, 07:32 | about: UNIS, includes: BIOD Disclosure: I am long UNIS. (More...)

On Friday, July 12, we spoke with Stephen Allan, Unilife's (UNIS) Vice President of Marketing & Communications to receive his take about the company's current commercial initiatives and an update about the company's finances and strategy. Our conversation left us convinced that Unilife's long-term potential remains intact, and that fiscal 2014, which covers the 2nd half of 2013 and first half of 2014, will be a meaningful period for Unilife, and one through which investors should maintain exposure to the company.

Commercial Developments & Market Opportunity

Stephen Allan reiterated Unilife's November 2012 guidance (presented at its annual meeting) that it will generate revenue from 12 different programs in calendar 2013, and in April, Unilife inked a contract with Biodel (BIOD) to utilize its EZMix dual-chamber devices for use in Biodel's glucagon rescue device. In June, Biodel announced that it plans to submit its NDA to the FDA in 2015. Of note is the fact that this is a 15-year contract, whereas the typical medical device contract usually lasts for much less, perhaps 2-3 years. The deal between Biodel and Unilife gives Biodel exclusive access to EZMix for this glucagon device, but as Stephen Allan noted, does not preclude Unilife from partnering with other companies in the area of severe hypoglycemia treatment, only from partnering with companies that wish to develop identical versions of Biodel's platform. In addition, Unilife is set to receive royalties on sales of this glucagon rescue device, which is likely to meaningfully expand the market. Biodel estimates that the total market for glucagon rescue totals just $125 million in the United States, despite the fact that over 200,000 people are hospitalized each year due to severe hypoglycemia. Market growth is restrained due to the complexity of existing rescue kits, something that Biodel believes will be resolved by the use of Unilife's EZMix platform, which will automatically reconstitute lyophilized glucagon, and includes automatic, user-controlled needle retraction. It is likely that this is the contract that Unilife announced in early April; the company disclosed that this was a 15-year contract for the EZMix platform, but did not disclose the identity of the customer (more on this issue in general a bit later). At the time, Unilife estimated that the total value of this contract would be $110 million over the course of 15 years, and includes $6 million in payments by April 2014. Stephen Allan stated that Unilife has already begun generating revenue from this deal, and we expect more detail when the company reports its Q4 2013 results, most likely in late July or early August.




http://seekingalpha.com/article/1552242-un...ar?source=kizur


  Forum: By Share Code

pacestick
Posted on: Jul 4 2013, 09:08 AM


Group: Member
Posts: 339

two significant announcements in 24 hours

http://www.drillsearch.com.au/sites/...Wet_Gas_JV.pdf
In which Drillsearch and Santos form joint venture
and the positive monthly drilling update for june
http://www.drillsearch.com.au/compan...port-june-2013
  Forum: By Share Code

pacestick
Posted on: Jun 29 2013, 03:56 AM


Group: Member
Posts: 339

http://www.proactiveinvestors.com.au/compa...tion-44936.html

Drillsearch Energy www.drillsearch.com.au

Drillsearch Energy (ASX: DLS) is primarily focused on the Cooper-Eromanga Basins in Australia.

inShare Email
Drillsearch Energy doubles Cooper Basin oil production
Thursday, June 27, 2013 by Bevis Yeo

Drillsearch Energy (ASX: DLS) has nearly doubled oil production from the PEL 91 Joint Venture in the Cooper Basin since the Bauer-to-Lycium export pipeline was commissioned in late April 2013.

For the week of 17 June 2013, gross daily production and export from PEL 91 averaged 10,300 barrels per day of oil, or 6,180bpd net to Drillsearch.

This compares to the company’s net oil production of 3,200bpd from the permit at the time of the pipeline’s commissioning.

Drillsearch added that at this current rate, it is on track to confirm its oil production exit forecast to 30 June 2013 of about 6,000bpd.

The company holds a 60% interest in PEL 91 while operator Beach Energy (ASX: BPT) holds 40%.



Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

  Forum: By Share Code

pacestick
Posted on: Jun 17 2013, 10:28 PM


Group: Member
Posts: 339

THIS LETTER WAS RELEASED BY THE COMPANY IN RESPONSE TO AN ASX QUERRY

June 17, 2013
Dear Unilife stockholders
I am pleased to advise that multiple deals with pharmaceutical customers relating to our Unifill® platform and other game-changing technologies are now either complete or in the final stages of negotiation.
We have successfully completed negotiations with a global pharmaceutical company for a major long-term
supply contract for the Unifill syringe as referred to during our last earnings call. I can advise that this
contract is finalized with all terms having been agreed upon by both parties. The formal process of having
the execution copy of the contract signed is now taking place, and we have been advised by the customer
that it may require an additional few days or weeks to complete. While this process is taking slightly longer
than both parties originally anticipated, it is understandable given the size of the Company and the number
of steps involved.
I share the eagerness of many of our stockholders regarding this upcoming news, which I believe will
accelerate our commercial progress. However I am also not concerned about one contract with one
customer taking a little longer to announce than expected. Our focus is to build long term partnerships with a
diversified customer base and deliver substantial revenue and sustainable growth over coming years. In that
regard, I am very pleased with the fundamentals of our Company and excited about our future. I would
therefore like to take this opportunity to update you on some other significant commercial developments.
We expect to finalize negotiations with several additional pharmaceutical companies relating to our Unifill
platform of syringes this calendar year. I believe that some of these upcoming agreements have the
potential to be of equal or even greater financial magnitude than the contract I referred to above. In parallel,
we are also continuing to supply Unifill syringes to a number of other pharmaceutical companies who are
conducting human factor studies, drug compatibility studies and fill-finish integration studies. In each case,
the customer’s goal is to commercialize their drugs in various configurations from our Unifill platform. For
example, I can advise that batches of Unifill syringes will be delivered to four separate pharmaceutical
companies this week alone.
We must also not forget our first supply contract for the Unifill syringe that was signed last year, under which
we are supplying the product to a customer for use with a generic injectable drug in the autoimmune
therapeutic class. Significant commercial revenue and exclusivity fees are expected to begin under this
seven year contract during fiscal year 2014.
However Unilife is not a one product company. In recent years, our investments in R&D have created the
most expansive and highly differentiated portfolio of injectable drug delivery systems in the world. Our
proprietary technology platforms today span prefilled syringes, auto-injectors, wearable injectors,
reconstitution systems, intraocular delivery systems and specialized devices. Commercial negotiations
regarding customization programs and commercial supply contracts are now underway with multiple
pharmaceutical companies for more than a dozen products across these six platforms.

In April 2013, we announced our first long-term contract for the EZMixâ„¢ dual-chamber syringe, a gamechanging
system for the reconstitution and mixing of liquid or dry drug combinations. We have already
begun to generate revenue under the 15-year contract, and will be conducting user evaluation studies with
the customer this week. With the EZMix requiring only one intuitive step for reconstitution, we expect our
product will play a key role in differentiating their drug from the competition to rapidly secure market share
within this fast-growing market. We therefore look forward to the commercial launch of this product, targeted
for filing with the FDA in 2015, where, in addition to revenues from the sales of the EZMix syringe, we will
also share in their net drug sales via the receipt of exclusivity and royalty fees.
This customer is one of more than 15 pharmaceutical companies now pursuing products from within our
EZMix platform. Given the revolutionary nature of this proprietary technology, I can advise that many of
these prospective customers desire exclusivity to our EZMix products for use with a target drug. Having now
been informed by several customers that they have selected EZMix for use with target drugs, we look
forward to the finalization of some exciting agreements over the coming year.
Another significant area of commercial opportunity for Unilife relates to our wearable injectors (also known
as patch pumps or bolus injectors) for the subcutaneous delivery of long-duration or large volume drugs.
Several pharmaceutical companies have now advised us of their selection of our wearable injectors for use
with target programs that each includes up to seven pipeline drug candidates. In each case prior to our
selection, the pharmaceutical company conducted extensive evaluations comparing our wearable injectors
against competitor devices. This market sector is poised to experience hyper-rates of growth over the
coming decade, and we are considered to be the clear market leader by our customers.
We will begin to recognize revenue via customization programs and product sales for our wearable injectors
from several customers throughout fiscal year 2014. Many of these companies have also requested
exclusivity rights for a target therapy.
Significant progress is also being made with a multitude of other pharmaceutical customers seeking access
to additional products within our portfolio including the RITAâ„¢ disposable auto-injector, the LISAâ„¢ reusable
injector, Depot-jectâ„¢, Ocu-jectâ„¢ and Micro-jectâ„¢. Furthermore, I am pleased to advise that we have
successfully completed the first phase of a clinical development program announced in 2011 with a global
pharmaceutical company for our specialized device that will deliver a novel drug directly into a target organ.
The next program phase is now underway with additional revenue to be recognized in 2014.
With so many programs with so many customers now accelerating rapidly in parallel, a steady progression
of transformational, revenue-generating announcements can be expected between now and the end of the
calendar year. Together, I expect these upcoming agreements will herald our emergence as the new global
leader for injectable drug delivery. We remain fully on track to achieve our business milestones for calendar
year 2013 and beyond. Thank you for your continued support.
Yours sincerely
Alan Shortall
  Forum: By Share Code

pacestick
Posted on: Jun 16 2013, 07:08 AM


Group: Member
Posts: 339


http://www.proactiveinvestors.com.au/companies/news/43678/china-import-ban-on-low-grade-coal-becomes-clearer-43678.html





China import ban on low grade coal becomes clearer
Friday, May 24, 2013 by Proactive Investors

China's proposed ban on the import of lower grade thermal coal is becoming clearer after Platts has published the draft regulation.

This month, China's National Energy Administration (NEA) said it was proposing imports of thermal coal should have a calorific value of at least 4,540 kcal/kg on a net-as-received basis, a maximum sulfur content of 1%, and a maximum limit for ash of 25% on an as-received basis.

It did not include any detail on total moisture. NEA is a government body that promulgates energy policy in China.

The reasons given by the NEA for its ban on some coal imports was to better regulate the production and distribution of coal products in China.

Another reason given by the NEA for its regulation was that it wanted to improve the utilization of cleaner coal products in China, given the continued smoggy weather in northern China.

It is understood there was no time frame given for how long the edict would remin in place or when the ban would commence.

Domestically produced metallurgical coal would also not escape the net as it the regulation would mean this coal would have a maximum ash content of 12%, a maximum total moisture content of 12%, and a maximum sulfur content of 1.75%.

The ban if put in place would have significant ramifications for coal miners and explorers globally.

  Forum: Macro Factors

pacestick
Posted on: Jun 8 2013, 10:37 AM


Group: Member
Posts: 339

http://www.youtube.com/watch?v=J6TcpfBHlbs

Ray stevens view on Q.E.
  Forum: Off Topic Chat

pacestick
Posted on: Jun 7 2013, 06:42 AM


Group: Member
Posts: 339

<h1 itemprop="headline">Biodel Plans To Submit NDA To FDA In 2015 For Novel Glucagon Rescue Device</h1> By RTT News, June 06, 2013, 06:13:00 AM EDT Vote up



(RTTNews.com) - Biodel Inc. ( BIOD ) announced that it plans to submit a New Drug Application or NDA to the FDA in 2015 for a novel glucagon rescue device to treat severe hypoglycemia.

The company said it expects to select a final formulation of its novel glucagon therapy and appoint a contract manufacturing partner during the current calendar quarter. Previously Biodel signed a long-term commercial supply agreement for bulk glucagon.

The submission of an Investigational New Drug application to the FDA is expected during the next 12 months. Initiation of a pivotal clinical study is expected to occur during the second half of 2014, putting the company in a position to file an NDA to the FDA under the 505(b)(2) regulatory pathway in 2015, the company said.

In preparation for the anticipated regulatory filing and commercial launch of its glucagon rescue product, Biodel has signed a 15-year supply agreement with Unilife Corporation for a customized proprietary device from its EZMix platform of dual-chamber devices with worldwide exclusivity for use with glucagon.

According to the company, the device has been customized for convenient portability and ease of use to enable rapid treatment during emergency situations with little to no training. The device automatically reconstitutes lyophilized glucagon when prepared for injection and features automatic, user-controlled retraction of the needle upon full dose delivery, virtually eliminating dosing errors and the risk of needle stick injuries.

For comments and feedback: contact editorial@rttnews.com

http://www.rttnews.com


This article appears in: News Headlines
Referenced Stocks: BIOD, UNIS



Read more: http://www.nasdaq.com/article/biodel-plans...6#ixzz2VTDV9tUz
  Forum: By Share Code

pacestick
Posted on: Jun 4 2013, 07:59 AM


Group: Member
Posts: 339

The short term depends on whether shortall backs up his cc statement re contract with an actual signing before he presents at the Jeffries If not his credibility is absolutley ruined At the question time he will be burnt to a nuclear waste Even tho I for one believe that the part of the statement at the cc that said the contract is complete and only waiting signing is accurate
  Forum: By Share Code

pacestick
Posted on: May 25 2013, 11:57 AM


Group: Member
Posts: 339

Not surprising with a significant announcement due my guess is between 30 may and 8 JUne
  Forum: By Share Code

pacestick
Posted on: May 23 2013, 07:51 AM


Group: Member
Posts: 339

<h1 class="title entry-title" itemprop="name"> $UNIS - Analyst Updates in Case you missed them </h1> Ladenburg
Subject: UNIS: Company Reports Another Financially Lackluster Quarter (Q3-2013) But That They Will Soon Announce a New Large Multi-Year Unifill Contract. Reiterating Buy Rating and Price Target of $4.75.
Please click on the link below to view the complete report on UniLife Corp. (UNIS):

UNIS: Company Reports Another Financially Lackluster Quarter (Q3-2013) But That They Will Soon Announce a New Large Multi-Year Unifill Contract. Reiterating Buy Rating and Price Target of $4.75.
Unilife reported a net loss of $14.1 million and $0.17 per share on revenues of $685,000 for the quarter as compared to our estimates for a loss $0.14 and $3.2 million of revenue and consensus estimates calling for a loss of $0.13 and revenue of $2.5 million. Adjusted EPS loss for the quarter was $0.12 per share and a loss of 9.4 million. R&D and SG&A for the quarter were $5.5 million and $7.3 million as compared to our estimates of $5.3 million and $7.9 million respectively.
We believe that the revenue miss for the quarter was largely due to delays in converting development and supply agreements for the Company's product portfolio.
However, the Company did reiterate that "CY-2013 would be the inflection point for their business" and that they "have turned the corner" and will "now be entering a period of hyper-growth and [that they] expect to generate accelerating, recurring revenue from an expanded base of customers.
In addition to last month's announcement for a 15-year $110 million dollar supply contract for their EZMix dual-chamber, Unilife announced that they are getting ready to announce their first major long term supply contract for the Unifill syringe which would result in a significant multi-year contract with a major pharmaceutical company and would generate revenues immediately (Q1-2014). The Company plans to hold a press conference in the next couple of weeks in New York.
A of March 31st 2013 the company had $9.6 million in cash and restricted cash ($2.0 million) and had agreed to preliminary terms with a major life science financing firm for a debt funding program which is expected to become finalized in late May. Unilife also currently has an active $45 million at-the-market (ATM) facility with a current available remaining balance $41.2 million.
Previous FY-2013 and FY-2014 EPS and revenue estimates of $11.3 million (-$0.57) and $43.8 million (-$0.22) have been adjusted to $2.8 million
(-$0.67) and $34.8 (-$0.29) respectively. Cash burn for the quarter was approximately $12.5 million and comparable with the previous quarter (Q2-2013).
We are encouraged by the news of a large impending contract and anxiously await material evidence which could impact the Company's revenue and growth profile.
Our price target of $4.75 is based upon the average of two valuation metrics which include a price to earnings (P/E) ratio based upon FY-2016 earnings, and an appropriate enterprise value to revenue multiple.
For detailed information and disclosures, including risks pertaining to this specific recommendation, please see the full research report and refer to Appendix A – for important research disclosures.
Jefferies

http://carpedmstocks.blogspot.com.au/

Unilife Corporation (UNIS): Aces in Hand: Commercial Deal Flow Appears Imminent

Rating BUY Price Target $3.50 Price $1.85 Key Takeaway Unilife's F3Q print was a non-event as revenues remain minimal and cash burn high. The bigger stories are the EZMix and Unifill deals which are forecasted to drive meaningful revenue come F14. We stay at Buy as the story transitions into the initial growth phase. 3Q light as revenues still slow to materialize. Unilife reported light F3Q results with revenues of $0.7mn and ($0.17) better than our $0.7mn and ($0.18) forecast but below the Street's $2.6mn and ($0.14) forecast. The company ended the F3Q with $7.6mn in cash (net of $1.9mn in restricted cash); this is down from $15.5mn earlier in the Q and is inclusive of $9.6mn in net proceeds from the Feb 13 equity raise. EZMix deal inked; Unifill deal imminent. The EZMix deal announced in early April '13 is for a proprietary version of a lyophilized drug that is in late stage clinical development, although the therapy itself is already approval. The deal is sized to bring in $110mn in revenues over a 15-year period; the $7.3mn in annual revenue will be a combination of customization and production scale-up fees, commercial device sales, and royalties in exchange for worldwide exclusivity on EZMix. The more meaningful deal is the first commercial supply agreement for Unifill with an undisclosed pharmaceutical partner that is positioned to generate immediate commercial revenue flow also beginning in F14. Staying at Buy into commercial deal flow. So far this year, Unilife has delivered on two of 13 active deals expected to contribute in calendar year 2013. So while the company has fallen short on its initial timelines to generate commercial revenues, this previously disclosed pipeline is slowly transitioning into backlog. With the cash burn still high, we see the potential for much better performance as deals mature followed by a dramatic ramp upon commercialization as reasons to own the stock.
Valuation/Risks
Our $3.50 PT is derived using a forward EV/Sales target of 3x multiple on our revised F15E revenue forecast. Risks include delays in Unifill commercialization agreements and ability to scale manufacturing
  Forum: By Share Code

pacestick
Posted on: May 18 2013, 08:35 AM


Group: Member
Posts: 339

With the Nasdaq settling down last night after a bit of a retrace The following is the situation re unilife and income
1. The Unitract 1ml syringe continues to be produced and sold to existing customers but no more contracts are being sought
2. The Unifill sales contract already signed with an unknown pharmaceutical company has brought in a small amount of income but is scheduled to ramp up production from July when it should have a positive impact on the cash burn rate
3. The ezymix syringe has a sales contract signed and had cash accompany it .The volume of sales of ezymix will not be as high as the unifill but the profit margin is expected to be higher.
4. A contract has been prepared with a major pharmaceutical company and is to be signed in the near future. This contract is for over one billion dollars but it is quite likely that not all of this is for sales some may be special fees and some may be costs of production lines we have to wait and see

All in all a company that is moving from development stage to a commercial one
With so much of Unilifes product taking market share off The major players in the field a takeover attempt can not be ruled out
  Forum: By Share Code

pacestick
Posted on: May 13 2013, 10:03 PM


Group: Member
Posts: 339

nasdaq up 20% two hours before opening
  Forum: By Share Code

pacestick
Posted on: May 11 2013, 01:08 PM


Group: Member
Posts: 339

Nasdaq closed up 64.8% on shorts churning 6,447,444 TRADED Monday asx next excitement
http://www.nasdaq.com/symbol/unis/real-time

  Forum: By Share Code

pacestick
Posted on: May 10 2013, 07:14 PM


Group: Member
Posts: 339

closed at 47cents Nasdaq tonight will be interesting could be a bloodbath for the shorts
  Forum: By Share Code

pacestick
Posted on: May 2 2013, 10:54 PM


Group: Member
Posts: 339

"Dear Shareholders
On behalf of Unilife Corporation (“Unilife” or “Company”) (NASDAQ: UNIS; ASX: UNS), I am pleased to attach the Appendix 4C for the fiscal 2013 third quarter. An earnings call where management and I will discuss the fiscal 2013 third quarter results, and also provide an update on operational and commercial activities, has been scheduled to occur on Thursday, May 9, 2013, from 4.30 p.m. U.S.
Eastern Daylight Time (Friday, May 10, 2013 from 6.30 a.m. Australian Eastern Standard Time).
At Unilife’s Fiscal 2012 Annual General Meeting of stockholders held in New York City on November
30, 2012, I had the opportunity to discuss our growth strategy and provide additional detail regarding
the breadth and depth of our commercial pipeline. This included highlighting a selection of 30 active
programs now underway with many of our current and prospective pharmaceutical customers, with a
dozen expected to generate agreements and revenue during calendar year 2013.
Unilife recently announced the first of these agreements – a 15-year customization and commercial supply contract with a U.S. pharmaceutical company for our EZMix™ dual-chamber syringe. We expect this contract to generate up to $110 million in cumulative revenue from customization
programs, production scale-up, device sales and a royalty from net drug sales.
This agreement validates many attractive aspects of our business model and highlights our capacity
to generate revenue from multiple sources. With Unilife now finalizing discussions with multiple
customers for other programs in our commercial pipeline, I expect the pace of news will soon begin
to accelerate as we announce a succession of additional agreements featuring a combination of
revenue streams including exclusivity fees, device customization programs and supply contracts.
Given the substantial size, complexity and long-term duration of many of these prospective
agreements, each takes significant time to negotiate and finalize. However, I believe this wait will be
more than justified as the agreements are announced and we transition into a new commercial
phase of business with a diversified customer base that will drive strong, accelerating rates of growth
and cash flow.
In recognition of the advanced status of some of these agreements, and our strong confidence in
them being announced in the near to medium term, we are consciously managing our cash position
to minimize dilution to existing shareholders.
I am therefore pleased to advise that we have agreed to preliminary terms with a leading U.S. life
science financing firm for a debt funding program that we expect to finalize shortly. Combined with
the anticipated revenue to be generated from new and existing customer agreements, we expect this
medium-term debt program to strengthen our balance sheet, reduce the need for a secondary stock
offering and thereby minimize potential dilution to existing shareholders.
We look forward to providing additional information regarding many of these exciting activities as
news unfolds, and during our earnings call on Thursday, May 9th (Friday, May 10th in Australia).
Yours sincerely
Alan Shortall CEO"
  Forum: By Share Code

pacestick
Posted on: May 2 2013, 11:58 AM


Group: Member
Posts: 339

Price in USA slumped overnight down 12cents usa as shorting continued like a viking longboat crew on a cooks tour of europe. With a week before the CC and combined analyst meeting its going to have to be something exceptionally good to involving a lot of cash to get it moving again
  Forum: By Share Code

pacestick
Posted on: Apr 22 2013, 07:11 AM


Group: Member
Posts: 339

It may be the answer to a something that has puzzled me for a while and that is with Sanofi tying up the unifill for vaccine purposes why their competitors in the vaccine field such as GSK did not do a simmilar deal with the select. These would appear to be refined or improved models .
  Forum: By Share Code

pacestick
Posted on: Apr 20 2013, 07:00 AM


Group: Member
Posts: 339




http://www.drillsearch.com.au/sites/defaul...e_Completion.pd




cash flow is in for an immediate kick up


  Forum: By Share Code

pacestick
Posted on: Feb 6 2013, 03:32 PM


Group: Member
Posts: 339

http://carpedmstocks.blogspot.com.au/2013/...s-boatload.html


$UNIS - JPMorgan Adds a Boatload

JP Morgan Chase & Co. just filed a form schedule 13-d http://www.sec.gov/Archives/edgar/data/196.../Unlifecorp.htm for its holdings in $UNIS. They have added an additional 1 million + shares to their holdings and now hold 8.8% of the company's stock. Other funds continue to add and there are a few newcomers as well. While the Nasdaq site hasn't updated to show this information, another major fund made an initial purchase of over 600,000 shares. This just bodes the question, at what point will the shorts be shorting shares that they have already shorted. Its possible this is already happening. Much of their enthusiasm is probably predicated on the logic that the company will report a similar quarter as the previous ones and that they'll be able to get weak hands to sell out with some pressure. The selling pressure of late has been met with equally strong buying pressure. The shares trading on the Nasdaq have been in a very narrow range. For the sake of simplicity if we assume that 42 million shares are available for trading on Nasdaq. Out of that 42 million shares, I estimate that 32 million are held by funds leaving 10 million shares left for the hoi polloi. Shorters have already sold over 10 million shares, which means that should there be any kind of news that generates real excitement, ie, revenue generation or supply contracts, they will be competing for an ever shrinking number of shares. Many will continue to short all the way up hoping that the stock will fall after the excitement dies down, but with so few shares truly available, they will have no place to go but back into the market. We know that the PR machine is primed and ready to go once the company is ready to announce some big news. The countdown clock may have already started.
  Forum: By Share Code

pacestick
Posted on: Feb 3 2013, 07:15 PM


Group: Member
Posts: 339

This chart from a poster on UNIS shows the effect of the shorts reaction see attachment
Attached thumbnail(s)
Attached Image


 
  Forum: By Share Code

pacestick
Posted on: Feb 3 2013, 07:02 AM


Group: Member
Posts: 339

Who ever wins they will not keep their hands off super thats a pre set norm for all federal governments in Australia
  Forum: Investment Discussion

pacestick
Posted on: Feb 2 2013, 07:23 AM


Group: Member
Posts: 339

The interesting points to me relate to the financing It would appear that the days of capital raisings may be over for some time This may explain the rise of the SP on the nasdaq as I suspect the shorts were counting on further dilution and have over extended themselves
  Forum: By Share Code

pacestick
Posted on: Jan 26 2013, 06:11 AM


Group: Member
Posts: 339


An Interview With Unilife's CEO: A Long-Term Opportunity And A Looming Short Squeeze
January 25, 2013 | about: UNIS Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. (More...)

By Ivan Deryugin

Earlier this week I had the pleasure of speaking with Alan Shortall, President and CEO of Unilife (UNIS), about the company's short and long-term prospects. Over the course of the next few months, a confluence of factors, including a commercialization ramp and a looming short squeeze, are likely to create value for Unilife investors. With UNIS down over 25% in the last six months alone, there is value to be found in the shares of this company.

Overview

Unilife's predecessor company was founded in 1985 and is currently based in York, Pennsylvania. The company develops a variety of injectable drug delivery systems, and while it has yet to begin generating revenue from meaningful sales of its delivery systems and syringes, 2013 is poised to be a pivotal year for Unilife as it recovers from past stumbles and begins to realize its potential. As Mr. Shortall noted, Unilife stands ready to take advantage of several key healthcare trends, trends that stand to benefit Unilife and its investors over the course of the coming months.

As healthcare costs continue to soar, both here in the United States and across the world, every player in the healthcare market is looking for new ways to drive down costs while preserving or improving the quality of care that patients receive. Self-administered and self-injected drugs are becoming more and more prevalent; according to Ernst & Young, up to 50% of healthcare will be administered outside of the traditional healthcare system (hospitals, clinics, etc…) by 2020. An accompanying shift toward biologics will also begin to change the American healthcare system. According to Mr. Shortall, there are currently around 1,000 different biologics in development in the pipeline of American pharmaceutical companies alone, and these biologics are more challenging to commercialize than traditional drugs. Many are complex and viscous compounds, requiring new methods of delivery. Enter Unilife. The company's Unifill and EZMix syringes allow patients to treat themselves quickly and easily. But Unilife's business model is not simply about helping patients. Rather, it's about helping pharmaceutical companies meet their unmet needs, and this is how Unilife plans to deliver value for its customers and investors.

Injecting Itself into the Pharmaceutical Supply Chain

As I spoke with Mr. Shortall, I came to see him as an executive with a clear vision as to how his company will succeed and a plan to turn that vision into a reality. While Mr. Shortall was certainly enthusiastic about the quality of life improvements that these syringes and delivery systems can have for patients, he was even more excited about the potential that these products hold for pharmaceutical companies. Mr. Shortall recounted how a large pharmaceutical company (defined by him as one of the five largest) was developing a new biologic, and was setting up clinical trials for it. However, the mechanism of action for this specific biologic required that the drug be delivered via surgery. This created a variety of complications for the clinical study, especially in recruiting patients (to say nothing of the complexities of managing such a drug post-FDA approval). The company turned to Unilife, awarding it a $1.4 million contract to find a better way. And Unilife delivered, producing an injectable drug delivery system that eliminates the need for surgical administration and allows the timing of delivery during administration. This leads to better clinical outcomes and higher odds of approval.

The crucial element here is perhaps the most easily overlooked: by creating this drug delivery system, Unilife has made it an essential part of the mechanism of action for this biologic, and if and when the drug is approved by the FDA, it will be approved as a "package deal," thereby injecting Unilife into the supply chains of its pharmaceutical customers. Mr. Shortall does not want his company to be another generic medical device company churning out high volumes of low-margin medical products. Rather, he wants Unilife to become an integral part of the pharmaceutical supply chain, and the company already counts Sanofi (SNY) as a customer.

In 2009, Unilife and Sanofi entered a 5-year industrialization agreement. Under the terms of the agreement, Sanofi received exclusive rights to the Unifill syringe in several indications, including antithrombotic agents, vaccines, and four other unnamed indications. Sanofi paid Unilife 17 million euros for this license, which expires on June 30, 2014. Unilife began supplying Sanofi with Unifill syringes in July 2011, and has received over $40 million from the global pharmaceutical company, which is estimated to be the world's largest buyer of prefilled syringes. Other pharmaceutical companies have begun deploying Unilife's technology as well. In early November, Unilife announced that a "global pharmaceutical company" had selected its Precision-Therapy bolus injection system for use in its clinical trial process. Unilife stated that the system is being used in five pipeline programs, with the first being in Phase III trials. Unilife has commenced shipments to the company, and expects to sign a supply agreement with the company, estimated to be worth $10 million over the next 18-24 months. The deal is set to be signed in fiscal 2013 (the company's fiscal year ends June 30). Unilife also stated that full product shipments are likely to commence in 2015, with annual revenue of $50 million per year from shipments of Precision-Therapy bolus injectors alone. The company also stated that it expects between $30-$70 million in supply revenue per drug from this deal. And in December, Unilife announced that a U.S. pharmaceutical company has begun to study its products for use in its clinical trials, as well as existing drugs. While Unilife did not give revenue projections for this deal, the company did state that it expects peak annual demand of 25-35 million injection units from this company alone.

At Unilife's annual meeting, held in late November, the company gave an update on its commercialization efforts. CEO Alan Shortall described five different EZMix programs that the company is working with 21 different customers, across 31 different development programs, and said that 13 of these are set to generate revenue in fiscal 2013, with peak sales estimated at $992 million.

(click to enlarge)

While Unifill is the company's most advanced product, Unilife is developing a variety of other injection systems. EZMix, designed for drug reconstitution, with five different EZMix programs set to begin generating revenue in fiscal 2013 and 2014. The company has one auto-injection platform set to begin generating revenue in 2013, and two in 2014. Four of the company's injection pump programs are set to begin generating revenue in 2013, as are two of its targeted delivery systems, which are designed for the delivery of drugs that require specific delivery sites, such as eye injections. The ramping of Unilife's sales can be seen through consensus estimates for the company's revenue, provided by Reuters (Unilife lost revenue of $5.519 million in fiscal 2012).



According to consensus estimates, Unilife is set to generate $20.1 million in revenue in fiscal 2013 (a growth rate of 264.17%), and $88.4 million in fiscal 2014, which would represent an acceleration of growth to 339.8%. And Cantor Fitzgerald, which has a $7.50 price target on Unilife, models revenue of $500 million by fiscal 2016, and sustainable profitability by the end of fiscal 2014. Unilife lost $0.78 per share in fiscal 2012, and those losses are projected to narrow in fiscal 2013 and 2014, to $0.48 and $0.09 per share, respectively.

Financials & Market Structure: Addressing the Need for Capital

Unilife's stock has been battered over the past year, falling almost 38% as the company depleted its capital reserves investing in future growth. Unilife ended its latest quarter with over $10 million in cash and investments on its balance sheet, and with a quarterly burn rate of over $10 million, it would seem that the company is going to need to raise capital imminently. However, the situation is more complex than it appears to be. Unilife already set up a controlled equity offering agreement for $45 million in early October, and to date has not utilized it according to Mr. Shortall. During our conversation, he stated that he wants to limit dilution as much as possible, and that the company has no immediate plans to issue new stock; if capital is needed, he prefers to issue debt. Unilife ended its latest quarter with over $10 million in debt, of which $6.7 million is due within the next 12 months. The remaining debt is long-term in nature, with maturities in 2020, 2021 and 2031. Mr. Shortall stated that any capital that the company will raise in fiscal 2013 will be minimal, and that a capital raise would be designed to bridge the company to the closing of new supply contracts, which he hopes to announce over the next few months. With shares down sharply over the past year, expectations of a capital raise are likely already priced in. While the Unilife story is a promising one, it is admittedly long-term in nature. However, there are short-term elements at work here as well. As Unilife begins to announce new deals with pharmaceutical companies, a number of factors may lead to a dramatic short squeeze.

A Looming Short Squeeze

Unilife was originally incorporated in Australia in 1985, and the company began trading on the NASDAQ in 2010, having transferred its operations to the United States from Australia. However, Unilife is not a reverse merger shell company (that being said, Australian financial reporting standards are equivalent to those of the United States in terms of rigor, for Australia is a highly stable democracy). Rather, Unilife made the decision to transfer its operations to the United States, for a variety of reasons. The company delisted itself from the ASX, and relisted on the NASDAQ via a traditional listing.

Unilife ended its latest quarter with over $10 million million shares outstanding, and according to the latest NASDAQ data, 10.2 million shares of Unilife were sold short (12.16% of all shares outstanding). While this level of short interest is already relatively high, Mr. Shortall pointed out, correctly in my view, that this data does not tell the whole story. Around 40 million of Unilife's shares are held by Australian investors via over $10 million CDIs, Australia's version of an ADR. While it's possible to convert Unilife's CDIs back into common stock, the process is long and cumbersome, and plays a role in artificially deflating Unilife's trading volume here in the United States (the company's average daily volume over the past 50 trading days has been around 305,000 shares). Mr. Shortall himself owns over 5.4 million shares of Unilife. Excluding restricted stock, he holds 3,158,043 shares, or 3.79% of the company. And Unilife's institutional ownership is highly concentrated. JP Morgan is the company's largest investor and owns over 6.1 million shares of Unilife. The company's five largest institutional investors own 14.9 million shares, or 17.95%. When the nuances of Unilife's ownership structure are taken into account, the company's true short interest is in fact much higher. When accounting for shares held by Australian investors, and Mr. Shortall's stake, Unilife's short interest jumps from 12.16% to over 25%. According to Mr. Shortall, he and what he described as "key investors" own a combined 25 million shares of Unilife. When the company's Australian shares, Mr. Shortall's direct stake, and the holdings of "key investors" are taken into account, Unilife's short interest soars to over 55%. Given that seven of Unilife's 15 largest institutional investors chose to up their stakes during the last few months of 2012 (five maintained their stakes and three decreased their holdings), I do not believe that they will be quick to let go of their shares when the company begins to announce supply deals over the coming months. The nuances of Unilife's capital markets structure are a recipe for a short squeeze, as only around half of Unilife's shares are even available in the United States, and millions of those shares are held by Mr. Shortall himself and long-term institutional investors (Fidelity, which owns 2.4% of the company, has been an investor since May 2011, and JPMorgan has been invested since November 2011).

Conclusions

Unilife offers something for both short-term and long-term investors. The company's stock has been battered over the past year as investors awaited a capital raise, one that has not materialized, nor is likely to materialize. Unilife's CEO has stated that he prefers debt financing to equity financing, and the company is set to begin announcing deals, with Mr. Shortall confident that the company will have announcements to make over the coming months. Unilife's products meet a clear medical need, and pharmaceutical companies are already utilizing Unilife products in both clinical trials and approved drugs. 2013 is likely to be a transformational year, with a number of the company's development programs set to begin generating revenue. And as the company continues to execute on its development strategy, the nuances of its capital markets structure are setting the stage for a short squeeze. In my view, investors could consider adding to or initiating positions in a company whose best days are ahead if it.

Additional disclosure: PropThink is a team of editors, analysts, and writers. This article was written by Ivan Deryugin. We did not receive compensation for this article, and we have no business relationship with any company whose stock is mentioned in this article. Use of PropThink’s research is at your own risk. You should do your own research and due diligence before making any investment decision with respect to securities covered herein.You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as "PropThink") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. Our full disclaimer is available at www.propthink.com/disclaimer.

This article was sent to 340 people who get email alerts on UNIS. Get email alerts on UNIS About this article Emailed to: 340 people who get UNIS real-time alerts and 212,595 people who get Investing Ideas daily. Tagged: Investing Ideas, Long Ideas, Healthcare, Medical Instruments & Supplies Problem with this article? Please tell us. Disagree with this article? Submit your own.
http://seekingalpha.com/article/1133981-an...rticle_readmore



  Forum: By Share Code

pacestick
Posted on: Jan 17 2013, 07:32 AM


Group: Member
Posts: 339

good to see shorters may just may be having problems crocodile tears fromme
  Forum: By Share Code

pacestick
Posted on: Jan 13 2013, 02:09 PM


Group: Member
Posts: 339

Finance & Investing News Services Get free industry updates via email.
Daily News
Weekly News
Equipment Updates
Weekly Job Register
Monthly Event Guide
Our privacy
pledge.


Drillsearch Completes Purchase of Acer, Enlarges Cooper Basin Footprint by Quintella Koh|Rigzone Staff|Friday, January 11, 2013
Drillsearch Energy disclosed Friday that it "now holds the largest discovered, uncommitted conventional gas resource in the prolific Cooper Basin outside of the Cooper Basin Joint Venture partners", following the completion of its compulsory acquisition of Acer Energy.

In a statement, Drillsearch said that former Acer shareholders whose shares were acquired under the compulsory acquisition process have been posted a claim form to finalize payment of the consideration owed to them.

Drillsearch on Oct.25 last year offered to purchase Acer's shares at 28.5 Australian cents per Acer share. Drillsearch's offer – which placed Acer's value $137.1 million (AUD 132.3 million) – was accepted by the latter's shareholders.

Drillsearch is an oil and gas explorer and producer focused on the highly-prospective onshore Cooper-Eromanga Basin. Acer has oil and gas exploration plays in the same area, as well as the Bass Basin.
  Forum: By Share Code

pacestick
Posted on: Jan 12 2013, 07:14 AM


Group: Member
Posts: 339

http://www.4-traders.com/UNILIFE-CORP-5977761/consensus/
  Forum: By Share Code

pacestick
Posted on: Dec 24 2012, 08:39 PM


Group: Member
Posts: 339

CHRISTMAS COUNTDOWN
performed by by
Frank Kelly Day One
Dear Nuala,
Thank you very much for your lovely present of a partridge in a pear-tree. We're getting the hang of feeding the partridge now, although it was difficult at first to win its confidence. It bit the mother rather badly on the hand but they're good friends now and we're keeping the pear-tree indoors in a bucket. Thank you again. Yours affectionately,
Gobnait O'Lúnasa

Day Two
Dear Nuala,
I cannot tell you how surprised we were to hear from you so soon again and to receive your lovely present of two turtle doves. You really are too kind. At first the partridge was very jealous and suspicious of the doves and they had a terrible row the night the doves arrived. We had to send for the vet but the birds are okay again and the stitches are due to some out in a week or two. The vet's bill was £8 but the mother is over her annoyance now and the doves and the partridge are watching the telly from the pear-tree as I write. Yours ever,
Gobnait

Day Three
Dear Nuala,
We must be foremost in your thoughts. I had only posted my letter when the three French hens arrived. There was another sort-out between the hens and the doves, who sided with the partridge, and the vet had to be sent for again. The mother was raging because the bill was £16 this time but she has almost cooled down. However, the fact that the birds' droppings keep falling down on her hair whilen she's watching the telly, doesn't help matters. Thanking you for your kindness. I remain,
Your Gobnait

Day Four
Dear Nuala,
You mustn't have received my last letter when you were sending us the four calling birds. There was pandemonium in the pear-tree again last night and the vet's bill was £32. The mother is on sedation as I write. I know you meant no harm and remain your close friend. Gobnauit

Day Five
Nuala,
Your generosity knows no bounds. Five gold rings ! When the parcel arrived I was scared stiff that it might be more birds, because the smell in the living-room is atrocious. However, I don't want to seem ungrateful for the beautiful rings. Your affectionate friend, Gobnait

Day Six
Nuala,
What are you trying to do to us ? It isn't that we don't appreciate your generosity but the six geese have not alone nearly murdered the calling birds but they laid their eggs on top of the vet's head from the pear-tree and his bill was £68 in cash ! My mother is munching 60 grains of Valium a day and talking to herself in a most alarming way. You must keep your feelings for me in check. Gobnait

Day Seven
Nuala,
W e are not amused by your little joke. Seven swans-a-swimming is a most romantic idea but not in the bath of a private house. We cannot use the bathroom now because they've gone completely savage and rush the door every time we try to enter. If things go on this way, the mother and I will smell as bad as the living-room carpet. Please lay off. It is not fair. Gobnait

Day Eight
Nuala,
Who the hell do you think gave you the right to send eight, hefty maids-a-milking here, to eat us out of house and home ? Their cattle are all over the front lawn and have trampled the hell out of the mother's rose-beds. The swans invaded the living-room in a sneak attack and the ensuing battle between them and the calling birds, turtle doves, French hens and partridge make the Battle of the Somme seem like Wanderly Wagon. The mother is on a bottle of whiskey a day, as well as the sixty grains of Valium. I'm very annoyed with you. Gobnait

Day Nine
Listen you louser !
There's enough pandemonium in this place night and day without nine drummers drumming, while the eight flaming maids-a-milking are beating my poor, old alcoholic mother out of her own kitchen and gobbling everything in sight. I'm warning you, you're making an enemy of me. Gobnait

Day Ten
Listen manure-face,
I hope you'll be haunted by the strains of ten pipers piping which you sent to torment us last night. They were aided in their evil work by those maniac drummers and it wasn't a pleasant sight to look out the window and see eight hefty maids-a-milking pogo-ing around with the ensuing punk-rock uproar. My mother has just finished her third bottle of whiskey, on top of a hundred and twenty four grains of Valium. You'll get yours ! Gobnait O'Lúnasa

Day Eleven
You have scandalised my mother, you dirty Jezebel,
It was bad enough to have eight maids-a-milking dancing to punk music on the front lawn but they've now been joined by your friends ~ the eleven Lords-a-leaping and the antics of the whole lot of them would leave the most decadent days of the Roman Empire looking like “Outlook”. I'll get you yet, you ould bag !

Day Twelve
Listen slurry head,
You have ruined our lives. The twelve maidens dancing turned up last night and beat the living daylights out of the eight maids-a-milking, ‘cos they found them carrying on with the eleven Lords-a-leaping. Meanwhile, the swans got out of the living-room, where they'd been hiding since the big battle, and savaged hell out of the Lords and all the Maids. There were eight ambulances here last night, and the local Civil Defence as well. The mother is in a home for the bewildered and I'm sitting here, up to my neck in birds' droppings, empty whiskey and Valium bottles, birds' blood and feathers, while the flaming cows eat the leaves off the pear-tree. I'm a broken man.

Gobnait O'Lúnasa
  Forum: Off Topic Chat

pacestick
Posted on: Dec 20 2012, 07:53 AM


Group: Member
Posts: 339

Another U.S. Pharmaceutical Company Commences Unifill Stability Studies Aimed At Multiple Target Injectable Drugs

Target drugs include both late-stage pipeline and commercially approved drugs




YORK, Pa., Dec. 19, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or "Company") (NASDAQ: UNIS, ASX: UNS) today announced that another U.S. based pharmaceutical company has commenced stability and evaluation studies of the Unifill syringe for use with multiple injectable drugs.

The target drugs, which include both pipeline drugs as well as commercially approved drugs that will benefit from lifecycle extension, are high-value therapeutics for chronic diseases and require periodic injections. The customer is also reviewing other Unilife devices for use with additional injectable drugs in their portfolio.


Mr. Alan Shortall, CEO of Unilife, said: "The supply of Unifill syringes to this pharmaceutical customer for use with so many of their injectable drugs at one time is a major accomplishment. The customer cited the unique value proposition of the Unifill syringe, with its automatic, integrated and highly intuitive safety features, as a key factor in their selection process. This is not surprising given how attractive and differentiated the Unifill syringe is compared to conventional prefilled syringe technologies.

"The commercial value of the strong relationship we have established with this pharmaceutical customer should rapidly expand beyond near-term device sales as we formalize a series of clinical development agreements and commercial supply contracts. We expect to generate accelerating, incremental revenues with this customer moving forward, with peak annual demand of between 25 million and 35 million units of Unifill annually for their initial series of target drugs."

"This customer is just one of many pharmaceutical companies that are selecting our devices to enable or enhance the delivery and commercial success of their injectable therapies. As I stated during our recent Annual General Meeting, there is a tremendous amount of business activity now occurring across our commercial pipeline. In the last month alone, we have held meetings with senior executives from more than a dozen pharmaceutical companies as part of advanced, ongoing discussions that relate to every device platform across our portfolio. We look forward to announcing the formalization of many of these commercial relationships in the weeks and months ahead," Mr. Shortall concluded.

About Unilife Corporation
Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. Unilife's broad portfolio of proprietary device technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, long-duration subcutaneous pump delivery systems and targeted delivery systems. Each of these innovative and highly differentiated device platforms can be customized by Unilife to address specific customer, drug and patient requirements. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information, please visit www.unilife.com or download the Unilife IRapp on your iPhone, iPad or Android device.

About the Unifill Syringe
The Unifill ready-to-fill (prefilled) syringe is the world's first and only known prefilled syringe with automatic safety features fully integrated within the glass barrel. It is a primary drug container, a safety device and a needle containment system all rolled into one. The Unifill syringe is supplied as per standard handling systems for integration into fill-finish systems used for equivalent conventional prefilled syringes. Compared to ancillary safety products attached onto prefilled syringes, Unifill can help streamline fill-fill systems and significantly reduce transport, packaging, and storage costs. USP Class Six compliant materials reside within the drug-fluid path.

The Unifill syringe is designed for safe, simple, and convenient use by either healthcare workers or patients who self-administer prescription medication. An audible, tactile click signals the injection of the full dose and the automatic activation of a needle retraction mechanism. Operators can control the speed of needle retraction directly from the body into the barrel of the syringe. The combination of automatic, operator-controlled retraction features within the Unifill syringe can help to virtually eliminate the risk of infection from needlestick injuries. The plunger is automatically locked after needle retraction, to prevent re-use of the device and encourage convenient and compact disposal.

The Unifill syringe is now in production at Unilife's production facilities in York, Pennsylvania, and available for supply to interested pharmaceutical parties.

Forward-Looking Statements
This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

  Forum: By Share Code

pacestick
Posted on: Dec 1 2012, 06:11 AM


Group: Member
Posts: 339

My understanding is that the pharma already receiving unifill has to increase their orders in order to maintain their geographic exclusivity I would expect this to happen before mid 2013 The other income shown for commencement in 2013 may not be that large but will build up during 2014
  Forum: By Share Code

pacestick
Posted on: Nov 9 2012, 05:00 AM


Group: Member
Posts: 339

Unilife's Bolus Injector Platform Targeted by Global Pharmaceutical Company for Use in Multi-Drug Program

Cumulative device revenues expected to exceed $300MM for the first of five or more target drugs




YORK, Pa., Nov. 8, 2012 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced that its Precision-Therapyâ„¢ platform of bolus injection systems has been selected by a global pharmaceutical company to enter the next stage of collaboration as its preferred choice for long-duration subcutaneous drug delivery.

Unilife has been advised that the global pharmaceutical company (the "Customer") is targeting more than five pipeline injectable drugs for use with the Precision-Therapy platform of bolus injectors (wearable, disposable pumps). The first of these target drugs identified by the Customer is in Phase III clinical trials.

Unilife has recently commenced the initial supply of its Precision-Therapy devices to the Customer. Initial revenues will be generated by Unilife during the current fiscal year as it supports the immediate needs of the Customer under this partnership program.

Unilife expects to enter into a development agreement with the Customer during the current fiscal year to customize Precision-Therapy devices for use in the first target drug's upcoming human clinical trials. Unilife expects the first of these development agreements to generate in excess of $10 million in revenue over an 18 to 24 month period. Unilife expects to successively enter into a series of additional development agreements with similar terms relating to the other target drugs.

Unilife further expects that it will begin commercial supply of Precision-Therapy bolus injectors to the Customer in 2015 to support the anticipated market launch of the first target drug. Commercial supply contracts for each targeted drug under the program are expected to have an initial term of seven years. Based upon indicated customer requirements for the first drug candidate, Unilife expects to generate commercial revenues of approximately $50 million per year under an initial supply contract.

Unilife expects that it will enter into separate commercial supply contracts for each target drug brought to market by the Customer. Across the full portfolio of target drugs identified by the Customer, Unilife expects that commercial supply revenues per drug will range between $30 million and $70 million a year.

For commercial purposes and due to confidentiality clauses within the agreement, additional terms of the contract and the identity of the pharmaceutical company are to remain confidential at this time.

Mr. Alan Shortall, CEO of Unilife, said, "Our Precision-Therapyâ„¢ platform of bolus injectors and Flex-Therapyâ„¢ platform of infusion pumps are consistently being identified by pharmaceutical companies as the preferred technology for the long-duration subcutaneous delivery of injectable drugs.

"It is important to note that today's announcement regarding the selection of our bolus injection platform by a global pharmaceutical company follows an extensive evaluation process involving many of our device competitors. The customer has advised that their rationale for the selection of Unilife was our deep industry expertise, advanced operational capabilities, strong patent position and ability to consistently exceed program requirements. They believe our superior device technology will represent a major part of the value proposition to support the successful commercial launch of a series of injectable therapies that currently reside within their clinical pipeline.

"The platform-based approach we have utilized in the development of our Precision-Therapy bolus injectors means that we will play an integral role in the clinical development, regulatory approval and commercial success of a broad portfolio of injectable therapies under a long-term collaboration with this customer.

"We look forward to the signing of an initial development agreement this fiscal year to customize a device from our Precision-Therapy platform that will address the specific needs of this customer for the first of their target drugs. I expect each commercial supply contract that we sign under this program can ultimately generate hundreds of millions of dollars in cumulative revenues during its full term. Such long-term collaborations underpin the strength of the strategic relationships that we continue to build with a number of pharmaceutical companies for drug-device combination products.

"This marks the start of a multi-stage, multi-drug long-term partnership with this global pharmaceutical company. However it is just one of many exciting opportunities that now reside within our fast-expanding commercial pipeline. We look forward to entering into similar partnerships with other pharmaceutical companies that are now at various stages in the evaluation and selection of devices from our broad portfolio of technology platforms that will enable and enhance their target pipeline and approved drugs," Mr. Shortall concluded.

Precision-Therapyâ„¢ Bolus Injector Platform and Flex-Therapyâ„¢ Infusion Pump Platform

Unilife has developed the Precision-Therapy platform of bolus injectors and Flex-Therapy platform of infusion pumps to help enable and enhance bolus or rate-based injectable therapies that require the long-duration subcutaneous delivery of doses between 1mL and 30mL in volume. Featuring a primary container with standard materials in the fluid path, they are designed for integration into existing fill-finish lines and can be customized to address specific customer or patient needs including dose volume, delivery rate and duration, drug viscosity, and ergonomic design. Compact in size and highly intuitive for use, they can be comfortably worn on or off the body of a patient during the designated dose duration. Patients simply push a button to commence the automatic delivery of the dose via a soft, indwelling catheter. Visual and audible electronic indicators communicate with the patient during each stage of use. Upon the delivery of the full dose, the device can be removed from the body for convenient disposal.

About Unilife Corporation

Unilife Corporation (NASDAQ:UNIS / ASX: UNS) is a U.S. based developer and commercial supplier of injectable drug delivery systems. The Unifill® syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of a broad portfolio of innovative, highly differentiated devices. In addition to prefilled syringes with automatic needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, bolus injectors, infusion pumps and targeted delivery systems. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit www.unilife.com

Forward-Looking Statements

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

Investor Contacts (US):

Analyst Enquiries

Investor Contacts (Australia)

Media Contact

Todd Fromer / Garth Russell

Lynn Pieper

Jeff Carter

Eve McGrath

KCSA Strategic Communications

Westwicke Partners

Unilife Corporation

Rubenstein PR

P: + 1 212-682-6300

P: + 1 415-202-5678

P: + 61 2 8346 6500

P: + 1 212 843-8490



SOURCE Unilife Corporation

You are subscribed to Unilife Corporation Investor Relations' e-mail alerts as calder@wix.com.au.
  Forum: By Share Code

pacestick
Posted on: Nov 2 2012, 07:03 AM


Group: Member
Posts: 339

DLS now have over 5o% of ACN and should therefore reap the benefits of the just started drilling program
  Forum: By Share Code

pacestick
Posted on: Nov 2 2012, 06:12 AM


Group: Member
Posts: 339

DLS has now obtained over 50% of ACN while ACN can continue the fact that SXY sold their holding to DLS means that their is no significant holder to block compulsory acquisition should/when DLS hits 90% I accordingly have sold acn on a about a 60 % profit and put the bulk into DLS The ACN fields being the primary reason.
I believe a number of people who bought into ACN after the announcement of the Takeover may have been burnt
This is one case where long term buying and averaging down has won over short term strategies
  Forum: By Share Code

pacestick
Posted on: Oct 26 2012, 07:23 AM


Group: Member
Posts: 339

Im absolutley certain it isnt I would rate this company at 40 to 50 cents . I am sure the SXY and a number of investors who bought in at above DLS original price and paid an average of about 28.5 cents see it the same way.
Republic have sold to DLS which brings their holding up to 40% The company is in negotiations with a third party is SXY or someone else So I will be watching for a statement from the company they called the 25.5 cents offer oppurtunistic I wonder what they will say about this
  Forum: By Share Code

pacestick
Posted on: Oct 25 2012, 05:32 AM


Group: Member
Posts: 339

http://www.youtube.com/watch?v=X-LbVnzk1W0...eature=youtu.be

interview with CEO as at 24 October
  Forum: By Share Code

pacestick
Posted on: Oct 23 2012, 06:14 AM


Group: Member
Posts: 339

www.acerenergy.com.au/



Acer Energy (ASX: ACN) holds a balance of exploration and producing assets in the Cooper, Bass and Darling basins, Australia.

inShare Email
Acer Energy increases Flax reserves by 280% to 88.5MM barrels of oil equivalent
Monday, October 22, 2012 by Bevis Yeo Acer Energy (ASX: ACN) has recorded a 280% increase in the in-place resources at its wholly-owned Flax oil and gas field in the Cooper Basin to 88.5 million barrels of oil equivalent (MMboe).

This was due to mapping of recently acquired 3D seismic, which delineated the Flax field as a much broader structure covering an area of 12.25 square kilometres, as well as including the upper and mid Patchawarra formation reservoirs.

The resource upgrade, which follows completion of the 12 month technical review of the company’s GMI Ridge assets, was audited and supported by independent petroleum consultant RISC.

Acer’s current Flax workover campaign and pending drilling program of up to six wells is focused on converting the increase resources into production using the existing 1,000 barrel per day faciltiies at the field.

Flax workover and drilling

The company is using the Savanna Energy Services Rig 66 to recomplete a well and carry out hydraulic fracture stimulation and production testing of the previously untested Patchawarra formation pay intervals and a previously fracture stimulated pay interval.

This will determine the effectiveness of the larger modern designed hydraulic fracture stimulations in both the Patchawrra and the previously stimulated pay intervals and test the hydrocarbon composition and productivity of the Patchawarra.

Acer will also install artificial lift in a selected well to test its impact on well productivity.

The results of this workover will be a key factor in the well completion design for the new appraisal and exploration drilling campaign of between three to six wells that is scheduled to start in October 2012.

This is targeted at appraising the potential large southern extension of the Flax field which has been mapped following interpretation of the new 3D seismic.

The Flax oil field had produced 5,013 barrels of oil during the quarter ended 30 June 2012.

Takeover target

Acer is also the subject of a takeover bid by Drillsearch Energy (ASX: DLS), which is dangling an all cash A$0.255 per share offer before Acer’s shareholders.

Drillsearch is targeting a consolidation of its western Cooper Basin position and the large discovered unconventional resource there.

Interestingly, Senex Energy (ASX: SXY) – Acer’s partner in PEL 100 and PEL 182 – has also acquired a 6.42% stake in Acer, raising the possibility of a bidding war.



Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

  Forum: By Share Code

pacestick
Posted on: Oct 22 2012, 08:01 AM


Group: Member
Posts: 339

Senex have increased their holding to 7.5% This follows DLS making their offer formal at 0.25c.
  Forum: By Share Code

pacestick
Posted on: Oct 15 2012, 08:32 PM


Group: Member
Posts: 339


Acer Energy urges shareholders to hold on Drillsearch Energy offer
Monday, October 15, 2012 by Bevis Yeo Acer Energy (ASX: ACN) continues to urge shareholders to take no action regarding Drillsearch Energy’s (ASX: DLS) A$118.4 million all cash takeover offer.

The company said it is reviewing the offer and that it will respond with its recommendation once the Offer document is despatched to Acer’s shareholders.

Acer also noted the recent substantial shareholder’s notice lodged by Senex Energy (ASX: SXY) advising that it had acquired a 6.42% stake in Acer.

Senex is a joint venture partner with Acer in two Cooper Basin tenements.

Drillsearch’s offer, which is fully funded by its existing cash reserves and a A$100 million 15-month debt facility from Commonwealth Bank, has already received the support of Acer’s largest shareholder Republic Investment Management.

Republic had previously sold 19.9% of Acer to Drillsearch and plans to accept the offer for its remaining 18.82% holding in the absence of a superior offer.

The acquisition is targeted at consolidating Drillsearch’s position in the western Cooper Basin and will give it the largest discovered unconventional gas resource outside of the Cooper Basin Joint Venture partners.

Post-consolidation, Drillsearch will have a combined Proved and Probable Reserves as well as best estimate Contingent Resource of 38.7 million barrels of oil equivalent.



Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

http://www.proactiveinvestors.com.au/companies/news/34508/acer-energy-urges-shareholders-to-hold-on-drillsearch-energy-offer-34508.html


  Forum: By Share Code

pacestick
Posted on: Oct 7 2012, 06:31 AM


Group: Member
Posts: 339

As far as I am aware various brokers have always done some form of dark pooling among their own clients
  Forum: Off Topic Chat

pacestick
Posted on: Oct 5 2012, 07:03 AM


Group: Member
Posts: 339

DLS have issued a statement that they will only recognise holders as at 7pm today .They cant like the idea of the share trading at above their offer price
  Forum: By Share Code

pacestick
Posted on: Oct 4 2012, 10:26 PM


Group: Member
Posts: 339

The only trade done at the offer price was republics the market is saying up the ante
  Forum: By Share Code

pacestick
Posted on: Oct 4 2012, 09:29 AM


Group: Member
Posts: 339

takeover offer from DLS 0.255cents cash only They are getting it for a song but largest holder already out
  Forum: By Share Code

pacestick
Posted on: Oct 1 2012, 06:27 PM


Group: Member
Posts: 339

SP continues to rise on first of a multi well workover and drilling program
  Forum: By Share Code

pacestick
Posted on: Sep 20 2012, 06:42 AM


Group: Member
Posts: 339


Acer Energy targets production upside with Flax oil field workover
Wednesday, September 19, 2012 by Bevis Yeo Acer Energy (ASX: ACN) is hoping to breathe new life into its Flax oil field in the Cooper Basin by carrying out workovers that seek to further appraise the field and increase production.

The company is using Savanna Energy Services Rig 66 to recomplete a well and carry out hydraulic fracture stimulation and production testing of the previously untested Patchawarra formation pay intervals and a previously fracture stimulated pay interval.

This will determine the effectiveness of the larger modern designed hydraulic fracture stimulations in both the Patchawrra and the previously stimulated pay intervals and test the hydrocarbon composition and productivity of the Patchawarra.

Acer will also install artificial lift in a selected well to test its impact on well productivity.

The results of this workover will be a key factor in the well completion design for the new appraisal and exploration drilling campaign of between three to six wells that is scheduled to start in October 2012.

This is targeted at appraising the potential large southern extension of the Flax field which has been mapped following interpretation of the new 3D seismic.

The Flax oil field had produced 5,013 barrels of oil during the quarter ended 30 June 2012.

It has being independently estimated to hold 15 million barrels of in-place oil and 34 billion cubic feet of in-place gas though this not include the mid-Patchawarra interval.

Acer has a 10% interest in the PRL 14, which hosts the Flax oil field.



Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

  Forum: By Share Code

pacestick
Posted on: Sep 19 2012, 04:29 PM


Group: Member
Posts: 339

two month drilling program began today
  Forum: By Share Code

pacestick
Posted on: Sep 3 2012, 09:38 AM


Group: Member
Posts: 339

up 6.2% on low volume Drilling due to start this month probably early this month
  Forum: By Share Code

pacestick
Posted on: Aug 11 2012, 01:03 PM


Group: Member
Posts: 339




ACER ENERGY (ACN)




The company recently posted reports from two different analysts on its Home Page




http://www.acerenergy.com.au/




The reports were from Breakaway Research and Casimir Capital

I have taken the following information from the two reports




Flax field oil originally in place 15mmbbls plus OGIP 34Bcf

a further possible 130mmbls of prospective resource has been estimated from the appraisal of the juniper field and surrounding area

The company is convinced that the present wells are under producing due to the poor method of drilling used and that they can significantly increasee production with modern methods




TIME LINE SHORT TERM




September 1. trial of a new designed fracture stimulation method in an existing well

          1. Test the oil and gas composition of shallower reservoirs frac these zones and test flow rates (this could result in resource estimate upgradeas they are not included in current resources )
          2. Recomplete and frac a new 9m productive interval in the flax1 well (again this is not included in the current resources estimate)
          3. Install a pump in the flax 5 well to test improved well production capability
The September programme is estimated to cost $4-6 mm




  1. October Drill 3-6 new exploration and appraisal wells This follows the company acquiring a 3D seismic data report and reprocessing a older 3D report hopefully this will prove the intercnectedness of the flax and juniper field If so the amount of oip increase will be large indeed

    The October programme has an estimated capex of $9-18m



MID TERM

Utilising the experience of senior executives in building LNG plant (Arrow) they intend to build a small scale LNG plant as an oppurtunity to commercialise gas and mgls This has an estimated capex of $40-50m funding details are not given






  Forum: By Share Code

pacestick
Posted on: Jul 21 2012, 04:43 PM


Group: Member
Posts: 339

Conflicting opinions in israel on what to do

http://news.yahoo.com/low-support-israel-u...001.html?_esi=1
  Forum: Macro Factors

pacestick
Posted on: Jul 20 2012, 06:22 AM


Group: Member
Posts: 339

Israeli tourists in Bulgaria killed by Hezbullah Israel blames Iran and says it will retaliate
  Forum: Macro Factors

pacestick
Posted on: Jul 16 2012, 10:20 PM


Group: Member
Posts: 339


Acer Energy makes gains on strong Cooper Basin position
Monday, July 16, 2012 by Bevis Yeo Acer Energy’s (ASX: ACN) strong acreage position in the Cooper Basin with large oil discoveries has proven to be a winning strategy.

The company holds 8 exploration permits covering 2853 square kilometres in the Basin, 6 of which it operates, and is planning to drill up to 6 wells from September 2012.

Five of the permits are located on the GMI ridge, which hold the Flax and Juniper oil discoveries, which could hold more than 100 million barrels of in-place oil, the company also has large gas prospects with 180 billion cubic feet of in-place potential.

These permits also have secondary Birkhead targets that may be tested in new Flax development well locations

The company is also exposed to the basin centred gas accumulation in the Basin espoused by Beach Energy (ASX: BPT) through its PEL 100 and PEL 10 permits that contain the Northern Patchawarra Trough.

Flax and Juniper

While historical Flax wells were chosen based on an enhanced oil recovery development plan, 3D seismic has allowed Acer to identify multiple top of Flax structure well locations for potential future development drilling.

This has also resulted in the mapping of the Flax South structure between the Flax and Juniper structures that besides appearing to be about 65% the size of Flax, appears to have thicker Patchawarra Formation sands.

Juniper also appears to have Patchawarra channel sands that show up on 3D seismic as being potential secondary targets.

To top it off, a further 130 million barrel of in-place potential exists should further work confirm that the Flax and Juniper structures be connected.

Basin centred gas accumulation

Acer’s interest in PEL 101 and operating position in PEL 100 gives it a direct exposure to a potentially Basin changing resources.

Beach Energy’s unconventional exploration in the Cooper Basin has reinforced the potential for the Patchawarra Trough to host a basin centred gas accumulation, which has traditionally proved to both more productive and less expensive to develop than shale gas plays.

To that extent, Acer is participating in a 250 square kilometre 3D seismic program that will cover most of PEL 100 later this year.

Future plans

Besides the 3-6 well program that Acer plans to start in mid-September, the company will also carry out fracture stimulation across the Tirrawarra / Basal Patchawarra sands in Flax-2 and recomplete Flax-1 across the full 9 metres of the newly proven mid-Patchawarra pay and frac the interval.

Acer will also install artificial lift on Flax-5 before testing the improved well production capability.



Proactive Investors is a market leader in the investment news space, providing ASX “Small and Mid-cap” company news, research reports, StockTube videos and One2One Investor Forums.

  Forum: By Share Code

pacestick
Posted on: Jun 29 2012, 05:30 PM


Group: Member
Posts: 339

I wondered why we had two days of sp dropping like a stone I must admit I figured one would come to get a production line but not at such a low sp
  Forum: By Share Code

pacestick
Posted on: Jun 26 2012, 07:14 AM


Group: Member
Posts: 339

Fridays performance in volume did not continue last night however JP Morgan have more than doubled their holdings
http://www.nasdaq.com/symbol/unis/institutional-holdings
More sales agreements are expected before september
  Forum: By Share Code

pacestick
Posted on: Jun 24 2012, 08:09 AM


Group: Member
Posts: 339

volume up 5.5 times on the nasdaq compared to normal trade sp up three cents will asx follow monday I have no idea
  Forum: By Share Code

pacestick
Posted on: Jun 22 2012, 11:21 AM


Group: Member
Posts: 339

http://www.acerenergy.com.au/

showing a lot of potential in this update
  Forum: By Share Code

pacestick
Posted on: Jun 19 2012, 07:11 AM


Group: Member
Posts: 339

press release

June 18, 2012, 11:49 a.m. EDT


Unilife Signs Long-Term Supply Contract for the Unifill Prefilled Syringe

--Unifill Chosen for Upcoming Launch of Generic Equivalent of Auto-Immune Therapy --7-Year Contract to Generate Annual Revenue of up to $15MM for Initial E.U. Geography --Exclusivity Fee for Initial E.U. Geography and Indication, Other Territories Reserved




YORK, Pa., June 18, 2012 /PRNewswire via COMTEX/ -- Unilife Corporation ("Unilife" or "Company") UNIS +5.43% (asx:UNS) today announced the signing of a seven-year commercial supply contract with a pharmaceutical company for the Unifill® ready-to-fill (prefilled) syringe.

Target Drug and Market This supply contract for the Unifill syringe relates to the planned launch of a generic equivalent of an approved auto-immune therapy that is currently available in a standard prefilled syringe format for use across several indications.

The auto-immune therapeutic space includes disease states such as rheumatoid arthritis, psoriasis, psoriatic arthritis, lupus and Crohn's disease. The cumulative U.S. patient population affected by auto-immune diseases is greater than seven million people and approximately twice that worldwide. The drug has also been shown to be effective for the treatment of several cancers including breast, head and neck, leukemia, lymphoma, lung, osteosarcoma, bladder and trophoblastic neoplasms.

Currently, the majority of injections within the auto-immune therapeutic class are self-administered by patients using either a standard prefilled syringe or a conventional auto-injector. The release of the generic drug utilizing the Unifill syringe will mark the first time an auto-immune therapy is supplied in a prefilled syringe with safety features that can prevent needlestick injuries and encourage more convenient, safer disposal.

Exclusivity of Supply An exclusivity fee will be added onto the negotiated unit price of the Unifill syringe when agreed exclusivity conditions are met. Unilife will grant to the pharmaceutical customer an exclusivity of supply right for the Unifill syringe for a specific indication and Western European geography.

The Unifill syringe was selected by the pharmaceutical customer because of its capacity to differentiate its drug from brand name or generic competitors. The implementation next year of a legally binding E.U directive mandating the use of needlestick prevention products within European healthcare facilities also played a significant role in the selection of the Unifill syringe. Exclusive access to the Unifill syringe further strengthens the pharmaceutical customer's competitive strategy.

Other international geographies have also been reserved for exclusivity by the pharmaceutical customer, and will be added subject to the agreement of terms by both parties.

Projected Revenue Initial sales of the Unifill syringe to the pharmaceutical customer will commence in July 2012. Sales are expected to progressively increase in anticipation of the scheduled commercial launch of the pharmaceutical customer's drug within international geographies after regulatory approvals are granted during Fiscal Year 2013. Annual unit volumes for the Unifill syringe within the initial European geography are expected to reach up to 10 million units during the contract period, generating up to $15 million in revenue per year.

The unit volumes for the Unifill syringe can increase as other reserved international geographies are added by the pharmaceutical customer.

For commercial purposes and due to confidentiality clauses within agreements, additional terms of the contract and the identity of the pharmaceutical company are to remain confidential at this time.

Comments by Unilife CEO Alan Shortall Mr. Alan Shortall, CEO of Unilife, said, "Pharmaceutical companies are actively seeking access to innovative, differentiated devices for delivery of their brand name, generic and biosimilar drugs. The long-term supply contract that we have signed today underscores this growing trend and demonstrates how our proprietary portfolio of innovative device technologies can enable and enhance their commercial strategies for injectable drugs.

"Through the pairing of the Unifill syringe with their drug, this pharmaceutical customer can set a new benchmark for safety and functionality within this high-value therapeutic class, and turn compliance with needlestick prevention laws into a competitive market advantage. We look forward to building a strong relationship with this pharmaceutical customer to help them generate powerful differentiation and market demand for their drug.

"While full terms of this long-term contract cannot be fully disclosed for commercial purposes, I am pleased that it contains multiple revenue-generating components, including exclusivity fees, an attractive unit price and significant commercial upside moving forward as other reserved international territories are added."

"This is just one of many supply contracts that we expect to be generated for the Unifill syringe moving forward. We expect the Unifill syringe will be selected for a number of brand name and generic drugs targeted for use across a wide variety of therapeutic indications that are either approved and at various stages in their commercial lifecycle, or in clinical development. To best align ourselves with the commercial strategies of these pharmaceutical customers, and to drive shareholder value for Unilife, I expect these upcoming contracts will all vary in terms of size, scope and structure."

About Unilife Corporation Unilife Corporation is a U.S. based developer and commercial supplier of advanced drug delivery systems. Unilife collaborates with pharmaceutical and biotechnology companies seeking innovative, differentiated devices that can enable or enhance the delivery of injectable drugs and vaccines supplied in either a liquid stable or lyophilized form. The Unifill syringe, the world's first and only prefilled syringe with fully integrated safety features, sits at the leading edge of this diversified portfolio. In addition to prefilled and hypodermic safety syringes with automatic, user-controlled needle retraction, Unilife has other proprietary technology platforms including drug reconstitution delivery systems, auto-injectors, auto-infusion pump systems and specialized devices for targeted organ delivery. Unilife's global headquarters and state-of-the-art manufacturing facilities are located in York, PA. For more information on Unilife, please visit www.unilife.com

Forward-Looking Statements This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements, including statements relating to anticipated sales and revenues pursuant to the supply agreement, expected future supply contracts for the Unifill syringe, and potential geographical exclusivity additions under the supply agreement, are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, the risk that projected sales under the supply agreement will not be achieved, the risk that delays in regulatory approvals or commercial launch, and those risks and uncertainties described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G


  Forum: By Share Code

pacestick
Posted on: Jun 17 2012, 04:29 PM


Group: Member
Posts: 339

sharks in stock markets go back to at least 1929


Wall Street’s 1929 Scams Return in Geithner Plan: Jonathan Weil
Commentary by Jonathan Weil - April 23, 2009 00:01 EDT
April 23 (Bloomberg) -- What would Ferdinand Pecora do?

Thirty-seven years after his death, the name of this former assistant district attorney from New York suddenly is on a lot of politicians’ lips.

Starting in 1933, as counsel to the Senate Banking and Currency Committee, the Sicilian-born Pecora led a yearlong series of sensational hearings into the causes of the 1929 stock-market crash. The Wall Street scandals he unearthed spurred the creation of the Securities and Exchange Commission and the passage of the Glass-Steagall Act, which separated commercial and investment banking until its repeal in 1999.

Now, House Speaker Nancy Pelosi says she will push for the deepest congressional inquiry into Wall Street’s abuses since the 1930s, using Pecora’s investigation as a model. Before Congress proceeds, though, there’s one thing its members should do: Read the Pecora Commission’s 1934 report.

Some of the abusive practices Pecora chronicled are similar to the machinations at the heart of the Treasury Department’s plan to revive the nation’s hobbled financial-services industry. To see how, let’s look at a 1920s-era scheme called a pool, which in those days was a common device for manipulating prices on the New York Stock Exchange.

A pool referred to an agreement between several people, usually more than three, to actively trade in a single security. The purpose, the Pecora Commission wrote, was “to raise the price of a security by concerted activity on the part of the pool members,” enabling them “to unload their holdings at a profit upon the public attracted by the activity or by information disseminated about the stock.”

Pool Sharks

Some bankers claimed there was a difference between “beneficent” and “nefarious” pools. The good kind supposedly helped stabilize market prices, while the bad kind let swindlers make a quick buck.

Pecora didn’t buy the distinction. Either way, these were not free, uncontrolled markets. “In all cases fictitious activity is intentionally created, and the purchaser is deceived by an appearance of genuine demand for the security,” the commission’s report said. “Motive furnishes no justification for the employment of manipulative devices.”

Compare that with Treasury Secretary Timothy Geithner’s latest proposal to help financial institutions remove unwanted loans and mortgage-backed securities from their balance sheets.

Under the Treasury’s Public-Private Investment Program, the size of which could hit $1 trillion, the government plans to invest side-by-side with private investors who place bids on toxic assets that have plummeted in value. Those buyers, lured by federal loans and guarantees, might include affiliates of the same struggling banks and insurance companies the program is designed to assist.

Pricing Power

The Treasury program’s goal is to drive up prices and stimulate trading, so the financial institutions can minimize their losses and replenish their capital. Should the prices later collapse, taxpayers could end up with the vast majority of any losses.

As with an old-fashioned pool, one of the public-private program’s biggest vulnerabilities is that it invites collusion. That was one of the points made in a report this week by the Troubled Asset Relief Program’s inspector general.

“In both the Legacy Loans Program and the Legacy Securities Program, the significant government-financed leverage presents a great incentive for collusion between the buyer and seller of the asset, or the buyer and other buyers, whereby, once again, the taxpayer takes a significant loss while others profit,” the report said.

Profit Sharing

One example from the report: Say a bank and a private- equity firm both agree that a group of the bank’s loans is worth $600 million. The private-equity firm, however, agrees to overpay for the loans and bid $840 million at auction. The private-equity firm invests $60 million, which the government matches with $60 million of TARP money, and which is leveraged by a $720 million loan guaranteed by the Federal Deposit Insurance Corp.

After the auction, the bank secretly pays the investor a $120 million kickback, or half the difference between the auction price and the real value. Even if the private-equity firm’s $60 million investment is wiped out, it still would get a $60 million profit because of the kickback. Meanwhile, the bank would make a $120 million profit, at taxpayer expense.

“Of course, in practice, the collusive scheme would be far more complex and would likely involve a series of affiliates and offsetting transactions, but the principle would be the same,” the inspector general’s report said.

No Controls

Similar collusion could occur in the program for mortgage- backed securities. Fund managers might agree to overpay for each other’s holdings, leaving taxpayers to bear the losses. So far, the report said, the Treasury Department hasn’t set up the systems it needs to ensure proper oversight, such as basic conflict-of-interest rules or disclosure requirements for the private-equity firms’ owners.

The main premise of Geithner’s plan is that the banks’ toxic assets are now priced at artificially low levels. As the federal bailout program’s Congressional Oversight Panel wrote in an April 7 report, “Treasury has not explained its assumption that the proper values for these assets are their book values,” rather than the prices unsubsidized investors would pay for them.

If Treasury’s premise proves false, we may end up looking back on the Public-Private Investment Program as an elaborate pump-and-dump game. Only this time, unlike with the pools that sucked in gullible investors during the 1920s, the big losers would be taxpayers -- who never had the choice of not playing.

It’s hard to imagine that Pecora would think any of this is a good idea.

(Jonathan Weil is a Bloomberg News columnist. The opinions expressed are his own.)

To contact the writer of this column: Jonathan Weil in New York at jweil6@bloomberg.net

To contact the editor responsible for this story: James Greiff at jgreiff@bloomberg.net


  Forum: Investment Discussion

pacestick
Posted on: Jun 17 2012, 07:25 AM


Group: Member
Posts: 339

The answer in my case is 3 mixture of both and I have not left my finances so vulnerable as to be dependent on the market for an income I use it to supplement my income This is where I do believe some complaints are justified those who were conned by semminars and by books telling them that making a return was guaranteed if you applied certain analytical techniques . The market has always been a pool that you should take shark repellent into In my case I work on only using that proportion of my income that I can afford to lose I am not saying that it is a good thing that is happening it is a bad thing it is just that it is the market changing as it always has done and always will do
  Forum: Investment Discussion

pacestick
Posted on: Jun 16 2012, 11:52 AM


Group: Member
Posts: 339

i couldnt agree more rogers anyone who eneters the market thinking there are fixed rules that giuarantee a return is only there to transfer their wealth to those who are more flexible
  Forum: Investment Discussion

pacestick
Posted on: Jun 16 2012, 07:14 AM


Group: Member
Posts: 339

well I got the covering bit wrong but then so did this guy

http://carpedmstocks.blogspot.com.au/2012/...-line-time.html

<h1 class="title"> Carpe DM Stocks </h1>

<h2 class="title">Looking to make profits in Penny Stocks?</h2> Click Here!
<h2 class="date-header">Tuesday, June 12, 2012</h2> <h3 class="post-title entry-title" itemprop="name"> $UNIS - Shorts Expanding Waist Line - Time for a Big Belly Squeeze </h3> Short Interest was reported yesterday and not surprisingly, it was up again. Shorts added 300,000 to their position to just under 8.2 million shares. Even with the continued movement of shares being converted from the Australian Exchange and being moved to Nasdaq, this number is pretty staggering. If we breakdown the numbers, we'll find approximately 27 million shares trade on Nasdaq. This is taking out any options or warrants into the count. Of those shares we alread know that Institutions hold 18 million shares, effectively leaving 9 million shares in the float. In the last quarter, funds added just shy of 2.6 million shares to their portfolios. For arguments sake, lets assume that they only add 1 million shares to their registers this quarter. That would leave just 8 million shares in the float at the end of June. This assumes that every single retail investor is a liquid one and isn't holding long term. If we continue the assumption that shorters will continue to short the stock, then we are looking at a situation where more than 100% of the entire float in the US is now short. As it stands right now, the numbers and the stock price are starting to tilt in the longs favor. Below is a copy of the three month chart that illustrates how the shorts are losing their grip on the stock. Three months ago, the stock had a short position of 6.1 million shares. While they have added 2.1 million to the outstanding number of shorts, this has not prevented the stock from moving upwards. The stock only seems to take hits when volume is low and they have a greater influence on price. It would appear that is when funds step in and as volume rises so does the price. We have had back to back days of over 600,000 shares traded. This continued activity can only put the shorts on high alert and force them to consider whether or not to cover. At their currently level, and assuming volume continues to be strong, it could take short 20 days to purchase back their shares. Buying begats buying in these situations and the more that cover, the more that will want to cover, the more that others will want to buy. As the price rises there will be new shorts added at higher levels, but will they be able to withstand the ultra tight float?
  Forum: By Share Code

pacestick
Posted on: Jun 13 2012, 09:29 PM


Group: Member
Posts: 339

another strong rise today If the Nasdaq continues at this pace tonight the shorts will be in one very big mess We could see large overseas buying thursday and friday as they try to get out
  Forum: By Share Code

pacestick
Posted on: Jun 7 2012, 11:49 AM


Group: Member
Posts: 339

Acer Energy eyes increased resource and cash flow from new target zone in existing oil field
Thursday, June 07, 2012 by Bevis Yeo Acer Energy (ASX: ACN) has identified multiple additional potential pay zones at its Flax oil field in the Cooper Basin following a successful re-entry of the Flax-1 well.

This resulted in additional production from an unstimulated 4.5 metre mid-Patchawarra pay interval – the accessible portion of a broader 9 metre interval that had not being previously produced.

Acer noted that this interval represented a new productive reservoir that has not been

included in the current independent resource estimate of 15 million barrels of in place oil for the Flax field.

It added the post test oil and gas composition remained largely unchanged, confirming the new reservoir contains hydrocarbons of a consistent ratio to that of the lower productive reservoirs.

Of most interest to the company is the fact the interval appears to be present in other wells and could increase the size of the Flax field resource if confirmed.

Acer noted that more recoverable resource from an already developed and producing oil field represents the lowest cost, lowest risk and highest margin opportunity for shareholders.

Foward plans

To fully test and validate this new resource, Acer plans to fracture simulate and test the entire 9 metre interval in both Flax-1 and the correlating reservoir within other Flax wells.

It will also complete all engineering and design work to test additional Patchawarra zones identified within the Flax wells and use recently acquired 3D seismic data to identify lateral extent and potential new well locations.

Patchawarra

The coal and carbonaceous shale of the Patchawarra Formation represent the principal source rocks of the Cooper Basin.

It has also emerged as a potential unconventional play with the South Australian Department of Primary Industries and Resources and companies such as Beach Energy (ASX: BPT) believing that it hosts a basin centred gas accumulation that could change the East Coast gas market.


SOURCED FROM PROACTIVE IVESTORS
  Forum: By Share Code

pacestick
Posted on: May 4 2012, 08:12 AM


Group: Member
Posts: 339

I am expecting only two supply agreements between now and September I Know Alan said between June and August but only when he was cornered and forced to give dates . They will be large the third agreement I suspect will be more complex involving the funding of a production line in return for some exclusivity along the lines of the Sanofi agreement but not identical and as such I expect an agreement coild be as late as the first quarter of next calendar year but it could come a bit earlier
  Forum: By Share Code

pacestick
Posted on: Apr 22 2012, 07:31 AM


Group: Member
Posts: 339

I said to the wife you better lift your game there are other women out there showing an interest in me
She replied

YOU HAVE TO STOP HANGING OUT AT THE BRAILLE FOUNDATION
  Forum: Off Topic Chat

pacestick
Posted on: Apr 9 2012, 08:56 AM


Group: Member
Posts: 339


They seem to be lining up to talk from memory May was given as the date when they might give up and resort to hostilities



  • http://www.reuters.com/article/2012/04/08/us-iran-usa-nuclear-talks-idUSBRE83701F20120408

U.S., allies to set demands for Iran nuclear talks: NYT


WASHINGTON | Sun Apr 8, 2012 8:31am EDT

(Reuters) - The United States and other Western nations plan to demand that Iran immediately close and ultimately dismantle a recently completed nuclear facility deep under a mountain as part of new talks with Tehran over its nuclear program, the New York Times reported on Saturday.

The Obama administration and its European allies also will call for a halt in the production of higher-level enrichment of uranium fuel, and the shipment of existing stockpiles of that fuel out of Iran, the newspaper said, citing U.S. and European diplomats.

The diplomats told the Times that they could not imagine any agreement that left Iran with a stockpile of fuel, enriched to 20 percent purity, that could be converted to the grade needed to make an atomic bomb in a matter of months.

"We have no idea how the Iranians will react," a senior Obama administration official told the newspaper. "We probably won't know after the first meeting."

The opening talks are tentatively set for Friday.

In January, major powers signaled willingness to reopen the talks about curbing Iran's suspected pursuit of nuclear weapons but said Tehran must show it was serious about negotiations. Iran says its nuclear program is aimed solely at generating power.

The United States, Britain, France, Russia, China and Germany are the six powers involved in diplomacy aimed at resolving the long-running row over Iran's atomic plans.

Russia and China recently joined the four Western powers in expressing "regret" over Iran's expansion of higher-grade enrichment, most of which is now taking place deep inside a mountain near the Shi'ite Muslim holy city of Qom to better protect it against Israeli or U.S. attacks.

The focus on diplomacy followed rising tensions between the West, which is seeking to cut Iran's oil sales, and Tehran, which threatened to close the Strait of Hormuz through which almost one-fifth of oil traded worldwide flows.

The United States has gradually tightened sanctions on Tehran due to its failure to answer questions about its nuclear program.

(Writing by Paul Simao; Editing by Nick Macfie)

World
  Forum: Macro Factors

pacestick
Posted on: Mar 24 2012, 06:38 AM


Group: Member
Posts: 339



WSJ.com's inside look at the markets
  • March 23, 2012, 10:29 AM

Crude Oil Prices Spike Then Pull Back After Iranian Exports Report
<h3 class="byline">By Steven Russolillo</h3> The major market action today is in oil prices, which spiked, then pulled back and now remain firmly higher after reports of a sharp drop in Iranian oil exports.

Nymex crude spiked sharply immediately after the news, jumping about 3% and hitting an intraday high of $108.25 a barrel, the highest level in three weeks. But prices have come back a bit in the last few minutes and recently were up 1.4% at $106.92.

Reuters reported crude exports from Iran are expected to drop by 300,000 barrels per day this month.

Turmoil in the Middle East has prompted oil prices to soar this year, which have reverberated to consumers in the form of higher gas prices. Rising gas prices are one of the biggest worries that could derail the U.S. economic recovery.

Earlier today President Obama chimed in on the issue, saying Middle East tensions could add about $20 to $30 to oil prices. Here’s a report from Dow Jones’s Jared Favole:

President Barack Obama said that tension in the Middle East adds about $20 to $30 to a barrel of oil and is helping drive up the price of gasoline.

“Right now the key thing that is driving higher gas prices is actually the world’s oil markets and uncertainty about what’s going on in Iran and the Middle East, and that’s adding a $20 or $30 premium to oil prices,” the president said in an interview with auto club AAA.

The president conducted the interview Thursday, while he was visiting an oil pipeline yard in the Cushing, Okla., area. The president has been touting his plan for U.S. energy production in recent weeks as gasoline prices have risen 8% over the last month.

  Forum: Macro Factors

pacestick
Posted on: Mar 21 2012, 02:07 PM


Group: Member
Posts: 339

Wednesday mar 21
The Irish Times - Wednesday, March 21, 2012
US war simulation reveals hazards of Israeli strike against Iran



If Israel launches attacks against Iran to prevent it getting the bomb, the United States would likely be sucked into the ensuing war, write MARK MAZZETTI and THOM SHANKER in Washington

A CLASSIFIED war simulation exercise held this month to assess the repercussions of an Israeli attack on Iran forecasts that the strike would lead to a wider regional war, which could draw in the United States and leave hundreds of Americans dead, according to US officials.

The officials said the so-called war game was not designed as a rehearsal for US military action and they emphasised that the exercise’s results were not the only possible outcome of a real-world conflict. But the game has raised fears among top US planners that it may be impossible to preclude US involvement in any escalating confrontation with Iran, the officials said.

The results of the war game were particularly troubling to Gen James Mattis, who commands US forces in the Middle East, Persian Gulf and southwest Asia, and told aides that an Israeli first strike would likely have dire consequences across the region and for US forces there.

The two-week war game, called Internal Look, played out a narrative in which the US found it was pulled into the conflict after Iranian missiles struck a US navy warship in the Persian Gulf, killing about 200 Americans. The US then retaliated by launching its own strikes on Iranian nuclear facilities.

The initial Israeli attack was assessed to have set back the Iranian nuclear programme by roughly a year and the subsequent US strikes did not slow the Iranian programme by more than an additional two years. However, other Pentagon planners have said that America’s arsenal of long-range bombers, refuelling aircraft and precision missiles could do far more damage to Iranian nuclear aspirations – if US president Barack Obama were to decide on a full-scale retaliation.

The exercise was designed specifically to test internal military communications and co-ordination among battle staffs in the Pentagon, Tampa, Florida, home of the Central Command headquarters, and in the Persian Gulf in the aftermath of an Israeli strike. However, the exercise was written to assess a pressing, potential, real-world situation.

In the end, the war game reinforced to military officials the unpredictable and uncontrollable nature of a strike by Israel and a counterstrike by Iran, the officials said.

US and Israeli intelligence services broadly agree on the progress Iran has made to enrich uranium. But they disagree on how much time there would be to prevent the Persian state from building a weapon if Tehran decided to go ahead with one.

With the Israelis saying publicly that the window to prevent Iran from building a nuclear bomb is closing, US officials see an Israeli attack on Iran within the next year as a possibility. They have said privately that they believe that Israel would probably give the US little or no warning should Israeli officials make the decision to strike Iranian nuclear sites.

Officials said that, under the chain of events, Iran believed that Israel and the US were partners in any strike against Iranian nuclear sites and therefore considered US military forces in the Persian Gulf as complicit in the attack. Iranian jets chased Israeli warplanes after the attack and Iranians launched missiles at a US warship in the Persian Gulf, viewed as an act of war that allowed an American retaliation.

Many experts have predicted that Iran would try to carefully manage the escalation after an Israeli first strike in order to avoid giving the US a rationale for attacking with its far superior forces.

Thus, it might use proxies to set off car bombs in world capitals or funnel high explosives to insurgents in Afghanistan to attack US and North Atlantic Treaty Organisation troops. While using surrogates might, in the end, not be enough to hide Iran’s instigation of these attacks, the government in Tehran could at least publicly deny responsibility.

Some military specialists in the US and in Israel who have assessed the potential ramifications of an Israeli attack believe that the last thing Iran would want is a full-scale war on its territory. Thus, they argue that Iran would not directly strike US military targets, whether warships in the Persian Gulf or bases in the region.

Their analysis, however, also includes the broad caveat that it is impossible to know the internal thinking of the senior Iranian leadership and is informed by the awareness that even the most detailed war games cannot predict how nations and their leaders will react in the heat of conflict.

Yet these specialists continue their work, saying that any insight on how the Iranians will react to an attack will help determine whether the Israelis launch a strike – and what the US position will be if they do.

Israeli intelligence estimates, backed by academic studies, have cast doubt on the widespread assumption that a military strike on Iranian nuclear facilities would set off a catastrophic set of events like a regional conflagration, widespread acts of terrorism and sky-high oil prices.

“A war is no picnic,” Israeli defence minister Ehud Barak told Israel Radio in November. But if Israel feels itself forced into action, the retaliation would be bearable, he said.

“There will not be 100,000 dead or 10,000 dead or 1,000 dead,” the defence minister said. “The state of Israel will not be destroyed.” – (New York Times service)

  Forum: Macro Factors

Poll: Politics
pacestick
Posted on: Mar 15 2012, 10:16 AM


Group: Member
Posts: 339

At this time both major parties are led by individuals unable to engage the people The end result is that whoever wins the Australian voter loses as the winner will take more notice of power games than voter wants
  Forum: Off Topic Chat

pacestick
Posted on: Mar 13 2012, 08:01 PM


Group: Member
Posts: 339

I will be accumulating
  Forum: By Share Code

pacestick
Posted on: Feb 29 2012, 04:55 PM


Group: Member
Posts: 339

has risen strongly perhaps on the back of drilling programme due to start next quarter
  Forum: By Share Code

pacestick
Posted on: Feb 21 2012, 07:55 AM


Group: Member
Posts: 339


Crude Oil Advances to Nine-Month High on Iran Export Halt, Europe Talks
By Grant Smith and Yee Kai Pin - Feb 21, 2012 7Oil rose to a nine-month high in New York after Iran said it halted some crude exports and investors bet that fuel demand will increase as Europe moves closer to bailing out Greece.

Futures climbed as much as 2.1 percent for a fourth day of gains, the longest rising streak since December. Iran will supply crude to “new customers” instead of companies in the U.K. and France, the oil ministry’s news website, Shana, said, citing Alireza Nikzad Rahbar, a spokesman. Prices also advanced as European finance ministers prepared to meet to discuss a 130 billion-euro ($172 billion) aid package for Greece, the country’s second rescue in less than two years.

“The heightened level of tension surrounding Iran’s nuclear program continues to support prices, as does satisfactory growth in the U.S. and China,” said Christopher Bellew, a senior broker at Jefferies Bache Ltd. in London, who correctly predicted last week that the price of Brent crude would advance to $120 a barrel.

Crude for March delivery rose as much as $2.20 to $105.44 a barrel in electronic trading on the New York Mercantile Exchange, the highest intraday price since May 5. The contract, which expires tomorrow, last traded at $104.92 at the 1:15 p.m. New York close of Globex electronic trading. The more actively traded April contract gained $1.66 to $105.26. Prices increased 4.6 percent last week and are up 6.2 percent so far this year.

Brent oil for April settlement on the London-based ICE Futures Europe exchange climbed as much as $1.57, or 1.3 percent, to $121.15 a barrel before settling at $120.05. The European benchmark contract was at a premium of $15.13 to New York-traded crude. The gap was a record $27.88 on Oct. 14.


Preempting Ban
Iran’s suspension of exports followed a warning by its oil minister that Tehran might preempt a European Union ban on purchases of the nation’s crude planned to start July 1, Rahbar said without giving further details, according to the Shana report yesterday. The EU and U.S. imposed sanctions on Iran, the second-largest oil producer in the Organization of Petroleum Exporting Countries, in an attempt to halt its nuclear program.

EU nations bought a combined 18 percent of Iran’s crude and condensate exports, or 452,000 barrels a day, in the first half of 2011, according to the most recent data on the website of the U.S. Energy Information Administration. France purchased 2 percent of Iran’s shipments, or 49,000 barrels a day, while the U.K. took less than 1 percent, the data showed.


Sufficient Stockpiles
The EU said it has sufficient supplies of oil and petroleum products to weather a disruption in Iranian supplies. Stockpiles are at 136 million tons or 120 days of consumption, “well above the 90-day minimum,” Marlene Holzner, an EU spokeswoman, said today in an e-mailed statement.

“The continuity of supplies of crude oil and petroleum products to European consumers should therefore not be immediately affected, even in case of an abrupt halt of all imports from Iran,” Holzner said.

Total SA, France’s biggest oil company, has stopped buying Iranian crude, Chief Executive Officer Christophe De Margerie told Bloomberg Television in a Jan. 27 interview in Davos. A Total spokesman didn’t respond to calls to his mobile phone or an e-mail yesterday.

BP Plc doesn’t buy crude from Iran, David Nicholas, a London-based spokesman, said by phone. An official for Royal Dutch Shell Plc, Europe’s largest energy company, said she had no comment when contacted by phone in London, asking not to be identified due to internal policy.


Finance Ministers Meeting
European governments moved toward a second rescue of Greece, calculating that the 130 billion-euro ($172 billion) cost of a fresh bailout is a price worth paying to prevent a default that could shatter the euro area.

Finance ministers will weigh the terms of new loans to Greece and a possible contribution by central banks at a meeting today in Brussels. They also aim to start a bond exchange with private investors meant to stave off a Greek bankruptcy next month.

Greek Prime Minister Lucas Papademos told ministers this weekend he found all the extra spending cuts needed to secure a bailout, according to an e-mailed transcript of a Feb. 18 cabinet meeting in Athens.

“Sentiment in the market has changed in the last week,” said Tetsu Emori, a commodity fund manager at Astmax Ltd. in Tokyo who predicts oil will reach $110 a barrel in the near term. “We had news that Iran stopped some exports so that might have pushed up prices. The euro countries have no choice but to accept an agreement; otherwise everything will collapse.”

Oil also increased with stocks after China cut reserve ratios at its banks to boost lending and economic growth as the country’s housing market cools and the European debt crisis weighs on exports. The MSCI Asia Pacific index was up 0.8 percent at 128 in Tokyo, extending the longest run of weekly gains since 2005.


Technical Resistance
China accounted for about 11 percent of global oil demand in 2010 and the 27 EU member states consumed 16 percent, according to BP’s annual Statistical Review of World Energy.

Crude in New York opened today’s trading above long-term technical resistance at $103.39 a barrel, according to data compiled by Bloomberg. On the weekly chart, that’s the 61.8 percent Fibonacci retracement of the drop to $32.40 in December 2008 from a record high of $147.27 in July that year. Buy orders tend to be clustered above chart-resistance levels.

“With the break in resistance, probably some fresh buying is coming into the market,” said Emori at Astmax. “Crude completely broke $100 so I think that will now be a very important support level.”


Hedge Funds
Hedge funds and other large speculators boosted their net- long position in crude futures to the highest level in nine months, according to the U.S. Commodity Futures Trading Commission. Managed-money bets that prices will rise, in futures and options combined, outnumbered short positions by 233,889 contracts in the week ended Feb. 14, the Washington-based regulator said in its report on Feb. 17. Net-long positions rose by 28,180 contracts, or 13.7 percent, from a week earlier.

Money managers raised bullish bets on Brent crude by 6,818 contracts last week, according to data from the ICE Futures Europe exchange. Speculative bets that prices will rise, in futures and options combined, outnumbered short positions by 97,213 lots, the London-based exchange said today in its weekly Commitment of Traders report. That’s up from 90,395 lots the previous week.

March-delivery gasoline rose 3.55 cents, or 1.2 percent, to $3.0511 a gallon on the Nymex. Prices gained 1.4 percent last week, and are up 14 percent so far this year.

Heating oil for March delivery gained 2.73 cents, or 0.9 percent, to $3.2162 a gallon on the exchange.

To contact the reporters on this story: Grant Smith in London at gsmith52@bloomberg.net; Yee Kai Pin in Singapore at kyee13@bloomberg.net

To contact the editor responsible for this story: Dan Stets at dstets@bloo

http://www.bloomberg.com/video/86606948/
  Forum: Macro Factors

pacestick
Posted on: Feb 14 2012, 06:11 PM


Group: Member
Posts: 339

Im still here and I am quite excited Australia
  Forum: By Share Code

pacestick
Posted on: Feb 11 2012, 05:52 AM


Group: Member
Posts: 339

tapis now at its highest since july 2011
http://www.bloomberg.com/quote/APCRTAPI:IND
  Forum: Macro Factors

pacestick
Posted on: Jan 22 2012, 05:46 AM


Group: Member
Posts: 339

<h1 id="yui_3_3_0_27_1327174963803452" class="headline">After threats, Iran plays down U.S. naval moves</h1>By Robin Pomeroy and Hashem Kalantari | Reuters – 3 hrs ago
TEHRAN (Reuters) - Iran's Revolutionary Guard Corps said on Saturday it considered the likely return of U.S. warships to the Gulf part of routine activity, backing away from previous warnings to Washington not to re-enter the area.

The statement may be seen as an effort to reduce tensions after Washington said it would respond if Iran made good on a threat to block the Strait of Hormuz - the vital shipping lane for oil exports from the Gulf.

"U.S. warships and military forces have been in the Persian Gulf and the Middle East region for many years and their decision in relation to the dispatch of a new warship is not a new issue and it should be interpreted as part of their permanent presence," Revolutionary Guard Deputy Commander Hossein Salami told the official IRNA news agency.

The apparently conciliatory comments may be a response to the European Union and Washington's rejection of Iran's declaration it was close to resuming negotiations with world powers and with the Pentagon saying it did not expect any challenge to its warships.

Crude prices have spiked several times this year on fears diplomatic tensions could escalate to military clashes as well as uncertainty about the effect of sanctions on the oil market.

Along with the EU, which is set to agree an embargo on Iranian oil next week, Washington hopes the sanctions will force Iran to suspend the nuclear activities it believes are aimed at making an atom bomb, a charge Tehran denies.

There has been no U.S. aircraft carrier in the Gulf since the USS John C. Stennis left at the end of December at a time when the Revolutionary Guard was conducting naval maneuvers.

On January 3, after U.S. President Barack Obama signed new sanctions aimed at stopping Iran's oil exports, Tehran told the Stennis not to return - an order interpreted by some observers in Iran and Washington as a blanket threat to any U.S. carriers.

"I recommend and emphasize to the American carrier not to return to the Persian Gulf," Iran's army chief, Major General Ataollah Salehi, said at the time. "We are not in the habit of warning more than once."

NEW MANOEUVRES

Washington says it will return to the Gulf and Defense Secretary Leon Panetta said any move to block Hormuz - through which around a third of the world's sea-borne traded oil passes - would be seen as a "red line," requiring a response.

Citing operational security, the Pentagon will not say when the next carrier will return to the Gulf but officials say it is only a matter of time and they do not expect any problems.

In the coming days or weeks, the Revolutionary Guard will begin new naval exercises in the Strait of Hormuz and the Gulf. Salami told IRNA these would go ahead as planned in the Iranian month of Bahman which runs from January 21 to February 19.

Iran has said it is ready to return to talks with world powers that stalled one year ago, but the West, concerned about Tehran's move of the most sensitive atomic work to a bomb-proof bunker, says it must first see a willingness from Tehran to address the nuclear issue.

French President Nicolas Sarkozy said on Friday "time is running out" for a diplomatic solution and urged Russia and China to drop their opposition to sanctions on Iranian oil.

Iran is OPEC's second biggest exporter and blocking its crude exports - through the EU embargo or U.S. moves to punish banks that trade with Iran - could have a devastating impact on its economy but there are no signs so far such pressure would force it to stop what it calls its peaceful nuclear rights.

(Writing by Robin Pomeroy; Editing by Sophie Hares)

@yahoonews on Twitter, become a fan on Facebook
  Forum: Macro Factors

pacestick
Posted on: Jan 15 2012, 03:22 PM


Group: Member
Posts: 339

<h1 id="yn-title">Nigeria labor says no agreement to end fuel strike</h1>












By BASHIR ADIGUN and JON GAMBRELL, Associated Press – Sat Jan 14, 9:18 pm ET ABUJA, Nigeria – Nigeria's government and labor unions failed to end a paralyzing nationwide strike over high gasoline costs, potentially sparking an oil production shutdown in a nation vital to U.S. oil supplies.

It was not immediately clear early Sunday whether a major oil workers' union had gone ahead with its threat to have its members walk off their jobs starting at midnight in an effort to halt oil production. But the fact labor unions left quickly from their meeting with the government and no one announced when talks would resume raised concerns the impasse would see Nigeria go through more days of disruptive strikes.

Nigeria, which produces 2.4 million barrels of oil a day, is the fifth-largest oil exporter to the United States. Any disruption to oil production could roil the oil futures market at a time traders remain concerned about world supply.

President Goodluck Jonathan did not show up for a meeting with union representatives held Saturday night at the presidential villa in Nigeria's capital Abuja, nor did Vice President Namadi Sambo. Instead, the nation's Senate president and its House speaker represented the government along with other officials.

After the meeting, Nigeria Labor Congress President Abdulwaheed Omar told waiting journalists: "We have not reached a compromise."

Asked whether oil production would immediately halt, Omar said: "We are taking these things gradually."

Senate President David Mark described the talks as "very fruitful," though he offered no other details.

Nigeria has been gripped by a paralyzing strike since Monday when labor unions called the nationwide work stoppage in response to a government decision to remove subsidies, causing fuel prices to more than double in Africa's most populous nation. However, oil workers mostly remained on the job.

On Thursday, the Petroleum and Natural Gas Senior Staff Association of Nigeria threatened to stop all oil production in Nigeria at midnight Saturday. President Babatunde Ogun and other union officials were not immediately available to confirm whether its members had left their posts.

The union's ability to enforce a shutdown across the swamps of Nigeria's southern delta to its massive offshore oil fields remains in question. Much of Nigeria's land-based oil fields remain largely automated and an increasing amount of production comes from large offshore oil fields far from the country's coasts.

But the threat of a strike caused jitters on global oil markets Friday. And if something breaks, if the pressure in the wells fluctuate, or if countless other problems occur that cause an automatic system shutdown, there wouldn't be anyone there to get production running again at the Nigerian fields.

The strike began Monday, paralyzing the nation of more than 160 million people. The root cause remains gasoline prices: President Goodluck Jonathan's government abandoned subsidies that kept gasoline prices low on Jan. 1, causing prices to spike from $1.70 per gallon (45 cents per liter) to at least $3.50 per gallon (94 cents per liter). The costs of food and transportation also largely doubled in a nation where most people live on less than $2 a day.

Anger over losing one of the few benefits average Nigerians see from being an oil-rich country, as well as disgust over government corruption, have led to demonstrations across this nation and violence that has killed at least 10 people. Red Cross volunteers have treated more than 600 people injured in protests since the strike began, the International Committee of the Red Cross said Friday.

Even if strikers are only partially successful, fears of tightened global supplies could raise oil prices by $5-$10 per barrel on futures markets next week. Gasoline prices would follow, rising by as much as 10 cents per gallon and forcing U.S. drivers to spend an additional $36 million a day at the pump.

Experts predict the national average in the U.S. could rise as high as $4.25 per gallon ($1.12 a liter) in 2012.

Companies with subsidiaries in Nigeria include Chevron Corp., Exxon Mobil Corp., Italy's Eni SpA, Royal Dutch Shell PLC and French firm Total SA, which operate in tandem with the state-run Nigerian National Petroleum Corp.

___

Jon Gambrell reported from Lagos, Nigeria and can be reached at http://www.twitter.com/jongambrellAP.

  Forum: Macro Factors

pacestick
Posted on: Jan 14 2012, 05:46 AM


Group: Member
Posts: 339


Another mysterious death of an Iranian nuclear scientist raises the possibility of war in 2012
By Michael Burleigh


Last updated at 8:27 AM on 12th January 2012


Target: Mostafa Ahmadi-Roshan who was killed in Tehran by a car bomb

On Saturday the Iranian Atomic Energy Organisation announced that production of uranium, enriched to 20 per cent, would commence at the underground facility of Fardow near the holy city of Qom.


The site consists of a bunker beneath a mountain. This level of uranium enrichment exceeds whatever might be involved in producing radiological therapies for cancer patients.

Almost like clockwork, yesterday morning two men on motorbikes attached a magnetic explosive device to a car containing Mostafa Ahmadi Roshan, a 32-year-old chemist who was deputy director for commercial procurement at the Natanz nuclear plant. He died immediately; his Revolutionary Guard bodyguard come driver expired a few hours later.

Yesterday was the second anniversary of the death of Masoud Ali Mohammadi, a nuclear scientist blown up outside his house by a bomb attached to a motorbike parked nearby on the same street. Three other Iranian scientists have also been killed using roughly the same MO.

Clearly being a nuclear scientist is not a very healthy occupation in Iran today.


More...
These assassinations have been accompanied by much tougher western sanctions. The US Congress has virtually criminalised anyone dealing with the Bank of Iran, which processes all international payments for oil and gas exports.


The EU is likely to follow within this month. In a further tightening of the noose, the US Treasury Secretary is touring China and Japan, encouraging them to stop buying Iranian crude oil.


Enlarge A crane lifts away the wreckage of Mr Roshan's car after he was killed by a magnetic bomb was attached to it

That will have a devastating effect on Iran, which needs income from crude oil and gas exports to pay for its imports of refined petrol, which thanks to its decrepit refining capacity, is in short supply. It would incentivise the sort of dissent we saw in 2009 over the stolen election.

Iran's responses to these measures have been predictably stupid. It has threatened to close the Strait of Hormuz, the 21 miles wide waterway, whose shipping channel narrows to 2 miles.


It recently carried out naval exercises there, and has warned the US not to patrol it with carriers from the Fifth Fleet, a warning the US Navy will ignore.


Iran's naval chief has boasted that closing the Strait will be as easy as drinking a glass of water. He forgets that one of those US carriers has more airpower on board than most countries dispose of, backed up by a huge strategic bomber fleet and satellite intelligence of incredible sophistication.

Spate: Four scientists apparently involved in Iran's nuclear programme have been killed in the last two years



Tensions: Type 45 Destroyer HMS Daring, which was sent to the Strait of Hormuz last week after Iran blockade threats

If they mine the Straits of Hormuz, the mines will go in the first 24 hours, followed by every minelaying ship Iran possesses. Today Iran is threatening to retaliate in kind for the mystery killing of its scientists and technicians.

In other words, it is refusing, as it has done all along, to enter into negotiations to find a way for it to have civil nuclear power, but not a bomb. There have been several perfectly reasonable suggestions on the table, including Russian offers to do the enrichment processing (to acceptable limits) for them.

Like most people, here, in the US or China and Japan, I don't want to see a war in the Persian Gulf, not least because it will send the price of oil through the roof, and tip all our economies into deep recession.


I was vaguely nauseated when the new Defence Secretary, Phillip Hammond, rattled Britain's little sabre in Washington, especially since the Pentagon is being much more cautious.

So on the crisis goes, in all likelihood, resulting in the Iranian regime making some serious misstep, which will result in a war at some point in 2012.

<a href="http://hitchensblog.mailonsunday.co.uk/">

Read more: http://www.dailymail.co.uk/debate/article-...l#ixzz1jMwXEUNn
  Forum: Macro Factors

pacestick
Posted on: Jan 7 2012, 10:27 AM


Group: Member
Posts: 339

<h1 id="yui_3_3_0_33_1325895767894452" class="headline">Exclusive: West readies oil plan in case of Iran crisis</h1>By Peg Mackey and Richard Mably | Reuters – 2 hrs 10 mins ago
  • EDITORS' NOTE: Reuters and other foreign media are subject to Iranian restrictions …
LONDON (Reuters) - Western powers this week readied a contingency plan to tap a record volume from emergency stockpiles to replace nearly all the Gulf oil that would be lost if Iran blocks the Strait of Hormuz, industry sources and diplomats told Reuters.

They said senior executives of the International Energy Agency (IEA), which advises 28 oil consuming countries, discussed on Thursday an existing plan to release up to 14 million barrels per day (bpd) of government-owned oil stored in the United States, Europe, Japan and other importers.

Action on this scale would be more than five times the size of the biggest release in the agency's history -- made in response to Iraq's 1990 invasion of Kuwait.

The maximum release, some 10 million bpd of crude and about 4 million bpd of refined products, could be sustained during the first month of any coordinated action, the plan says.

"This would form a necessary and sensible response to a closure of the strait," a European diplomat told Reuters. "It wouldn't take long to put in place if it was required ... and would be unlikely to prove controversial amongst the (IEA) membership."

A spokesman for the IEA confirmed that the Paris-based agency has an existing contingency plan that outlines a maximum stock release capability of 14 million bpd for a month. "We're watching the situation carefully," he said of Iran.

Tehran announced plans on Friday for new military exercises in the world's most important oil shipping lane, through which some 16 million barrels of crude pass each day.

Iranian officials have threatened to block the strait if new sanctions, aimed to discourage Iran's nuclear programme, harm Tehran's oil exports.

Many oil experts believe the threats are rhetoric aimed at pushing up oil prices in a bid to avert sanctions.

"The IEA is monitoring the situation very closely, and is fairly concerned about it," the diplomat said, confirming that senior management discussed Iran at the meeting on Thursday.

Western governments are targeting Iranian oil supplies and the European Union is readying a ban on the country's crude oil exports of about 500,000 bpd with the goal of a final decision by month's end, while Washington has already imposed financial measures to discourage business with Tehran.

Industry sources said the IEA is unlikely to release stocks in the event of an EU embargo on Iran. While Europe will import less Iranian oil, Tehran will seek to sell larger volumes to its biggest customers in Asia.

However, Bob McNally, a former White House energy advisor and now head of consultancy Rapidan Group, says even a more modest disruption -- if Iran were to shut in some of its own production due to sanctions pressure, for instance -- may require action.

"Given low OPEC spare capacity, IEA stock releases may need to be considered if prolonged supply disruptions even smaller than the flow through Hormuz were to take place," he said.

U.S. congressman Edward Markey, the top Democrat on the House of Representatives' Natural Resources Committee, said he would support U.S. releasing its reserves, although he views the emergency stockpiles as only a short term solution to the nation's energy problems.

"America should always be willing to use our strategic oil reserves as a weapon against OPEC dictators, Wall Street speculators and any manipulators of the oil markets, and the recent saber rattling from Iran is no different," Markey told Reuters in a statement.

Also watching closely are oil giants Saudi Arabia, Kuwait and Iraq who depend on the strait to move most of their crude.

If the Gulf channel gets blocked, Saudi Arabia, the world's top exporter, can route more crude through the country's East-West pipeline system to the port of Yanbu on the Red Sea.

PIPELINES AVAILABLE

Altogether that network has effective capacity of some 4.5 million bpd and after supplying Saudi domestic refineries in Jeddah, Riyadh, Rabigh and Yanbu - there is about 3 million bpd of export capacity available, said an industry source.

The neighboring United Arab Emirates also has export flexibility. It is nearing completion of the Abu Dhabi crude oil pipeline, which will bypass the strait to ship as much as 1.5 million bpd to the Indian Ocean. Industry sources said the pipeline has been tested and the first flow of oil has already been pumped.

"It's now only a matter of switching on a button," one industry source said.

The IEA tapped emergency stocks in June to help supply refiners caught short by supply lost to Libya's civil war. It was a move that angered the Organization of the Petroleum Exporting Countries which felt the consumer group had overstepped its bounds.

Founded in 1974 in the wake of the Arab oil embargo, the IEA has only drawn down reserves on three occasions. Apart from last summer, member countries released oil in 2005 after Hurricane Katrina damaged offshore oil facilities in the Gulf of Mexico and made available 2.5 million bpd in January 1991 after Iraq's invasion of Kuwait disrupted about 4.3 million bpd.

(Additional reporting by Muriel Boselli in Paris, Humeyra Pamuk in Dubai, Dmitry Zhdannikov in London and Joshua Schneyer in New York, editing by Anthony Barker, Marguerita Choy and Bob Burgdorfer)

@yahoonews on Twitter, become a fan on Facebook
  Forum: Macro Factors

pacestick
Posted on: Jan 6 2012, 05:25 AM


Group: Member
Posts: 339

<h1 class="headline">Analysis: Iran could close Hormuz -- but not for long</h1>By Peter Apps, Political Risk Correspondent | Reuters – 3 hrs ago
Related Content
  • Iran's Navy Commander Habibulah Sayari points at a map during a news conference in
LONDON (Reuters) - Should Iran's rulers ever make good their threats to block the Straits of Hormuz, they could almost certainly achieve their aim within a matter of hours.

But they could also find themselves sparking a punishing -- if perhaps short-lived -- regional conflict from which they could emerge the primary losers.

In recent weeks, a growing number of senior Iranian military and civilian officials have warned that Tehran could use force to close the 54 km (25 mile) entrance to the Gulf if Western states impose sanctions that paralyze their oil exports.

In 10 days of highly publicized military exercises, state television showed truck-mounted missiles blasting towards international waters, fast gunboats practicing attacks and helicopters deploying divers and naval commandos.

Few believe Tehran could keep the straits closed for long -- perhaps no more than a handful of days -- but that alone would still temporarily block shipment of a fifth of all traded global oil, sending prices rocketing and severely denting hopes of global economic recovery.

But such action would swiftly trigger retaliation from the United States and others that could leave the Islamic republic militarily and economically crippled.

"They can cause a great deal of mischief... but it depends how much pain they are willing to accept," says Nikolas Gvosdev, professor of national security studies at the U.S. Naval War College in Rhode Island.

He said he believed Tehran would only take such action as a last resort: "They are much more likely to threaten than to act."

The true purpose of its recent saber-rattling, many analysts suspect, may be more a mixture of deterring foreign powers from new sanctions and distracting voters from rising domestic woes ahead of legislative elections in March.

With the United States signing new sanctions into law on New Year's Eve -- although they will not enter force until the middle of the year -- and the European Union considering similar steps, few expect the pressure on Tehran to let up.

"This is probably less a genuine military threat than a bid to put economic pressure back on the West and split Western powers over sanctions that threaten Iran's oil economy," says Henry Wilkinson, head of intelligence and analysis at London security consultants Janusian.

"Iran now does not have much to lose by making such a threat and a lot to gain."

But many fear the more Iran is pushed into a corner, the greater the risk of miscalculation.

Its ruling establishment is also widely seen as deeply divided, with some elements -- particularly the well-equipped and hardline Revolutionary Guard -- much keener on confrontation than others.

SEA MINES, MISSILES, SUBMARINES, SPEEDBOATS

"I cannot see strategic sense in closing the straits, but then I do not understand the Iranian version of the 'rational actor'," said one senior Western naval officer on condition of anonymity.

"(But) one can be pretty certain that they will misjudge the Western reaction... They clearly find us as hard to read as we find them."

The capability to wreak at least temporary chaos, however, is unquestionably there.

The U.S. Fifth Fleet always keeps one or two aircraft carrier battle groups either in the Gulf or within striking distance in the Indian Ocean.

Keenly aware of conventional U.S. military dominance in the region, Iran has adopted what strategists describe as an "asymmetric" approach.

Missiles mounted on civilian trucks can be concealed around the coastline, tiny civilian dhows and fishing vessels can be used to lay mines, and midget submarines can be hidden in the shallows to launch more sophisticated "smart mines" and homing torpedoes.

Iran is also believed to have built up fleets of perhaps hundreds of small fast attack craft including tiny suicide speedboats, learning from the example of Sri Lanka's Tamil Tiger rebels who used such methods in a war with the government.

At worst, its forces could strike simultaneously at multiple ships passing out of the Gulf, leaving a string of burning tankers and perhaps also Western warships.

But a more likely initial scenario, many experts believe, is that it would simply declare a blockade, perhaps fire warning shots at ships and announce it had laid a minefield.

"All the Iranians have to do is say they mined the straight and all tanker traffic would cease immediately," says Jon Rosamund, head of the maritime desk at specialist publishers and consultancy IHS Jane's.

RETALIATION, ESCALATION

U.S. and other military forces would find themselves swiftly pushed by shippers and consumers to force a route through with minesweepers and other warships -- effectively daring Tehran to fire or be revealed to have made an empty threat.

During the so-called "tanker war" of the mid-1980s, Gulf waters were periodically mined as Iran and Iraq attacked each other's oil shipments.

U.S., British and other foreign forces responded by escorting other nations' tankers -- as well as conducting limited strikes on Iranian maritime targets.

This time, retaliation could go much further. In closing the straits, Tehran would have committed an act of war and that might prove simply too tempting an opportunity for its foes to pass up.

"We might well take the opportunity to take out their entire defense system," said veteran former U.S. intelligence official Anthony Cordesman, now Burke Chair of Strategy at the Centre for Strategic and International Studies in Washington DC.

"You'd almost certainly also see serious strikes on their nuclear facilities. Once the Iranians have initiated hostilities, there is no set level at which you have to stop escalation."

Whilst in theory it would be possible to push heavily protected convoys through the straits even in the face of Iranian attack, few believe shippers or insurers would have the appetite for the level of casualties that could involve.

Instead, they would probably hold back until Tehran's military had been sufficiently degraded. That, Western military officers confidently say, would only be a matter of time.

"Anti-ship cruise missiles are mobile, yet can... be found and destroyed," said one U.S. naval officer with considerable experience in the region, speaking on condition of anonymity.

"Submarines are short-duration threats -- they eventually have to come to port for resupply and when they do they will be sitting ducks."

"DANGEROUS GAME OF CHICKEN"

Given the forces arrayed against them, many analysts believe Tehran will ultimately keep the straits open -- not least to allow their own oil exports to flow -- whilst finding other ways to needle its foes.

If they did wish to disrupt shipping, they could briefly close off areas of the Gulf through declaring "military exercise areas," "accidentally" release oil into the main channel or perhaps launch one-off and more deniable hit-and-run attacks.

The rhetoric, however, looks almost certain to continue.

"This isn't the first time we have heard these types of threats," said Alan Fraser, Middle East analyst for London-based risk consultancy AKE. "Closing of the Straits of Hormuz is the perfect issue to talk about because the stakes are potentially so high that nobody wants it to happen."

Henry Smith, Middle East analyst at consultancy Control Risks, says he believes the only circumstances under which the Iranians would consider such action would be if the United States or Israel had already launched an overt military strike on nuclear facilities.

"Then, I think it would happen pretty much automatically," he said. "The Iranians have been saying for a long time that is an option, and they would have little choice but to stick to that. But otherwise, I think it's very unlikely."

For many long-term watchers of the region, the real risk remains that in playing largely to domestic audiences, policymakers in Washington, Tel Aviv and Tehran inadvertently spark something much worse than they ever intended.

"Both sides are talking tough," said Farhang Jahanpour, associate fellow at the Faculty of Oriental Studies at Oxford University. "Unfortunately it can very easily get out of hand and cause a conflagration. I blame hardliners on both sides. They are playing a very dangerous game of chicken." (Additional reporting by William Maclean)

(Reporting By Peter Apps; Edited by Richard Meares)

@yahoonews on Twitter, become a fan on Facebook
  Forum: Macro Factors

pacestick
Posted on: Jan 2 2012, 05:29 AM


Group: Member
Posts: 339

http://www.theaustralian.com.au/news/world...so-122623445530


<h1 class="heading">Iran test fires missile near Hormuz, oil supply fears of US bank sanctions </h1>
An Iranian navy boat fires a missile in a drill in the sea of Oman on Friday. Iran's navy chief has reiterated for a second time in less than a week that his country can easily close the strategic Strait of Hormuz at the mouth of the Persian Gulf, the passageway through which a sixth of the world's oil flows. Source: AP

IRAN said last night it tested a new medium-range missile during war games near the Straits of Hormuz, hours after US President Barack Obama signed a law tightening sanctions against Tehran over its nuclear program.

A military spokesman also announced that Iranian ships and submarines would today carry out manoeuvres designed to allow them to shut the strategic channel.

Iran also claimed its scientists had produced the nation's first nuclear fuel rod, a feat of engineering doubted by the West but it fears that such enrichment could be used for nuclear weapons.

The show of military muscle underlined a threat by Iran to shut the narrow strait - through which 20 per cent of the world's passes - if more Western sanctions were applied over its nuclear program.

The potential for that scenario, and possible open confrontation with US warships that patrol the Gulf, was given impetus when Mr Obama on Saturday signed tough new sanctions targeting Iran's central bank and financial sector.


Under the measures, foreign firms will have to choose between doing business with the Islamic republic or the economically mighty US. The aim is to put the squeeze on Iran's crucial oil revenues, most of which are processed by the central bank.

Iran has said such sanctions, and a possible oil embargo being mulled by the EU, could push it to close the Strait of Hormuz. Its war games have underlined the threat.

"From tomorrow morning , a vast majority of our naval units - surface and underwater, and aerial - will implement a new tactical formation, designed to make the passage of any vessel through the Strait of Hormuz impossible if the Islamic Republic of Iran's navy so chooses," navy spokesman Mahmoud Mousavi was quoted as saying by the ISNA news agency.

On Sunday, "for the first time, an anti-radar medium-range missile was successfully fired during the massive naval drills," Commodore Mousavi said.

"This medium-range surface-to-air missile is equipped with the latest technology to combat radar-evading targets and intelligent systems which try to disrupt missile navigation," he said.

Further details on the missile were not given. It was not immediately known whether it was fired from a ship or from land, nor what distance it is able to fly.

Oil market analysts have been watching developments near the Strait of Hormuz closely.

Oil prices climbed briefly after Iran's vice-president, Mohammad Reza Rahimi, vowed on Tuesday that "not a drop of oil will pass through the Strait of Hormuz" if more sanctions were imposed.

But they fell back again as analysts said such a closure would devastate Iran's own economy, and could be viewed as an act of war provoking military action by the US and its Gulf allies.

Iran, though, has kept the threat on the table.

The deputy commander of Iran's Revolutionary Guards, Hossein Salami, told ISNA last night that "we will carry out whatever it takes to implement our defensive strategies in line with Iran's defensive doctrine," regarding the strait.

"If the vital interests of our country are endangered by the enemy, we will respond to any threat with a many-pronged threat of our own," Brigadier General Salami said.

The US and many Western countries believe Iran is trying to make atomic weapons under the cover of its civilian nuclear program. Tehran denies this is so.

Tensions between Washington and Tehran - foes since Islamist students stormed the US embassy in Iran in 1979, taking 52 Americans hostage - entered a dangerous new phase in October, when US officials said the Revolutionary Guards had a hand in a thwarted plot to kill the Saudi ambassador to Washington.

AFP



  Forum: Macro Factors

pacestick
Posted on: Jan 1 2012, 08:55 PM


Group: Member
Posts: 339

still a lot of rhetoric perhaps but the screws have been tightened a littlle more on iran and this announcement is only two hours old at time of posting so could be seen as a response to the latest american pressure



http://english.farsnews.com/newstext.php?nn=9007279716

IRGC Commander Terms Strait of Hormoz Part of Iran's Defense Line

TEHRAN (FNA)- Lieutenant Commander of the Islamic Revolution Guards Corps (IRGC) Brigadier General Hossein Salami described the Strait of Hormoz in the Persian Gulf as a part of Iran's line of defense, and underlined that Iran responds to threats with stronger threats.



"We will respond to any threat by intensified threat and this fact has no time or geographical limitation," Salami told reporters in Tehran on Sunday.

He underlined that "the Strait of Hormoz is a part of our defense geography as well".

Salami also warned enemies that Iran will utilize all its possibilities and measures to strike back at aggressors if its vital interests are ever threatened.

Iranian officials have recently warned enemies that Iran is entitled to the right to close the strategic oil lifeline as a defensive option against foreign invasion or sanctions on its oil exports.

Iranian Vice President Mohammad Reza Rahimi warned last week that "not a drop of oil will pass through the Strait of Hormuz" if the West followed through with planned additional sanctions against Iran over its nuclear program.

A US Defense Department spokesman replied with a declaration Wednesday that "interference with the transit... of vessels through the Strait of Hormuz will not be tolerated."

Then on Thursday, Salami dismissed the US warning over the closure of the strategic Strait of Hormuz, and stressed that powerful Iran acts on its own and never asks for anyone's permission to carry out what it desires.

"The US is not in a position" to affect Iran's decisions, Salami told FNA on Thursday. "Iran does not ask permission to implement its own defensive strategies."

General Salami also told FNA on Thursday that "our response to threats is threats."

"We have no doubt about our being able to carry out defensive strategies to protect our vital interests - we will act more decisively than ever," he said.

"The Americans are not qualified to give us permission for carrying out our military strategy," he said.

Israel and its close ally the United States have recently intensified their war rhetoric against Iran. The two arch foes of the Islamic Republic accuse Iran of seeking a nuclear weapon, while they have never presented any corroborative document to substantiate their allegations. Both Washington and Tel Aviv possess advanced weapons of mass destruction, including nuclear warheads.

Iran vehemently denies the charges, insisting that its nuclear program is for peaceful purposes only. Tehran stresses that the country has always pursued a civilian path to provide power to the growing number of Iranian population, whose fossil fuel would eventually run dry.

Iran has, in return, warned that it would target Israel and its worldwide interests in case it comes under attack by the Tel Aviv.

The United States has long stressed that military action is a main option for the White House to deter Iran's progress in the field of nuclear technology.

Iran has warned that in case of an attack by either the US or Israel, it will target 32 American bases in the Middle East and close the strategic Strait of Hormuz.

An estimated 40 percent of the world's oil supply passes through the waterway.







  Forum: Macro Factors

pacestick
Posted on: Jan 1 2012, 07:30 AM


Group: Member
Posts: 339

Obama signs new Iran sanctions into law Agence France-Presse
Hawaii, January 01, 2012 First Published: 02:33 IST(1/1/2012)
Last Updated: 02:34 IST(1/1/2012)
US President Barack Obama on Saturday signed into law tough new sanctions targeting Iran's central bank and financial sector, in a move likely to deepen acrimony between Washington and Tehran. The measures, meant to punish Iran for its nuclear program, were contained in a mammoth $662 billion defense bill, which Obama signed despite having reservations about its provisions on Iran and on detaining terror suspects. The sanctions require foreign firms to make a choice between doing business with Tehran's oil and financial sectors or central bank or the mighty US economy and financial sector.

Foreign central banks which deal with the Iranian central bank on oil transactions could also face similar restrictions under the new law, which has sparked fears of damage to US ties with nations like Russia and China which trade with Iran.

The White House held intense negotiations with Congress on the terms of the law's implementation, given concern that sanctions on Iran's central bank could spark chaos in the global financial system and hike the price of oil.

Obama said in a statement issued as he signed the bill that he was concerned the measure would interfere with his constitutional authority to conduct foreign relations by tying his hands in dealings with foreign governments.

The bill, which passed with wide majorities in Congress, did reserve some wiggle room for Obama, granting him the power to grant 120-day waivers if he judges it to be in the national security interests of the United States.

The president signed the law in Hawaii where he is on vacation, at a time or rising tension with Tehran, which has threatened to block the Strait of Hormuz -- through which more than a third of the world's tanker-borne oil passes.

Earlier this month, Treasury Secretary Timothy Geithner wrote to Congress to express concern against an earlier, tougher sanctions measure along the same lines saying it could harm the US push with its partners to isolate Iran.

Geithner argued that foreign allies could resent the new US measures and make it less likely they would cooperate and the sanctions would have the "opposite effect" of their intended purpose of isolating Iran.

There are fears that increased sanctions on Iran's central bank could force the global price of oil to suddenly soar, and actually give Tehran a financial windfall on its existing oil sales.

Rising oil prices could also crimp the fragile economic recovery in the United States and inflict pain on American voters in gas stations -- at a time when Obama is running for reelection next year.

The Obama administration argues that it has imposed the toughest-ever sanctions on Iran by the United States and its allies and says the measures are now having a punishing impact on the Iranian economy and petroleum sector.

The West alleges Tehran is seeking to acquire a weapons capability under the guise of its nuclear research program. Iran denies any such ambition and says its work is only for civil energy and medical purposes.

In recent weeks, Iranian officials have insisted the country was ready to face new sanctions against the oil sector and central bank.

The Wall Street Journal reported this month that US and European officials were seeking assurances from major oil producers, such as Saudi Arabia, Kuwait and the United Arab Emirates, that they would increase exports to the West and Asian nations if tighter sanctions on Tehran's energy exports are enforced.

  Forum: Macro Factors

pacestick
Posted on: Dec 3 2011, 02:47 PM


Group: Member
Posts: 339

supply contracts around mid 2012 thats why they needed the fund raising to keep going to then even the 1.25million for the new device onlyreduces the loss next quarter
  Forum: By Share Code

pacestick
Posted on: Oct 21 2011, 02:19 AM


Group: Member
Posts: 339

I dont get carried away about options Its one of those things you have to live with This one seems unusual in the he has to pay the full price of the sp at the time he exercises them I have never seen that before
  Forum: By Share Code

pacestick
Posted on: Oct 6 2011, 05:46 AM


Group: Member
Posts: 339

Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced it has been awarded a two-year contract by Premier Purchasing Partners, L.P., the group purchasing enterprise of the Premier healthcare alliance, for the supply of its Unitract® 1mL safety syringes.

Premier, Inc. is the nation's largest healthcare alliance, helping to improve performance and providing group contracting to more than 2,500 U.S. hospitals and over 76,000 healthcare sites nationwide.

Mr. Alan Shortall, CEO of Unilife said: "Our Unitract 1mL safety syringes, which are designed for use when drawing medication from a vial or ampoule, can provide optimal protection to healthcare workers and others at risk of infection from needlestick injuries. Unitract represents the first and only known range of insulin and tuberculin syringes with automatic, operator-controlled needle retraction features that are fully integrated within the syringe.

"We are delighted to have signed our first Group Purchasing Organization (GPO) contract with Premier for the sale of our Unitract 1mL syringes to U.S. healthcare facilities. In addition to being one of the largest GPOs in the U.S., Premier is also a leading national advocate for injection safety. Despite the widespread conversion of U.S. healthcare facilities to the mandatory use of needlestick prevention products, healthcare workers continue to remain at risk of harm from many types of conventional safety syringe technologies. We look forward to supporting Premier and its members to enhance the level of protection offered to U.S. healthcare workers."

For additional Unitract inquiries, please visit www.unitract.com, or contact Unilife at info@unitract.com or the Unitract customer service department toll free number: +1 888 698 1133. Premier members seeking to purchase Unitract 1mL syringes are encouraged to quote contract number SD-NS-007.
  Forum: By Share Code

pacestick
Posted on: Oct 1 2011, 10:36 AM


Group: Member
Posts: 339

Anyway if time travel was possible where are the tourists from the future

they cant afford it due to QE 312
  Forum: Off Topic Chat

pacestick
Posted on: Oct 1 2011, 08:58 AM


Group: Member
Posts: 339

sorry try this
http://oilprice.com/Energy/Natural-Gas/Mas...aels-Coast.html
  Forum: Macro Factors

pacestick
Posted on: Oct 1 2011, 08:55 AM


Group: Member
Posts: 339

It would appear to be only a matter of time before Greece leaves Euro However the EU cant afford to have them leave and it is questionable if they can afford to have them stay

http://www.stratfor.com/analysis/20110928-...c69d8ad238aeced

This news clip from stratfor although not covering the recent friendship between Greece and Israel would give a lead as to why they are moving closer together As Israel has in recent months fallen out with its closest thing to a friend in the middle east (Turkey) Greece has moved closer to Israel Your enemy is my enemy sort of scenario Israel may not be a major economic player but Greece is desparate and there is all that gas off the Palistinian coast

http://oilprice.com/Energy/Natural-Gas/Mas...sraels-Coast.ht
  Forum: Macro Factors

pacestick
Posted on: Sep 18 2011, 08:55 PM


Group: Member
Posts: 339

GSK hs been described as the first company into the patent cliff and the first out of it
GSK vaccines accounted for 29% of the world market in 2009

They represent 15% of GSK total sales

http://www.gsk.com/investors/presentations...ndrews-citi.pdf

GSK would seem to be the ideal candidate for the Unilife select



GSK has a sizeable investment in generic vaccines where the use of unifill select would differentiate its product
http://theinvestmentsblog.blogspot.com/201...ofiting-on.html
While this does not prove that GSK will move on the select it shows the case to do so that the senior management will be looking at
  Forum: By Share Code

pacestick
Posted on: Sep 18 2011, 08:59 AM


Group: Member
Posts: 339

scottish breath test

http://www.youtube.com/watch?v=RY8YeLErbEg...feature=related
  Forum: Off Topic Chat

pacestick
Posted on: Sep 15 2011, 06:20 AM


Group: Member
Posts: 339

Roman and Renshaw presentation here


http://www.wsw.com/webcast/rrshq20/unis/
  Forum: By Share Code

pacestick
Posted on: Sep 1 2011, 10:07 AM


Group: Member
Posts: 339

however you look at it the comMitment to the company by the CEO and the COO is hard to criticise
  Forum: By Share Code

pacestick
Posted on: Aug 27 2011, 03:18 PM


Group: Member
Posts: 339

http://www.youtube.com/watch?v=jWFq-v7TKdQ...feature=related

this is one mans attempt to stimulate the british economy through tourism
  Forum: Off Topic Chat

pacestick
Posted on: Aug 21 2011, 03:00 PM


Group: Member
Posts: 339

I am not even going to try! I queried the rate to see if it was a gouging interest rate which might indicate that UNS was a trifle desparate. The complexity of it might indicate it is so unless you people can come up with a better idea.

I dont think so its just that its as specialised field with its own methodology and terminology
  Forum: By Share Code

pacestick
Posted on: Aug 21 2011, 12:25 PM


Group: Member
Posts: 339

Form 8-K for UNILIFE CORP 19-Aug-2011

Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligatio


Item 1.01 Entry into a Material Definitive Agreement On August 15, 2011, Unilife Medical Solutions, Inc. ("UMSI"), a subsidiary of Unilife Corporation (the "Company") entered into a Master Lease Agreement dated as of August 15, 2011 (the "Master Agreement") with Varilease Finance, Inc. ("Varilease"). Under the Master Agreement, Varilease agreed to provide lease financing in an amount of $10 million for the production equipment for the Unifill� ready-to-fill syringe (the "Equipment"). UMSI may apply funds it receives from Varilease under the Master Agreement as reimbursement for payments UMSI has previously made to the manufacturer of the Equipment.

Under the terms of the Master Agreement, UMSI will lease the Equipment from Varilease for a two-year base term, and UMSI will pay rent in 24 equal monthly installments over the base term. The monthly rent payments include a Base Lease Rate Factor of 0.04195, which is subject to increase 0.00006775 for every five
(5) basis point increase in 24-month U.S. Treasury Notes, until all the Equipment has been installed. The 24-month U.S. Treasury Note yield used as the basis for the derivation of the Base Lease Rate Factor is .33%. UMSI will pay a deposit equal to two months rent, which will be applied towards the last two months rental payments.

The Master Agreement contains covenants and provisions for events of default customarily found in lease agreements.


http://biz.yahoo.com/e/110819/unis8-k.html In connection with the Master Agreement, the Company executed a Guaranty dated as of August 15, 2011 (the "Guaranty") in favor of Varilease pursuant to which the Company unconditionally guaranteed UMSI's performance under the Master Agreement, including payment of all rent payments or other amounts owed by UMSI under the Master Agreement. The Guaranty is unsecured, and the Company is not required to pledge any of its assets as security for its obligations under the Guaranty.

All capitalized terms that are not otherwise defined herein have the meanings ascribed to them in the Master Agreement.

The foregoing contains forward-looking statements, which are based on management's beliefs and assumptions and on information currently available to our management. The Company's management believes that these forward-looking statements are reasonable as and when made. The Company does not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from the Company's historical experience and its present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" in the Company's registration statement on Form 10-K and those described from time to time in other reports which the Company files with the Securities and Exchange Commission.




http://biz.yahoo.com/e/110819/unis8-k.html

Paragraph two seems to be the appropiate one although I havent fully worked out what it mean ssurely its not 0.7% being 0.33 plus 0.04195
  Forum: By Share Code

pacestick
Posted on: Aug 21 2011, 08:35 AM


Group: Member
Posts: 339

Sorry I just realised that you are probably referring to the ten million dollar lease back I dont know I will try to find out as it is a good question It is probably considerably less than if they had done it in Australia given the current interest rate difference between the two countries
  Forum: By Share Code

pacestick
Posted on: Aug 21 2011, 07:43 AM


Group: Member
Posts: 339

eme if you are referring to the CEOS intention to purchase 1 million dollars of shares the interest rate he pays is irrelevant to shareholders as it is between him and his lender
  Forum: By Share Code

pacestick
Posted on: Aug 13 2011, 07:38 AM


Group: Member
Posts: 339

USA calls for boycott of Syrian oil and gas but note it actually dosent directlyaffect the USA as they buy very little if any from Syria Will anyone actually bother

http://news.yahoo.com/hillary-clinton-urge...-160433331.html
  Forum: Macro Factors

pacestick
Posted on: Aug 9 2011, 08:02 AM


Group: Member
Posts: 339

Moodys holds AAA rating for USA dosent seem to make much difference as The VIX is up 50%

Anyone on borrowed money must be reaching maximum tolerance levels



http://money.cnn.com/2011/08/08/news/econo...htm?iid=Popular


http://www.bloomberg.com/apps/quote?ticker=VIX:IND
  Forum: Macro Factors

pacestick
Posted on: Aug 6 2011, 06:49 PM


Group: Member
Posts: 339

These guys are predicting a rally

http://www.bloomberg.com/news/2011-08-05/s...n-earnings.html
  Forum: Macro Factors

pacestick
Posted on: Jul 28 2011, 09:58 PM


Group: Member
Posts: 339

The beta video player was superior to the VHS but the only people who used it were TV stations brillant marketing was the reason
This company has with the prefill syringe positioned itself well but that in itself is not enough Its just as well that one of the strengths of the CEO is sales. As the company has told us they were in advanced negotiations with six companies and two companies have since taken initial shipments It is to be hoped that number three will turn up soon
  Forum: By Share Code

pacestick
Posted on: Jul 20 2011, 10:17 PM


Group: Member
Posts: 339

Still; gets my vote for wife of the year and no wonder shes good at volley ball
  Forum: Off Topic Chat

pacestick
Posted on: Jul 14 2011, 06:29 AM


Group: Member
Posts: 339

SALES OF PREFILL HAVE BEGUN

<h1 class="newsartsubtitle">Unilife Commences Initial Supply of the Unifill® Syringe to Sanofi</h1>



YORK, Pa., July 13, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (NASDAQ: UNIS; ASX: UNS) today announced it has commenced the initial supply of validated product of the Unifill® syringe to Sanofi, as per the terms of the industrialization agreement between both parties.

Since signing the Exclusive Agreement in July 2008, Sanofi has paid Unilife a total of approximately $40 million, comprising a $16 million (euro 10 million) fee in exchange for the exclusive right to negotiate the purchase of the Unifill syringe, and to help fund the Industrialization Program for the device up to a maximum of $24 million (euro 17 million). Sanofi has secured exclusivity for the Unifill syringe within the full therapeutic classes of antithrombotic agents and vaccines, plus an additional four smaller sub-groups, until June 30, 2014.

Unilife is now in a position to also commence initial sales of the Unifill syringe to other pharmaceutical companies. Upon the receipt of the Unifill syringe, these pharmaceutical customers will typically conduct drug compatibility and stability studies that will test the device in combination with their injectable drugs. The resulting data is then filed as the last step in completing the regulatory process for the drug-device combination product.

Mr. Alan Shortall, CEO of Unilife, said, "The start of initial sales of the Unifill syringe is arguably the most significant achievement in our company's history. We very much appreciate the support of Sanofi since 2003, when they had the initiative and vision to approach us to develop a new generation of prefilled syringes that can help to improve patient care, while also enhancing and saving the lives of healthcare workers.

"The Unifill syringe is generating strong interest from an increasing number of pharmaceutical companies for use in therapeutic classes outside of those retained by Sanofi. These pharmaceutical companies recognize the significant potential of the Unifill syringe to help generate powerful brand differentiation for their injectable drugs within competitive therapeutic drug classes."

Dr. Ramin Mojdeh, COO of Unilife, said, "The integration of safety features within the glass barrel of a prefilled syringe was a challenge that many within the device and pharmaceutical industries thought to be impossible. Yet, through our operational expertise, core technology platform and innovative spirit, we have successfully overcome a number of technical obstacles to commercialize a game-changing device that is now poised to revolutionize the $2.7 billion market for prefilled syringes.

"The Unifill syringe sits at the leading edge of a rich and diverse platform of advanced drug delivery devices that we are now developing in collaboration with a number of pharmaceutical partners. Having recognized our capacity for device innovation with the Unifill syringe, these top tier pharmaceutical companies are selecting Unilife as their partner to develop other innovative, differentiated and proprietary devices that are customized to address the specific and unmet needs of their biological drugs. These partnerships will enable us to build upon the success of the Unifill syringe and expand our horizons across several additional high-value market sectors for injectable drug delivery devices."

About Unilife Corporation

Unilife Corporation (NASDAQ: UNIS / ASX: UNS) is a U.S. based developer, manufacturer and supplier of advanced drug delivery systems with state-of-the-art facilities in Pennsylvania. Established in 2002, Unilife works with pharmaceutical and biotechnology companies seeking innovative devices for use with their parenteral drugs and vaccines. Unilife has developed a broad, differentiated proprietary portfolio of its own injectable drug delivery products, including the Unifill® and Unitract® product lines of safety syringes with automatic, operator controlled needle retraction. Unifill represents the world's first prefilled syringe technology integrating safety within the primary drug container. The products are ideally positioned to help pharmaceutical companies maximize the lifecycle of their injectable drugs and enhance patient care. Unifill syringes, together with other devices that are part of the Unilife technology platform, can either be supplied to pharmaceutical customers ready for use, or customized to address the specific requirements of targeted novel drugs.

For more information on Unilife, please visit www.unilife.com.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

This follows orders for the unitract at the end of last year and followm up orders for the same

http://ir.unilife.com/releasedetail.cfm?ReleaseID=530400
  Forum: By Share Code

pacestick
Posted on: Jun 29 2011, 06:59 PM


Group: Member
Posts: 339

First sales agreement within two to three weeks is my guess it should be only for 500,00 syringes probaly sanofi but other pharmas now have no reason not to sign and in the case of some such as pfiser very good reasons to sign in order to protect market share ramp up through 2012 to hit full production probably within 12 months . Expect an order for the high speed line to be placed soon after the sales start if not before all positive here
  Forum: By Share Code

pacestick
Posted on: Jun 26 2011, 12:42 PM


Group: Member
Posts: 339

product validation in days , sales contracts 2 to 3 weeks first shipments before end of july information from following ceos appearance on cramners mad money initial sales will lead to a ramp up in 2012 requiring more assembly lines

http://www.unilife.com/content/view/645/275/


http://www.unilife.com/content/view/646/275/


http://www.proactivenewsroom.com/Blog/bid/...e-business-plan

  Forum: By Share Code

pacestick
Posted on: Jun 25 2011, 03:22 PM


Group: Member
Posts: 339

http://www.youtube.com/watch?v=1sFy5_kmEi4...feature=related

what a voice

gambling is a terrible addiction

In 2006, Black completed bankruptcy proceedings in Manhattan, after he accrued a $500,000 debt in back taxes to the IRS as a result of his gambling addiction. The IRS initially sought to force him to sell the rights to perform as "Jay Black" as well as the trademark for "Jay and the Americans" in order to satisfy his debt to the IRS. Black did however win a partial victory in the case, which granted him the right to continue to use the name "Jay Black", but he was required to sell the rights to perform as "Jay and the Americans". The trademark to "Jay and the Americans" was purchased by former members of "Jay and the Americans". He can no longer perform as "Jay Black and the Americans" and now performs as "Jay Black and the Alley Cats".
  Forum: Off Topic Chat

pacestick
Posted on: Jun 12 2011, 11:27 AM


Group: Member
Posts: 339

Ive been moving into vanadium as a requirement for the long life batteries that cars require it has a strong future
  Forum: Investment Discussion

pacestick
Posted on: Jun 9 2011, 07:17 PM


Group: Member
Posts: 339

http://www.youtube.com/watch?v=E_9gliE5wmk...feature=related

well we remember the girl as miss brahms from are you being served but before this she did the female part on this big hit
  Forum: Off Topic Chat

pacestick
Posted on: May 28 2011, 08:46 AM


Group: Member
Posts: 339

T BOONE Pickens on fracking he says it safe Changing trucks from diesel to gas and an expected shortfall in oil production re demand in US fourth quarter I am not sure if they use the same counting of quarters as we do

http://www.bloomberg.com/video/69291466/
  Forum: Macro Factors

pacestick
Posted on: May 15 2011, 08:46 AM


Group: Member
Posts: 339

By DARLENE SUPERVILLE and DINA CAPPIELLO, Associated Press Darlene Superville And Dina Cappiello, Associated Press – 2 hrs 40 mins ago WASHINGTON – Amid growing public unhappiness over gas prices, President Barack Obama is directing his administration to ramp up U.S. oil production by extending existing leases in the Gulf of Mexico and off Alaska's coast and holding more frequent lease sales in a federal petroleum reserve in Alaska. But the moves won't calm spiraling prices at the pump any time soon.

Obama said Saturday that the measures "make good sense" and will help reduce U.S. consumption of imported oil in the long term. But he acknowledged anew that they won't help to immediately bring down gasoline prices topping $4 a gallon in many parts of the country, and an oil industry analyst agreed.

"There is practically nothing that Washington can do that would materially change the price of fuel in this country," said Raymond James analyst Pavel Molchanov, noting that the United States produces about 5 percent of the world's petroleum while consuming about 20 percent. "Given that imbalance, there is simply no policy shift that could plausibly come from the federal government that can significantly change that dynamic."

An oil industry group praised Obama's move as a first step with a "couple of positive nuggets" but contended that more was needed to boost oil production. Erik Milito, upstream director for the American Petroleum Institute, called in a statement for more access to key shale reserves and construction of a pipeline that would import crude from Canadian oil sands.

Sen. Robert Menendez, D-N.J., who is opposed to drilling off the Atlantic coast, expressed concern about possible dangers to the environment. "I think it is disappointing he would pursue a strategy that comes with considerable risk while offering no hope of driving down gas prices," Menendez said in a statement.

[ For complete coverage of politics and policy, go to Yahoo! Politics ]
Obama's announcement followed passage in the Republican-controlled House of three bills — including two this week — that would expand and speed offshore oil and gas drilling. Republicans say the bills are aimed at easing gasoline costs, but they too acknowledge that benefits won't come fast.

The White House had announced its opposition to all three bills, which are unlikely to pass the Democratic-controlled Senate, saying the measures would undercut safety reviews and open environmentally sensitive areas to new drilling.

But Obama is adopting some of the bills' provisions.

Answering the call of Republicans and Democrats from Gulf Coast states, Obama said in his weekly radio and Internet address that he would extend all Gulf leases that were affected by a temporary moratorium on drilling imposed after last year's BP oil spill. That would give companies additional time to begin drilling.

The administration had been granting extensions case by case, but senior administration officials said the Interior Department would institute a blanket one-year extension.

New safety requirements put in place since the BP spill also have delayed drilling in Alaska, so Obama said he would extend lease terms there for a year as well. An oil lease typically runs 10 years.

Lease sales in the western and central Gulf of Mexico that were postponed last year will be held by the middle of next year, the same time period required by the House. A sale off the Virginia coast still would not happen until 2017 at the earliest. But Obama said he would speed up environmental reviews so that seismic studies to determine how much oil and gas lies off the Atlantic Coast can begin.

To further expedite drilling off the Alaskan coast, where such plans by Shell Oil Co. have been delayed by an air pollution permit, Obama said he would create an interagency task force to coordinate the necessary approvals. He also will hold annual lease sales in the vast National Petroleum Reserve on Alaska's North Slope. Officials said the most recent sale was last year, but that they had not been held on any set schedule.

The moves come as Americans head into the summer driving season and gas prices remain high. A gallon of regular cost $3.97 on average nationwide Saturday, according to the AAA, Wright Express and Oil Price Information Service. That's up from $3.81 a month ago and $2.88 a year ago, but it's about a penny less than a week ago.

The price of gasoline increased every day between March 23 and May 6 for a total of about 30 percent, essentially tracking a 35 percent rise in crude oil prices that started in mid-February as investors pushed more and more money into commodities. Refinery shutdowns also contributed. And gas prices tend to rise every spring as refineries follow federal regulations to produce summer gasoline blends that evaporate less readily but are more expensive to make.

Molchanov said global oil prices also have risen because the global supply and demand picture has tightened the past few months due to volatility in the Middle East and North Africa.

Even if the U.S. government started offering new leases in Alaska and new areas of the Gulf or off the East Coast, it would probably take at least a year to start drilling and then another five years for that to translate into barrels of production, the analyst said. Wells that can produce quickly tend to be small.

"Even if all that works out, it still would not materially change global oil supply, and therefore would not materially change fuel prices in this country or any other," Molchanov said. "In the grand scheme of things, none of this changes the reality of $4 gasoline at the pump."

House Natural Resources Committee Chairman Doc Hastings of Washington, sponsor of the three measures that recently passed the House, said it was "ironic" that Obama "is now taking baby steps in our direction" after the White House and congressional Democrats criticized the bills.

"The president is finally admitting what Republicans have known all along, that increasing the supply of American energy will help lower prices and create jobs," Hastings said.

Philip Johnson, a petroleum engineer and University of Alabama professor, cautioned that new leases offer no guarantee that a company will find oil. Leases give a company permission to explore an area and set limits for what the company can do.

"You've got strong suspicions because you know what the underground structure looks like," he said. "But until you stick a hole in it you don't know what's in that structure."

Johnson noted, for instance, that while there are about 3,000 producing wells in the Gulf of Mexico in U.S. waters, about 50,000 wells have been drilled including many that have been emptied.

Obama on Saturday also reiterated his call on Democrats and Republicans to vote to eliminate $4.4 billion in taxpayer subsidies to oil and gas companies. Industry advocates, including most Republicans in Congress, have argued that doing away with the tax breaks will raise companies' cost of doing business, crimp their investment in exploration and production and lead to higher gas prices.

The 41 U.S. oil and gas companies that break out their federal taxes said they paid Uncle Sam $5.7 billion in 2010, more than any other industry, according to data compiled by Compustat. Exxon alone paid $1.3 billion.

The industry's federal tax bill would rise 70 percent without the subsidies, but it would remain highly profitable: Oil companies' combined pre-tax profits could hit $200 billion this year.

In the weekly Republican message, Alabama Rep. Martha Roby said it's time for Washington to get serious about the challenges facing the country, including straightening out its finances and tackling the gas price issue. She praised the House for passing measures to expand domestic energy production "because when we're talking about energy, we're talking about jobs."

"The greatest threat to our economy, job creation, and the future of our children is to do nothing," Roby said. "We have to act. It is what we were sent to Washington to do."

  Forum: Macro Factors

pacestick
Posted on: May 8 2011, 08:26 AM


Group: Member
Posts: 339

Misrata domestic and export storage tanks on fire

http://news.yahoo.com/s/nm/20110507/ts_nm/us_libya
  Forum: Macro Factors

pacestick
Posted on: Apr 28 2011, 08:04 AM


Group: Member
Posts: 339

UP 10% on nasdaq should follow today
  Forum: By Share Code

pacestick
Posted on: Apr 24 2011, 12:02 PM


Group: Member
Posts: 339

sorry chapter winds to an end

http://www.pike.co.nz/
  Forum: NZX

pacestick
Posted on: Apr 10 2011, 06:38 AM


Group: Member
Posts: 339

This article shows just how concerned Sanofi is about generic competition it is no wonder that they were prepared to spend the relativly small amount they did to get NS up and running with prefill syringes and thereby protect their drugs from generics

http://www.businessspectator.com.au/bs.nsf...nt&src=hp14
  Forum: By Share Code

pacestick
Posted on: Apr 9 2011, 11:47 AM


Group: Member
Posts: 339

INP has risen steadily in price since Republic began to dominate the register. The replacement of management with individuals who have a sound record in exploration and company management seems to have brought on a level of confidence that was previously lacking. After three averaging down purchases and with the rise over the last few weeks I am slightly in the green Will the show of confidence from the market continue I have no idea
  Forum: By Share Code

pacestick
Posted on: Apr 9 2011, 08:18 AM


Group: Member
Posts: 339

tapis through $130.00

http://www.upstreamonline.com/marketdata/markets_crude.htm
  Forum: Macro Factors

pacestick
Posted on: Apr 2 2011, 07:19 AM


Group: Member
Posts: 339

oil still rising on combination of supply demand fundamentals expectations and political / war turmoil

http://www.businessspectator.com.au/bs.nsf...ent&src=hp1
  Forum: Macro Factors

pacestick
Posted on: Mar 27 2011, 05:49 PM


Group: Member
Posts: 339

I think this is more likely what they are getting at However it is of no great concern the original statement at time of contract specified that it would be installed in the fourth quarter of 2010 however the 15 march statement says it is being installed now i.e. first quarter 2011

The development of this commercial line is expected to commence next month, with its scheduled installation into Unilife's new production facility in Pennsylvania during the fourth quarter of 2010. This commercial line will support the completion of the Unifillâ„¢ industrialisation program which Unilife is currently undertaking in conjunction with its major pharmaceutical partner.



http://ir.unilife.com/releasedetail.cfm?ReleaseID=442424







Last week the Company successfully commissioned the cleanrooms at its state-of-the-art production facility in York, PA. Following the completion of this essential regulatory milestone, Unilife has now moved toward the final steps required to commence production of its Unifill and Unitract® safety syringe products at its new site. This includes the installation and final qualification of production systems utilized in the assembly of the Unifill syringe. As part of its planning to commence production, Unilife has begun to build up its inventory of components and other materials to be utilized in the assembly of the Unifill syringe.

http://ir.unilife.com/releasedetail.cfm?ReleaseID=556954



  Forum: By Share Code

pacestick
Posted on: Mar 22 2011, 06:50 PM


Group: Member
Posts: 339

henrietta
There is a very significant announcent due not later than 31 March i.e. nine days away . That announcement is the installation of the assemby line . The announcement so far was only a partial installation the full installation is scheduled by months end . After this the Mikron technicans will test run it looking for such things as an ability to achieve the contracted speed . After they are happy with it they will sign it over to the company who will begin to stockpile product for the first shipment to sanofi at the end of June
  Forum: By Share Code

pacestick
Posted on: Mar 19 2011, 07:37 AM


Group: Member
Posts: 339

IMHO its either a fund moving in or Becton Dickinson beginning a move to protect its market share more likely the first
  Forum: By Share Code

pacestick
Posted on: Mar 16 2011, 01:05 AM


Group: Member
Posts: 339

We have made the big time while the figures do not look good to theuninitiated the mere fact that we are being used as a comparison is some thing that would not have happened 12 months ago

http://www.fool.com/investing/value/2011/0...-much-cash.aspx
  Forum: By Share Code

pacestick
Posted on: Mar 15 2011, 06:52 PM


Group: Member
Posts: 339

This is just the beginning Its going to be announcement afetr announcement looking at the line up of milestones now in sight
  Forum: By Share Code

pacestick
Posted on: Mar 12 2011, 01:59 PM


Group: Member
Posts: 339

note page 11 graph 8 companies have requested samples for validation. This is not the first they have seen the syringes rather they have been shown at medical conferences for many years now . The reason they need the samples would appear to be related to them a essentially doing a dry run in loading the syringes with drugs so that they can proceed to have them liscenced following aging tests

It should be remembered that sanofi Aventis long association with Unilife has allowed them to go past this level already
  Forum: By Share Code

pacestick
Posted on: Mar 8 2011, 05:28 AM


Group: Member
Posts: 339

Surely the effect can only be limited in time because of the finite supply in strategic reserve . From the users point of view the price of petrol goes down for a short period and then when the reserve is gone or at least as much of it has been used as the white house wishes to provided the situation causing the price rise has not been eliminated the price goes back up .
INMO the poilitical instability has months if not years to ride out yet
  Forum: Macro Factors

pacestick
Posted on: Mar 3 2011, 08:29 AM


Group: Member
Posts: 339

http://www.stratfor.com/analysis/20110301-...ian-gulf-unrest

This report from stratfor shows the spread of unrest across the arab countries of the Persian gulf . Disruption in this geographic area will push oil way up so that the Lybian performance will look very small indeed
  Forum: Macro Factors

pacestick
Posted on: Feb 23 2011, 04:59 PM


Group: Member
Posts: 339

Hopefully its the wild gyrations before the big announcement scenario I can well understand anyone who is leveraged jumping ship. However I will keep my holding simply because despite a delay in the timeline to production does not mean the fundamentals are changed
  Forum: By Share Code

pacestick
Posted on: Feb 18 2011, 07:20 PM


Group: Member
Posts: 339

CFE has now sold out of SPM SPM continued to rise while CFE was selling down from its major shareholding position Without that downward pressure it will hopefully rise even faster
  Forum: By Share Code

pacestick
Posted on: Feb 10 2011, 04:55 PM


Group: Member
Posts: 339

Living in hope that they are about to stick the plug in on the RTF of have an exclusivity agreement with second pharma
  Forum: By Share Code

pacestick
Posted on: Feb 8 2011, 06:58 PM


Group: Member
Posts: 339

these photos are listed as final photos of the new building note the interior photos showing two different assembly lines presumably the unitract 1ml and the prefill .We must be within weeks if not days of production and supply agreements

http://www.unilife.com/index.php?option=co...&Itemid=290
  Forum: By Share Code

pacestick
Posted on: Feb 4 2011, 07:38 AM


Group: Member
Posts: 339

Reading a bit into the C E O s comments but it would appear that the installation and therefore production from the Mikron line delayed from the original date of 31 December is getting close rolleyes.gif
  Forum: By Share Code

pacestick
Posted on: Feb 4 2011, 06:22 AM


Group: Member
Posts: 339

nilife Appoints Dr. Ramin Mojdeh as Chief Operating Officer Former BD Pharmaceutical Systems Leader to Help Drive Unilife Towards Global Leadership Position


span.prnews_span { font-size: 8pt; font-family: "Arial"; color: black; }span.prnews_wider { background-color: yellow; font-size: 10pt; font-family: "courier new"; color: black; margin: 0in 0in 0.0001pt; }a.prnews_a { color: blue; }li.prnews_li { font-size: 8pt; font-family: "Arial"; color: black; }p.prnews_p { font-size: 8pt; font-family: "Arial"; color: black; }

YORK, Pa., Feb. 3, 2011 /PRNewswire/ -- Unilife Corporation ("Unilife" or the "Company") (Nasdaq: UNIS; ASX: UNS) today announced that it has appointed Dr. Ramin Mojdeh, formerly Vice President and General Manager of Becton Dickinson (BD) Pharmaceutical Systems, North America, and Worldwide Vice President of Research and Development, BD Medical, as its new Chief Operating Officer and Executive Vice President, effective February 7, 2011.

Dr. Mojdeh comes to Unilife with more than 25 years of business leadership experience across multiple industries, including 18 years in the design, development, manufacturing, sales and marketing of therapeutic and diagnostic medical devices for several multinational companies, including BD, GE Healthcare and Boston Scientific (formerly "Guidant Corporation"). He has developed and maintained strong relationships with many pharmaceutical manufacturers that utilize prefilled syringes for their injectable drugs and vaccines.

As COO, Dr. Mojdeh will lead Unilife's operating team as the Company prepares to enter its next phase of business expansion with the commercial production of the Unifill® ready-to-fill (prefilled) syringe this quarter, and its supply to pharmaceutical customers. Dr. Mojdeh will also help to expand and accelerate discussions with pharmaceutical companies regarding the Unifill syringe, as well as the commercialization of a number of key pipeline products being developed by the Company.

Dr. Mojdeh spent the last eight years working with BD, one of the world's leading suppliers of medical devices, including prefilled syringes. He served as the Vice President and General Manager of BD Medical, Pharmaceutical Systems, North America from 2008 to 2010. In this role, he directed all aspects of the North America operations including sales, marketing, business development, commercial development, finance, R&D, manufacturing, operations, quality assurance, regulatory affairs, legal affairs and human resources.

During this time, Dr. Mojdeh served as a key board member of the Business Strategy Council that led the worldwide business growth strategy for BD Pharmaceutical Systems, whose annual revenues exceeded $1 billion. He also led the creation of an innovative new growth business for BD Pharmaceutical Systems in advanced drug delivery.

From 2002 to 2008, Dr. Mojdeh held the position of the Worldwide Vice President of Research and Development for BD Medical, responsible for technology and product innovation and commercialization for the business areas of medical surgical systems, diabetes care, pharmaceutical systems and ophthalmic systems with combined annual revenues of over $4 billion. During this time, he led the process of revamping the product development functions for BD Medical.

He was also a board member of BD Ventures Inc., the venture capital arm of BD, which oversaw all technology and innovation activities across BD. Furthermore, he has served as the Chairman of the Advanced Drug Delivery Council, aimed at identifying and developing new growth strategies in the drug delivery device space.

Prior to his work with BD, Dr. Mojdeh held the position of Business Director, Invasive Cardiology at GE Healthcare in 2002, and spent ten years with Guidant Corporation, where he held several management positions including Business Director, Advanced Patient Management from 1999 to 2002 and Business Director, Advanced Patient Monitoring System from 1996 to 1999.

Mr. Alan Shortall, Chief Executive Officer of Unilife, stated, "The addition of Dr. Mojdeh to our executive team and as the leader of our operational divisions is a clear indication of Unilife's commitment to rapid growth and the production of the highest quality medical devices. Our ability to attract executives with the experience and reputation of Dr. Mojdeh is an affirmation of the potential for Unilife's innovative product line. Dr. Mojdeh has extensive experience in driving product innovation, manufacturing advanced medical devices and launching new business ventures. His detailed knowledge of how prefilled syringes are manufactured and supplied to the highest industry standards should help us secure, expand and consolidate strong commercial relationships with many of the world's largest pharmaceutical and healthcare companies.

"The appointment of Dr. Mojdeh as COO comes at the right time for Unilife. We are now preparing to commence commercial production of the Unifill syringe, with several key sections of the manufacturing system now either in place or being prepared for delivery to our new facility in York. And the commissioning of our cleanrooms and the requalification of our Unitract® 1mL syringe assembly line are now approaching completion. In addition, Dr. Mojdeh's extensive experience working with pharmaceutical companies will be invaluable as our commercial discussions are now accelerating with a significant number of pharmaceutical companies relating to the Unifill syringe, as well as some of our pipeline products. The appointment of Dr. Mojdeh puts us in a strong position to take Unilife to the next level and attain a true global leadership position in the pharmaceutical market for drug delivery devices."

Dr. Ramin Mojdeh commented, "I am extremely pleased to join the executive team of such a unique and innovative company as Unilife. Unilife is developing an exceptional portfolio of innovative products, with the Unifill syringe in particular representing game-changing technology within the pharmaceutical market for prefilled syringes. With Unilife's new global headquarters complete and commercial production of the Unifill syringe about to commence, the Company is in an extraordinary position to now undertake significant expansion on an international scale. I am excited to have an opportunity to help Unilife expand its commercial relationships and capitalize on its tremendous growth potential."

Dr. Mojdeh received his Ph.D. in Computer Science from the University of Minnesota, Minneapolis Minnesota, and his MBA from Kellogg Graduate School of Management, Northwestern University, Evanston, Illinois.

About Unilife Corporation

Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic, operator-controlled needle retraction features which are fully integrated within the barrel, and are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485-certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our Annual Report on Form 10-K and those described from time to time in other reports which we file with the Securities and Exchange Commission.

General: UNIS-G

  Forum: By Share Code

pacestick
Posted on: Feb 1 2011, 10:15 PM


Group: Member
Posts: 339

Im not sure how it works but I think some are buying now so that they can get the non renouncable rights at 11.5 cents then they intend to sell presumably at a profit both on the shares they buy now and the rights . But this would surely put a limit on the rise because the averaging down effect is limited to one third of the held shares
  Forum: By Share Code

pacestick
Posted on: Jan 31 2011, 09:19 PM


Group: Member
Posts: 339

31 MILLION DOLLAR RECAPITALISATION

placement of shares to Republic at 19 cents per share
1 for 3 rights non renouncable rights issue at 11.5 cents
Republic will end up with approximatly 39% of INP

so does that put a floor under the SP at 19cents or a ceiling at the same price
  Forum: By Share Code

pacestick
Posted on: Jan 21 2011, 06:53 AM


Group: Member
Posts: 339

could be one of the projects funds were put aside for from the revent capital raising.Project viper i think it was called Love to hear an update on the prefill assembly line installation they must be doing it about now
  Forum: By Share Code

pacestick
Posted on: Jan 1 2011, 07:01 AM


Group: Member
Posts: 339

http://www.energyandcapital.com/peakoilclock/

Worth keeping an eye on
  Forum: Macro Factors

pacestick
Posted on: Dec 31 2010, 06:48 AM


Group: Member
Posts: 339

OK its US based the prices are in usd and us gallons not imperial but its showing the same trend as others

OPEC and Peak OilBy Nick Hodge | Thursday, December 30th, 2010Editor's Note: In light of recent energy price spikes, this article by my colleague Nick Hodge seems especially relevant. It was originally published in our sister publication, Energy and Capital. If you're interested in learning more about peak oil — and its implications for investors — EAC is a daily must-read.

Adam Sharp
Analyst, Wealth Daily

——————————

Now that peak oil production has passed, all sorts of interesting tidbits are emerging.

Take the December 13th BusinessWeek article that declared OPEC is cheating the most since 2004...

Apparently, the oil cartel pumped 26.78 million barrels per day (mmbd) this year. Yet they have a production limit of only 24.845 mmbd, set at the end of 2008 in response to the recession.

So your friendly neighborhood fuel gang has been breaking its output limit by 1.934 million barrels — everyday, all year long.

Advertisement
A Shocking Prediction for 2011

A wealthy U.S. businessman recently made a shocking prediction.

He says that over the course of one day next year, everything in America will change... the way we shop, travel, and even retire.

Before you dismiss this prediction altogether, keep in mind that this is the same multi-millionaire businessman who recently predicted the fall of Fannie Mae, Freddie Mac, GM, and General Growth Properties (the nation's biggest mall owner).

While his next prediction actually has nothing to do with the stock market – it could change your life in ways you probably haven't yet imagined.

Click here to watch the full video presentation...

With crude at its highest price in two years, overproduction allows OPEC members to boost profits without formally changing output targets.

An extra 1.934 mmbd at $80 works out to a nice “informal” $56.47 billion boost.

OPEC's been lying... That's nothing new.

What's important here is to note the willingness to extract as much as they can as prices rise.

Analysts, start your engines

If the price of oil creeps high enough, OPEC will officially raise its target to cash in.

$100 seems to be the obvious trigger to make that happen, and the consensus is that it will happen this year.

Oil's at $91.43 as I write this — up 30% from the year's low.

Goldman says it'll “average $100 in 2010 and $110 in 2012.” JPMorgan says we'll see $120 by the end of 2012.

Adding to the pricing fire, U.S. stockpiles declined by 19 million barrels this month thanks to intense cold and holiday travel. That's the biggest monthly decrease since December 2006.

I'm sure you've noticed gas station marquee numbers are back on the march.

A $3.00 appetizer

Prices at the pump have officially broken $3.00 for the first time since October 2008. And they aren't expected to ease anytime soon.

John Hofmeister (former President of Shell, current Head of Citizens for Affordable Energy) is touring TV land this week with a new prediction:

We'll be paying $5.00 per gallon in less than two years, and sometime between 2018 and 2020 there will be another 1970s-style energy shortage requiring rationing.

And this guy didn't just jump on the bandwagon; he's been saying for years that “the last days of affordable gas are behind us.”

He's been attacking our national energy policy since the turn of the century, saying business as usual would lead us to an “energy abyss”.

And like an ever-increasing cadre of oil execs, he admits conventional oil production is in decline, and is convinced we must turn to unconventional sources to fill the gap — and avoid gas station rationing.

There's still time to put this trend to work for your portfolio. Oil at $200 per barrel implies a 122% increase from today's prices.

Buying an oil or gasoline fund like United States Gasoline (NYSE: UGA) or ProShares Ultra Crude Oil (NYSE: UCO) or top unconventional oil plays will ensure rising oil prices translate into personal profits...

Those stocks and funds are already marching in step:



To maximize your investment, you'll want to check out our latest oil webinar.

It explains the future of drilling for hard-to-get oil, and the one company that will make shareholders rich as it unlocks billions of barrels worth of unconventional reserves.

Call it like you see it,






wd-eletter@angelnexus.com
  Forum: Macro Factors

pacestick
Posted on: Dec 23 2010, 10:23 PM


Group: Member
Posts: 339

republic is a singapore based investment fund
  Forum: By Share Code

pacestick
Posted on: Dec 23 2010, 05:07 AM


Group: Member
Posts: 339

tapis is now knocking on the door of $100.00 usd
http://www.upstreamonline.com/marketdata/markets_crude.htm
  Forum: Macro Factors

pacestick
Posted on: Dec 23 2010, 05:04 AM


Group: Member
Posts: 339

Its really weird republic blocked the merger Republic holds large shares in both companies and has increased its holding in INP since the merger failure does anyone know their reasoning
  Forum: By Share Code

pacestick
Posted on: Dec 5 2010, 12:05 PM


Group: Member
Posts: 339

brilliant post flower your chart confirms the conclusion I was coming to
  Forum: Macro Factors

pacestick
Posted on: Dec 5 2010, 07:09 AM


Group: Member
Posts: 339

anyone able to work out how much of the rise is due to demand and how much to some form of hedging against decline in USD
  Forum: Macro Factors

pacestick
Posted on: Dec 4 2010, 06:47 AM


Group: Member
Posts: 339

will they buy unfortunatly looks like not yet still it is a good buying oppurtunity for those of us who want large profits over the next 2 to 4 years
  Forum: By Share Code

pacestick
Posted on: Nov 25 2010, 11:20 AM


Group: Member
Posts: 339

Trading halt re capital raising I can only hope that it is to acclerate the purchase of high speed production lines althoough I would prefer if the pharmas funded them
  Forum: By Share Code

pacestick
Posted on: Oct 25 2010, 04:48 PM


Group: Member
Posts: 339

BLACKROCK IS THE LARGEST INSTITUTIONAL SHAREHOLDER OF 25 LISTED INSTITUTIONS HOLDING SHARES IN UNIS



Blackrock appears twice on UNIS insider list



Once as the single largest institutional shareholder with

1,044,382 shares and the second time as the fifth largest shareholder with 83,290 shares. This combined amount is nearly twice as much as the second largest institution Barclays Global 562452 shares however just to complicate matters further and show how committed Blackrock is to UNIS Blackrock owns Barclays through having purchased it in dec 2009

http://www.nyse.com/about/listed/blk.html



It is listed on the NYSE as BLK and a major shareholder is the Bank of America



The purchase of UNIS shares is consistent with the views of Bob Doll (not Bob Dole politician) vice chairman of Blackrock and chief equity strategist for Fundamental Equities who in his annual economic and market predictions for the next year given July 22 2010 predicted that Healthcare would be one of three growth areas in the USA and that investors should be overweight in healthcare shares .

http://www2.blackrock.com/global/home/News/index.htm



Just thought you might to know who they are and why they are here in a size that exceeds that which could be reasonably considered following our entry to the Russell index



  Forum: By Share Code

pacestick
Posted on: Oct 23 2010, 12:49 PM


Group: Member
Posts: 339

The US government has guarranteed 10 million dollars of unis mortgage

Unilife Secures U.S. Government Financial Backing for the Completion of New Global Headquarters and Manufacturing Facility in York, PA

Construction of state-of-the-art safety syringe manufacturing facility remains on-schedule for completion in late-2010


LEWISBERRY, Pa., Oct 21, 2010 /PRNewswire via COMTEX News Network/ -- Unilife Corporation ("Unilife" or "Company") (Nasdaq: UNIS, ASX: UNS) today announced that it has secured U.S. Government financial backing to support the construction of its new global headquarters and manufacturing facility in York, Pennsylvania.

The U.S. Department of Agriculture (USDA) has agreed to guarantee $10 million of an $18 million mortgage Unilife has now obtained from Metro Bank of Harrisburg to support construction of the 165,000 square foot state-of-the-art facility.

Unilife previously qualified for an additional $5.4 million in grants and loans from the Commonwealth of Pennsylvania, the majority of which relates to the development of the York facility. The combined financial commitments by U.S. and Pennsylvania Government agencies represent approximately half of the total $31 million projected cost of the York facility.

Mr. Alan Shortall, Chief Executive Officer of Unilife, stated, "We wish to thank government leaders for their continued collaboration with Unilife. This round of government financial support improves our balance sheet and offers us access to capital under very favorable terms. The support and interest we have received at the federal and state level has been overwhelmingly positive.

"I believe this strong government backing reflects our status as a fast-growing Pennsylvania company that is committed to local high-skilled job creation, and the production of best-in-class syringes which can provide a safer environment for healthcare workers and enhanced care for patients."

Mr. Tom Williams, State Director of the USDA, stated, "The USDA is working to ensure that rural communities have the tools they need to expand economic opportunity and improve their quality of life. The USDA congratulates Unilife on its strong life science investment into central Pennsylvania, bringing with it high-skill jobs in a high-tech, fast growing market sector."

Michael J. Bunn, Vice President and Regional Manager of Metro Bank, stated, "Together with the USDA, Metro Bank is proud to help make possible the growth and job creation underway at Unilife and proud to have a positive impact on economic development in our region. We are also pleased to have another growing global company among our expanding portfolio."

To ensure facility construction timelines continue to align with the accelerated industrialization program for the Unifill® ready-to-fill (prefilled) syringe, Unilife has already invested approximately $10 million of its own cash reserves in the project. The Company does not expect it will be required to lay out any additional cash to finance the completion of the York facility.

Construction of the York facility remains fully on schedule for completion in late-2010. The facility has been designed by leading pharmaceutical architects to have the annual capacity to manufacture up to 400 million units of Unilife's proprietary range of safety syringes.

The York facility shall feature world-class manufacturing, environmental control and material handling systems that will maximize overall production efficiencies and meet the highest pharmaceutical standards for primary drug containers. It will incorporate eight Class 8 (100,000) and three Class 7 (10,000) clean rooms where environmental factors such as temperature, humidity and particulate matter will be tightly controlled. An advanced Water-for-Injection (WFI) system will meet established pharmaceutical standards of water purity required for the production of the Unifill® ready-to-fill syringe.

Additional amenities that further enhance Unilife's capacity to be a preferred supplier to pharmaceutical customers includes a product development center, a microbiology lab, quality inspection and control rooms and a fully segregated warehouse for efficient inventory management.

Since initial ground breaking commenced in December 2009, Unilife and its construction partners have made rapid progress in the development of the York facility. Activities completed to-date include the erection of all exterior walls and roofing, as well as the installation of cooling towers, piping and sprinklers in the 110,000 square foot production wing. Installation of clean rooms, air-conditioning and other essential systems in the production wing are also well under way, clearing the path for the scheduled installation of initial automated assembly lines and other production equipment later this year.

In addition, construction of the framework of the 54,000 square foot office wing, which will serve as Unilife's global headquarters and support management functions, has recently been completed. Unilife is targeting the relocation and consolidation of staff from its current Lewisberry sites to the new facility to occur in mid-December.

"We are excited by the progress we have made at the construction site for our new headquarters and manufacturing facility," continued Shortall. "Despite construction starting in December 2009, which marked the beginning of one of the worst winters on record in Pennsylvania's history, the construction of the facility remains on schedule. We are confident that the facility will be ready for operations by the end of this year to align with the industrialization program for the Unifill® syringe. This state-of-the-art facility, together with the rapid expansion of our operational capabilities and internal expertise, will help us meet anticipated demand for our products, and become a preferred, long-term supplier to a number of pharmaceutical companies."

Unilife has also secured zoning approval for a potential 100,000 square foot extension at the York facility that would increase total annual production capacity of the site to an optimal target of one billion units of Unilife's proprietary range of safety syringes.

Please visit the Unilife website (www.unilife.com) to see the progress and for a full description of the facility's capabilities. Photos of Unilife's York facility can be viewed at the site.

About Unilife Corporation

Unilife Corporation is a U.S.-based medical device company focused on the design, development, manufacture and supply of a proprietary range of retractable syringes. Primary target customers for Unilife products include pharmaceutical manufacturers, suppliers of medical equipment to healthcare facilities and patients who self-administer prescription medication. These patent-protected syringes incorporate automatic and fully-integrated safety features which are designed to protect those at risk of needlestick injuries and unsafe injection practices. Unilife is ISO 13485 certified and has FDA-registered medical device manufacturing facilities in Pennsylvania.

This press release contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and on information currently available to our management. Our management believes that these forward-looking statements are reasonable as and when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in "Item 1A. Risk Factors" and elsewhere in our registration statement on Form 10 and those described from time to time in our periodic reports which we file with the Securities and Exchange Commission.

General: UNIS-G

  Forum: By Share Code

pacestick
Posted on: Oct 16 2010, 09:19 AM


Group: Member
Posts: 339

Any one know of a company with a large vanadium deposit where the ceo is about to address an investment conference in china I for one think that the days of volatility are over for vanadium for some time see this article for a view of what is happening in the vanadium world and the future for NIP is very good on its vanadium deposit alone


http://vanadiuminvestingnews.com/900...adium-paradox/
  Forum: By Share Code

pacestick
Posted on: Oct 8 2010, 06:42 PM


Group: Member
Posts: 339

the managing director of DLS speaks about Dls and Inp at a conference today

http://www.abnnewswire.net/multimedia/en/63893/Drillsearch
  Forum: By Share Code

pacestick
Posted on: Sep 17 2010, 07:53 PM


Group: Member
Posts: 339

<